File Name,Date of Response,Identity of Submitting Entity,Source_Year
FDA-2000-P-0060-0006_FDA_CFSAN_Response_to_Iceberg_Industries_Corporati.pdf,"September 
28,200",Iceberg Industries Corporati,2000
FDA-2000-P-0060-0012_Response_from_FDA_CFSAN_to_Iceberg_Industries_Corp.pdf,"September 19,2000",FDA CFSAN to Iceberg Industries Corp,2000
FDA-2000-P-0098-0001_FDA_Office_for_Policy_Response_to_Center_for_Food_.pdf,"May 29, 1992",Center for Food,2000
FDA-2000-P-0126-0009_CFSAN_ONPLDS_Response_to_Patton_Boggs__LLP___Lette.pdf,"February 18,2000",Patton Boggs  LLP   Lette,2000
FDA-2000-P-0126-0010_CFSAN_ONPLDS_Response_to_Patton_Boggs__LLP__Stuart.pdf,"February 18, 2000",Patton Boggs  LLP  Stuart,2000
FDA-2000-P-0126-0094_Letter_to_Zimmerman_Reed__P_L_L_P___Response_to_FD.pdf,"June 28, 2013",Zimmerman Reed  P L L P   Response to FD,2000
FDA-2000-P-0126-0132_International_Dairy_Foods_Association__Response_to.pdf,"April 14, 2023",,2000
FDA-2000-P-0126-0134_Compliance_Extension_Request_Response_Letter_from_.pdf,"April 13, 2023",,2000
FDA-2000-P-0126-0135_International_Dairy_Foods_Association__Response_to.pdf,"May 18, 2023",,2000
FDA-2000-P-0134-0011_Final_Response_from_FDA_CFSAN_to_Zuckerman_Spaeder.pdf,"May 6,2004",FDA CFSAN to Zuckerman Spaeder,2000
FDA-2000-P-0134-0012_Response_Letter_from_FDA_CFSAN_to_W__Schultz_and_C.pdf,"November 4, 2019",FDA CFSAN to W  Schultz and C,2000
FDA-2000-P-0213-0002_Final_Response_Letter_from_the_FDA_CDRH_to_Maet_In.pdf,"June 23, 2000",the FDA CDRH to Maet In,2000
FDA-2000-P-0252-0008_Interim_Response_Letter_from_FDA_CDRH_to_Boston_Sc.pdf,"September 22, 2000",FDA CDRH to Boston Sc,2000
FDA-2000-P-0412-0019_Interim_Response_Letter_from_FDA_CDER_to_Arnall_Go.pdf,"May 23, 2000",FDA CDER to Arnall Go,2000
FDA-2000-P-0755-0001_30_Day_Response_Letter_from_FDA_CFSAN_to_Arnall_Go.pdf,"May 6, 2024",FDA CFSAN to Arnall Go,2000
FDA-2000-P-0916-0003_Interim_Response_Letter_from_FDA_CFSAN_to_The_Huma.pdf,"March 10,200",FDA CFSAN to The Huma,2000
FDA-2000-P-0918-0001_Denial_Letter_from_CFSAN_to_Public_Voice_for_Food_.pdf,"January 18, 2017",CFSAN to Public Voice for Food,2000
FDA-2000-P-0940-0001_30_Day_Response_Letter_from_FDA_CFSAN_to_Consumer_.pdf,"May 6, 2024",FDA CFSAN to Consumer,2000
FDA-2000-P-1064-0003_Interim_Response_Letter_from_FDA_CFSAN_to_Mead_Joh.pdf,"February 3, 2000",FDA CFSAN to Mead Joh,2000
FDA-2000-P-1218-0003_FDA_CDER_Interim_Response_to_Public_Citizen_Health.pdf,"March 13,200",Public Citizen Health,2000
FDA-2000-P-1218-0005_Partial_Approval_Denial_from_FDA_CDER_to_Public_Ci.pdf,"October 30, 2008",FDA CDER to Public Ci,2000
FDA-2000-P-1373-0009_Interim_Response_Letter_from_FDA_CDER_to_American_.pdf,"November 1, 2000",FDA CDER to American,2000
FDA-2000-P-1375-0001_Response_Letter_from_FDA_CFSAN_to_Arnall_Golden___.pdf,"May 6, 2024",FDA CFSAN to Arnall Golden,2000
FDA-2000-P-1400-0023_Interim_Response_from_FDA_CDER_to_Genelabs_Technol.pdf,"April 19,2000",FDA CDER to Genelabs Technol,2000
FDA-2000-P-1558-0005_Approval_Letter_from_FDA_CDER_to_GensiaSicor_Pharm.pdf,"June 20,2000",FDA CDER to GensiaSicor Pharm,2000
FDA-2001-P-0030-0003_FDACDER_Response_to_Duramed_Pharmaceuticals__Inc__.pdf,7/9/02,"Duramed Pharmaceuticals, Inc.",2001
FDA-2001-P-0122-0007_Interim_Response_Letter_from_FDA_CFSAN_to_Ruth_Arm.pdf,7/27/01,Ruth Armstrong,2001
FDA-2001-P-0123-0029_FDA_Response_to_The_Center_for_Reproductive_Law___.pdf,6/9/06,The Center for Reproductive Law & Policy,2001
FDA-2001-P-0153-0001_FDA_Office_of_Legislation_Response_to_the_Honorabl.pdf,"January 29,2003",The Honorable Louise M. Slaughter (CI),2001
FDA-2001-P-0153-0002_FDA_CFSAN_Response_to_Heather_Brodie_Perry___Petit.pdf,03/15/10,Heather Brodie Perry,2001
FDA-2001-P-0154-0005_Interim_Response_from_FDA_CDER_to_ASTA_Medica__Inc.pdf,01/30/02,"Asta Medical, Inc.",2001
FDA-2001-P-0239-0006_Final_Response_from_FDA_CFSAN_to_Krislov___Associa.pdf,7/2/20,"Krislov & Associates, Ltd.",2001
FDA-2001-P-0452-0001_Approval_Letter_from_FDA_CDER_to_AA1_International.pdf,"August 30,2001",FDA CDER to AA1 International,2001
FDA-2001-P-0483-0008_FDA_Office_for_Policy_Response_to_the_Center_for_F.pdf,"June 21,2004",the Center for F,2001
FDA-2001-P-0521-0004_Interim_Response_Letter_from_FDA_CDER_to_Bennett__.pdf,"May 8,200",FDA CDER to Bennett,2001
FDA-2001-P-0524-0003_FDA_CDER_Interim_Response_to_Lawrence_D__Bernhardt.pdf,"June 22, 2012",Lawrence D  Bernhardt,2001
FDA-2002-P-0001-0005_Response_Letter_from_FDA_CDER_to_CorePharma_LLC.pdf,05/28/03,"Corepharma, Llc",2002
FDA-2002-P-0007-0002_Interim_Response_to_The_Weinberg_Group_Inc.pdf,"September 
16, 
2002",The Weinberg Group Inc,2002
FDA-2002-P-0007-0013_FDA_CDER_Response_to_The_Weinberg_Group_Inc_Denial.pdf,"June 1, 2004",The Weinberg Group Inc Denial,2002
FDA-2004-P-0001-0003_FDA_CBER_Interim_Response_to_Coalition_for_Mercury.pdf,02/04/05,Coalition for Mercury-free Drugs (CoMeD),2004
FDA-2004-P-0001-0004_FDA_CBER_Response_to_Coalition_for_Mercury_free_Dr.pdf,09/26/06,Coalition for Mercury-free Drugs (CoMeD),2004
FDA-2004-P-0001-0007_FDA_CBER_Response_to_Coalition_for_Mercury_Free_Dr.pdf,"October 21, 2006",Coalition for Mercury Free Dr,2004
FDA-2004-P-0001-0008_FDA_CBER_Response_to_Coalition_for_Mercury_Free_Dr.pdf,"March 12, 2007",Coalition for Mercury Free Dr,2004
FDA-2004-P-0006-0004_Response_Letter_from_FDA_CDER_to_Lachman_Consultan.pdf,04/14/05,Lachman Consultant Services Inc,2004
FDA-2004-P-0094-0003_FDA_CFSAN_Interim_Response_to_National_Starch_and_.pdf,12/29/04,National Starch And Chemical Company,2004
FDA-2004-P-0115-0004_REDACTED_Interim_Response_from_FDA_CDER_to_Barbara.pdf,11/05/15,Barbara E. Kennedy-Neslusan,2004
FDA-2004-P-0151-0003_FDA_CDER_Interim_Response_to_McNeil_Consumer___Spe(1).pdf,09/07/04,Mcneil Consumer & Specialty Pharmaceuticals,2004
FDA-2004-P-0151-0003_FDA_CDER_Interim_Response_to_McNeil_Consumer___Spe(2).pdf,09/07/04,Mcneil Consumer & Specialty Pharmaceuticals,2004
FDA-2004-P-0151-0003_FDA_CDER_Interim_Response_to_McNeil_Consumer___Spe.pdf,09/07/04,Mcneil Consumer & Specialty Pharmaceuticals,2004
FDA-2004-P-0158-0001_Response_Letter_from_FDA_CDRH_to_Roche_Diagnostics(1).pdf,1/28/04,Roche Diagnostics Corporation,2004
FDA-2004-P-0158-0001_Response_Letter_from_FDA_CDRH_to_Roche_Diagnostics(2).pdf,1/28/04,Roche Diagnostics Corporation,2004
FDA-2004-P-0158-0001_Response_Letter_from_FDA_CDRH_to_Roche_Diagnostics.pdf,1/28/04,Roche Diagnostics Corporation,2004
FDA-2004-P-0215-0038_FDA_CDER_Response_to_Hill_Dermaceuticals__Inc____P.pdf,"September 30, 2004",Hill Dermaceuticals  Inc    P,2004
FDA-2004-P-0279-0009_Final_Response_from_FDA_CFSAN_to_Center_for_Scienc.pdf,"April 5, 2024",FDA CFSAN to Center for Scienc,2004
FDA-2004-P-0294-0051_FDA_Response_to_Office_of_the_Attorney_General_Sta.pdf,"MAY 
2003",Office of the Attorney General Sta,2004
FDA-2005-P-0003-0003_FDA_CDER_to_Sandoz_Inc____Interim_Response.pdf,05/04/06,Sandoz Inc.,2005
FDA-2005-P-0007-0004_FDA_CVM_Interim_Response_to_the_Environmental_Defe.pdf,10/4/05,Environmental Defense,2005
FDA-2005-P-0007-0007_FDA_Response_to_the_Environmental_Defense___Petiti.pdf,11/7/11,Environmental Defense,2005
FDA-2005-P-0064-0006_FDA_CDER_Response_to_Illinois_Attorney_General_s_O.pdf,07/24/08,Gregory E. Skipper. M. D.,2005
FDA-2005-P-0070-0006_Neurological_Devices__Denial_of_Request_for_Change.pdf,"May 28, 1976",,2005
FDA-2005-P-0120-0003_FDA_CDER_Interim_Response_to_Shire_Pharmacueticals.pdf,04/17/06,Shire Pharmaceuticals Group,2005
FDA-2005-P-0120-0030_FDA_CDER_Response_to_Shire_Pharmaceuticals_Inc_Par.pdf,06/22/12,Shire Pharmaceuticals Group,2005
FDA-2005-P-0122-0003_Interim_Response_Letter_from_FDAFDA_CDER_to_Buchan.pdf,06/07/06,Buchanan Ingersoll PC,2005
FDA-2005-P-0192-0003_Interim_Response_to_Public_Citizen_s_Health_Resear.pdf,04/18/06,Public Citzen'S Health Research Group,2005
FDA-2005-P-0194-0002_Interim_Response_Letter_from_FDA_CDER_to_Warren_Ru.pdf,6/21/06,Warren Rucker,2005
FDA-2005-P-0194-0003_Response_letter_from_FDA_Warren_Rucker_Redacted.pdf,7/27/17,Warren Rucker,2005
FDA-2005-P-0196-0003_Interim_Response_from_FDA_CFSAN_to_the_Center_for_.pdf,6/5/06,Center For Science In The Public Interest (Cspi),2005
FDA-2005-P-0196-0056_FDA_Final_Response_to_CSPI_on_Sodium___2016_06_01.pdf,6/1/16,Center For Science In The Public Interest (Cspi),2005
FDA-2005-P-0198-0002_Interim_Response_Letter_from_FDA_CFSAN_to_Perricon.pdf,7/18/05,Perricone Juices,2005
FDA-2005-P-0221-0009_FDA_CDER_Response_to_UCSF_National_Center_of_Excel.pdf,4/19/13,Ucsf National Center Of Excellence In Women'S Health,2005
FDA-2005-P-0256-0001_Interim_Response_Letter_from_FDA_CDER__to_Public_C.pdf,10/4/05,Public Citizen,2005
FDA-2005-P-0266-0007_FDA_CDER_Response_Letter_to_Lachman_Consultant_Ser.pdf,10/1/09,"Lachman Consultant Services, Inc.",2005
FDA-2006-P-0282-0015_Response_Letter_from_FDA_CDER_to_The_States_of_Kan.pdf,3/22/21,"The States of Kansas, Minnesota, Vermont and Wisconsin from FDA CDER",2006
FDA-2006-P-0286-0004_FDA_CDER_to_Strides__Inc____Final_Response_to_Citi.pdf,2/2/10,Strides Inc.,2006
FDA-2006-P-0329-0003_Interim_Response_to_Mylan_Laboratories_Inc_.pdf,9/12/06,Mylan Laboratories Inc.,2006
FDA-2006-P-0331-0004_Interim_Response_from_FDA_CDER_to_Rakoczy_Molino_M.pdf,11/2/06,Rakoczy Molino Mazzochi Siwik Llp,2006
FDA-2007-P-0003-0009_FDA_CDER_Response_to_Purdue_Pharma_L_P____Letter.pdf,4/30/08,Purdue Pharma L.P.,2007
FDA-2007-P-0009-0006_FDA_Response_to_the_Honorable_Dianne_Feinstein__in.pdf,"April 28, 2008",the Honorable Dianne Feinstein  in,2007
FDA-2007-P-0009-0009_Interim_Response_to_The_National_Center_on_Addicti.pdf,5/6/11,The National Center On Addiction And Substance Abuse At Columbia University (Casa),2007
FDA-2007-P-0009-0010_FDA_CDER_Response_to_National_Center_on_Addiction_.pdf,7/17/2013,The National Center On Addiction And Substance Abuse At Columbia University (Casa),2007
FDA-2007-P-0010-0013_FDA_Response_to_Axcan_Scandipharm__Inc____Letter.pdf,1/30/08,"Axcan Scandipharm, Inc.",2007
FDA-2007-P-0011-0003_FDA_CDER_Interim_Response_to_Lachman_Consultant_Se.pdf,7/16/07,"Lachman Consultant Services, Inc",2007
FDA-2007-P-0011-0006_FDA_CDER_Response_Letter_to_Lachman_Consultant_Ser.pdf,1/27/08,"Lachman Consultant Services, Inc",2007
FDA-2007-P-0013-0003_FDA_CDRH_Interim_Response_to_Fuerst__Humphrey__Itt.pdf,4/29/08,"Fuerst, Humphrey, Ittleman, Pl",2007
FDA-2007-P-0055-0003_Interim_Response_from_FDA_CDER_to_Pharmaceutical_S.pdf,7/28/07,Pharmaceutical Scientist Inc.,2007
FDA-2007-P-0055-0007_Denial_Letter_from_FDA_CDER_to_Therapeutic_Protein.pdf,11/20/16,Pharmaceutical Scientist Inc.,2007
FDA-2007-P-0056-0003_FDA_CDER_Interim_Response_to_Greenberg_Traurig__LL.pdf,9/7/07,Greenberg Traurig Llp,2007
FDA-2007-P-0065-0005_Interim_Response_Letter_from_FDA_CDER_to_Ropes___G.pdf,9/26/07,"Ortho-Mcneil, Inc.",2007
FDA-2007-P-0065-0015_FDA_CDER_Response_to_Purdue_Pharma_LP_Kleinfeld_Ka.pdf,2/18/09,"Ortho-Mcneil, Inc.",2007
FDA-2007-P-0108-0003_FDA_CDER_Interim_Response_letter_to_the_University.pdf,9/3/07,University Of Florida,2007
FDA-2007-P-0109-0005_FDA_Response_to_People_for_the_Ethical_Treatment_o.pdf,"November 14, 2007",People for the Ethical Treatment o,2007
FDA-2007-P-0109-0006_FDA_Response_to_The_Honorable_Peter_J__Visclosky__.pdf,"November 14, 2007",The Honorable Peter J  Visclosky,2007
FDA-2007-P-0109-0007_FDA_Response_to_The_Honorable_Peter_J__Visclosky__.pdf,"November 14, 2007",The Honorable Peter J  Visclosky,2007
FDA-2007-P-0109-0012_FDA_OC_Response_Letter_to_Meyer_Glitzenstein_and_C.pdf,5/19/10,Mandatory Alternatives Petition Coalition,2007
FDA-2007-P-0110-0003_FDA_CDER_Interim_Response_to_the_Physicians_Commit.pdf,6/12/08,Physicians Committee For Responsible Medicine (Pcrm),2007
FDA-2007-P-0111-0008_FDA_Response_to_Astellas_Pharma_US__Inc____Letter.pdf,3/13/08,"Astellas Pharma Us, Inc.",2007
FDA-2007-P-0117-0011_FDA_CDRH_Interim_Response_to_Health_Care_Without_H.pdf,5/4/09,Health Care Without Harm (Sanford Lewis),2007
FDA-2007-P-0122-0052_FDA_CFSAN_Interim_Response_to_Compassion_Over_Kill.pdf,"February 21, 2007",Compassion Over Kill,2007
FDA-2007-P-0122-0058_FDA_CFSAN_Response_to_Compassion_Over_Killing_and_.pdf,"June 18,2003",Compassion Over Killing and,2007
FDA-2007-P-0123-0009_FDA_Response_to_Mutual_Pharmaceutical_Company__Inc.pdf,4/17/08,"United Research Laboratories, Inc., Mutual Pharmaceutical Company, Inc.",2007
FDA-2007-P-0128-0003_FDA_CDER_Interrim_Response_to_King_Pharmaceuticals.pdf,3/24/08,"King Pharmaceuticals, Inc.",2007
FDA-2007-P-0130-0020_Denial_Letter_Response_to_National_Toxic_Encephalo.pdf,9/29/14,National Toxic Encephalopathy Foundation,2007
FDA-2007-P-0168-0013_FDA_CBER_Interim_Response_to_CareToLive___Letter.pdf,1/17/08,Caretolive,2007
FDA-2007-P-0168-0049_FDA_CBER_Response_to_Bellinger___Donahue__CareToLi.pdf,1/17/08,Bellinger   Donahue  CareToLi,2007
FDA-2007-P-0169-0006_FDA_to_Solvay_Pharmaceuticals__Inc____Response_Let.pdf,4/25/08,"Unimed Pharmaceuticals, Inc.",2007
FDA-2007-P-0170-0008_FDA_CDER_Interim_Response_to_Teva_Pharmaceuticals_.pdf,2/7/08,Teva Pharmaceuticals Usa,2007
FDA-2007-P-0170-0009_FDA_CDER_Response_to_Teva_Pharmaceuticals_USA___Pe.pdf,3/12/08,Teva Pharmaceuticals Usa,2007
FDA-2007-P-0171-0003_FDA_CDER_tp_Warner_Chilcott__Inc____Interim_Respon.pdf,10/9/07,Warner Chilcott Inc.,2007
FDA-2007-P-0178-0065_FDA_CFSAN_Interim_Response_to_John_Edwards_Erb___L.pdf,11/5/08,John Edward Erb,2007
FDA-2007-P-0180-0003_FDA_Response_to_the_Honorable_Steve_Israel___Answe.pdf,"February 13,2008",the Honorable Steve Israel   Answe,2007
FDA-2007-P-0180-0007_FDA_CDER_Interim_Response_to_Covington___Burling__.pdf,4/23/08,The Alliance Against Alveolar Soft Part Sarcoma And The Sarcoma Foundation Of America,2007
FDA-2007-P-0180-0008_FDA_Response_to_the_Honorable_Patrick_J__Kennedy__.pdf,"February 11,2008",the Honorable Patrick J  Kennedy,2007
FDA-2007-P-0180-0009_FDA_Response_to_the_Honorable_Edolphus__Ed__Towns_.pdf,"January 8,2008",the Honorable Edolphus  Ed  Towns,2007
FDA-2007-P-0180-0012_FDA_Response_to_the_Honorable_Orrin_G__Hatch__M_Or.pdf,"October 26, 2007",the Honorable Orrin G  Hatch  M Or,2007
FDA-2007-P-0180-0013_FDA_Response_to_the_Honorable_Tim_Ryan___Answer_.pdf,"October 26, 2007",the Honorable Tim Ryan   Answer,2007
FDA-2007-P-0180-0014_FDA_Response_to_the_Honorable_Richard_G__Lugar__S_.pdf,"October 26, 2007",the Honorable Richard G  Lugar  S,2007
FDA-2007-P-0180-0015_FDA_Response_to_the_Honorable_Mitch_McConnell__S_M.pdf,"October 26, 2007",the Honorable Mitch McConnell  S M,2007
FDA-2007-P-0180-0016_FDA_Response_to_the_Honorable_Richard_G__Lugar__E_.pdf,"October 26, 2007",the Honorable Richard G  Lugar  E,2007
FDA-2007-P-0180-0017_FDA_Response_to_the_Honorable_Richard_G__Lugar__M_.pdf,"October 26, 2007",the Honorable Richard G  Lugar  M,2007
FDA-2007-P-0180-0018_FDA_Response_to_the_Honorable_Olympia_J__Snowe__G_.pdf,"October 26, 2007",the Honorable Olympia J  Snowe  G,2007
FDA-2007-P-0180-0019_FDA_Response_to_Mr__Gerald_A__Cormier__Jr____Lette.pdf,"October 26, 2007",Mr  Gerald A  Cormier  Jr    Lette,2007
FDA-2007-P-0180-0020_FDA_Response_Letter_to_The_Honorable_Steve_Israel_.pdf,"March 25, 2009",The Honorable Steve Israel,2007
FDA-2007-P-0181-0004_FDA_CDER_Interim_Response_letter_to_Charles_E__Web.pdf,8/26/07,Charles E. Weber,2007
FDA-2007-P-0181-0014_FDA_CDER_Final_response_letter_to_Charles_E__Weber.pdf,2/6/12,Charles E. Weber,2007
FDA-2007-P-0184-0005_FDA_Response_to_Judy_Slome_Cohain___Citizen_Petiti.pdf,8/11/08,Judy Slome Cohain,2007
FDA-2007-P-0186-0005_FDA_CDER_Interim_Response_to_Kleinfeld_Kaplan_and_.pdf,9/7/07,Purdue Pharma L.P.,2007
FDA-2007-P-0186-0008_FDA_CDER_Response_to_Kleinfeld_Kaplan_and_Becker_L.pdf,2/18/09,Purdue Pharma L.P.,2007
FDA-2007-P-0188-0003_Interim_Response_Letter_from_FDA_CDER_to_Beckloff_.pdf,6/25/08,"Beckloff Associates, Inc.",2007
FDA-2007-P-0190-0003_FDA_CDER_Interim_Response_to_Public_Citizen_s_Heal.pdf,7/30/07,Public Citizen's Health Research Group,2007
FDA-2007-P-0232-0003_FDA_CBER_Interim_Response_to_the_Coalition_for_Mer.pdf,2/8/08,Coalition For Mercury-Free Drugs (Comed),2007
FDA-2007-P-0232-0004_FDA_OC_Response_to_the_Coalition_for_Mercury_Free_.pdf,11/21/08,Coalition For Mercury-Free Drugs (Comed),2007
FDA-2007-P-0234-0004_FDA_CDER_Interim_Response_to_Terence_J_Mix.pdf,5/28/08,"Terence J. Mix, Esq.",2007
FDA-2007-P-0234-0006_FDA_CDER_Response_Letter_to_Terence_J_Mix_Esq_Peti.pdf,9/8/09,"Terence J. Mix, Esq.",2007
FDA-2007-P-0234-0014_FDA_OC_to_Terence_J__Mix__Esq____Denial_of_Petitio.pdf,3/8/12,"Terence J. Mix, Esq.",2007
FDA-2007-P-0234-0017_FDA_CDER_Interim_Response_to_Terence_J__Mix.pdf,"NOVEMBER 26, 2007",Terence J  Mix,2007
FDA-2007-P-0236-0003_Interim_Response_letter_from_FDA_CDER_to_Foley___L.pdf,9/20/07,Three-Laboratory Consortium,2007
FDA-2007-P-0243-0006_Final_Response_Letter_to_Michael_J__Dochniak.pdf,7/14/20,Michael J. Dochniak,2007
FDA-2007-P-0245-0003_FDA_CDER_Interim_Response_to_Perdue_Pharma_L_P____.pdf,12/6/07,Purdue Pharma L.P.,2007
FDA-2007-P-0248-0004_Interim_Response_Letter_from_FDA_CDER_to_Cornersto.pdf,2/7/08,Cornerstone Regulatory,2007
FDA-2007-P-0248-0006_Final_Response_Letter_from_FDA_CDER_to_Cornerstone.pdf,9/9/15,Cornerstone Regulatory,2007
FDA-2007-P-0250-0003_FDA_Response_to_Kendle_International___Letter.pdf,3/13/08,"Sun Pharmaceuticals, Ltd.",2007
FDA-2007-P-0292-0003_FDA_CFSAN_Response_to_Prolacta_Bioscience___Petiti.pdf,3/19/09,Prolacta Bioscience,2007
FDA-2007-P-0294-0002_FDA_CDER_Interim_Response_to_Arnold___Porter__LLP_.pdf,3/13/08,Takeda Pharmaceuticals North America,2007
FDA-2007-P-0299-0002_Interim_Response_Letter_from_FDA_CDER_to_Clinical_.pdf,12/26/07,Clinical And Laboratory Standards Institute (CLSI),2007
FDA-2007-P-0300-0003_FDA_Response_to_AAIPharma___Letter.pdf,2/19/08,AAIPharma,2007
FDA-2007-P-0339-0003_Interim_Response_to_Anil_K__Mandal__M_D__.pdf,2/13/08,"Anil K. Mandal, M.D.",2007
FDA-2007-P-0339-0004_FDA_CDER_to_Anil_K__Mandal__M_D____Peititon_Denial.pdf,12/14/10,"Anil K. Mandal, M.D.",2007
FDA-2007-P-0345-0004_FDA_CDER_Interim_Response_to_HellerEhrman_LLP___Le.pdf,3/17/08,Hellerehrman Llp,2007
FDA-2007-P-0346-0011_FDA_CDER_Interim_Response_to_Palomar_College___Let.pdf,10/27/2010,"Richard Sauerheber, Palomar College",2007
FDA-2007-P-0346-0135_Agency_Response_Letter_to__Richard_Sauerheber__Ph_.pdf,10/27/2010,Richard Sauerheber  Ph,2007
FDA-2007-P-0349-0007_FDA_Response_to_Engel___Novitt__LLP___Letter.pdf,3/19/08,"Engel & Novitt, Llp",2007
FDA-2007-P-0352-0002_FDA_CDER_Interim_Response_to_Sheppard__Mullin__Ric.pdf,11/19/07,Sheppard Mullin Richter & Hampton Llp,2007
FDA-2007-P-0353-0001_Letter_from_FDA_CDER_Interim_Response_to_JRRapoza_.pdf,7/25/07,"Jrrapoza Associates, Inc.",2007
FDA-2007-P-0401-0003_FDA_CDER_Interim_Response_to_Public_Citizen_s_Heal.pdf,12/10/07,Public Citizen Health Research Group,2007
FDA-2007-P-0403-0003_FDA___Steven_D__Vaughn___Final_Response___Approval.pdf,11/27/07,Norbrook Inc.,2007
FDA-2007-P-0404-0005_FDA_CFSAN_Interim_Response_to_Ellen_M_Ashworth_Red.pdf,7/27/07,Ellen M. Ashworth,2007
FDA-2007-P-0404-0006_FDA_CFSAN_Response_to_Ellen_M_Ashworth_Redacted.pdf,5/29/20,Ellen M. Ashworth,2007
FDA-2007-P-0412-0005_Final_Response_Letter_from_FDA_CFSAN_to_Cary_Smith.pdf,9/13/17,C Smith,2007
FDA-2007-P-0413-0003_FDA_CDER_Response_Letter_to_the_Pharmacists_Planni.pdf,"March 30,2007",the Pharmacists Planni,2007
FDA-2007-P-0413-0004_FDA_CDER_Interim_Response_to_the_Pharmacists_Plann.pdf,8/17/07,"Pharmacists Planning Service, Inc.",2007
FDA-2007-P-0413-0007_FDA_CDER_Response_to_the_Pharmacists_Planning_Serv.pdf,6/12/13,"Pharmacists Planning Service, Inc.",2007
FDA-2007-P-0415-0003_FDA_CDER_Interim_Response_to_HARMD__Inc____Letter.pdf,12/12/07,Harmd (Helping America Reduce Methadone Deaths),2007
FDA-2007-P-0416-0004_Interim_Response_Letter_from_FDA_CDER_to_Sapna_Loh.pdf,5/15/08,Sapna Lohiya (Royal Medical Group),2007
FDA-2007-P-0416-0010_Interim_Response_Letter_from_FDA_CDER_to_Sapna_Loh.pdf,"November 20, 2007",FDA CDER to Sapna Loh,2007
FDA-2007-P-0483-0006_Denial_Response_Letter_from_FDA_CDER_to_Matrix_Lab.pdf,4/25/23,"Matrix Laboratories, Inc.",2007
FDA-2008-P-0278-0003_FDA_CDER_Interim_Response_to_Regulus_Pharmaceutica.pdf,5/2/08,Regulus Pharmaceutica,2008
FDA-2008-P-0279-0007_FDA_CDER_Interim_Response_to_Pedinol_Pharmacal__In.pdf,5/6/08,Pedinol Pharmacal  In,2008
FDA-2008-P-0284-0005_FDA_CDER_Interim_Response_to_Bedford_Laboratories_.pdf,5/9/08,Bedford Laboratories,2008
FDA-2008-P-0291-0003_FDA_CDER_Interim_Response_to_PRN_Publishing___Lett.pdf,5/13/08,PRN Publishing   Lett,2008
FDA-2008-P-0296-0018_FDA_CDER_Interim_Response_to_Public_Citizen___Lett.pdf,6/12/08,Public Citizen   Lett,2008
FDA-2008-P-0296-0023_FDA_CDER_response_to_Public_Citzen_Health_Research.pdf,6/12/08,Public Citzen Health Research,2008
FDA-2008-P-0300-0003_FDA_CDER_Interim_Response_to_Salix_Pharmaceuticals.pdf,"May 14, 2008",Salix Pharmaceuticals,2008
FDA-2008-P-0320-0003_FDA_CDER_Interim_Response_to_Lachman_Consultant_Se.pdf,6/2/08,Lachman Consultant Se,2008
FDA-2008-P-0320-0005_Final_Response_from_FDA_CDER_to_Lachman_Consultant.pdf,"May 28, 2008",FDA CDER to Lachman Consultant,2008
FDA-2008-P-0330-0003_FDA_CDER_Interim_Response_to_Rakoczy_Molino_Mazzoc.pdf,6/11/08,Rakoczy Molino Mazzoc,2008
FDA-2008-P-0330-0005_FDA_CDER_Response_to_Rakoczy_Molino_Mazzochi_Siwik.pdf,"May 30, 2008",Rakoczy Molino Mazzochi Siwik,2008
FDA-2008-P-0333-0003_Interim_Response_Letter_from_FDA_CDER_to_Michael_W.pdf,6/11/08,FDA CDER to Michael W,2008
FDA-2008-P-0333-0024_Response_Letter_from_FDA_CDER_to_Michael_Weber.pdf,MAY 10 2010,FDA CDER to Michael Weber,2008
FDA-2008-P-0336-0003_CFSAN_ONLDS_Interim_Response_to_Patton_Boggs_LLP__.pdf,6/12/08,Patton Boggs LLP,2008
FDA-2008-P-0346-0003_FDA_Office_of_Policy_Interim_Response_to_Jacob_S__.pdf,"June 4, 2008",Jacob S,2008
FDA-2008-P-0347-0005_Redacted_Response__Letter_from__JoAnne_Tobacman.pdf,"September 08, 2008",JoAnne Tobacman,2008
FDA-2008-P-0347-0008_Cornucopia_Institute_Response_to_FDA_CFSAN_Letter.pdf,"March 15, 2013",FDA CFSAN Letter,2008
FDA-2008-P-0349-0007_Interim_Response_Letter_from_FDA_CFSAN_to_the_Cent.pdf,"December 12, 2008",FDA CFSAN to the Cent,2008
FDA-2008-P-0358-0007_Interim_Response_Letter_from_FDA_CDER_to_James_P__.pdf,6/26/08,FDA CDER to James P,2008
FDA-2008-P-0363-0012_FDA_CBER_Interim_Response_to_Nordic_Cryobank_ApS__.pdf,"June 19,
2008",Nordic Cryobank ApS,2008
FDA-2008-P-0363-0013_FDA_CBER_Interim_Response_to_Nordic_Cryobank_ApS__.pdf,"January 8, 2009",Nordic Cryobank ApS,2008
FDA-2008-P-0368-0007_FDA_CDER_Interim_Response_to_ISTA_Pharmaceuticals_.pdf,7/1/08,ISTA Pharmaceuticals,2008
FDA-2008-P-0380-0004_FDA_CDER_Interim_Response_to_National_Association_.pdf,7/8/08,National Association,2008
FDA-2008-P-0384-0004_FDA_CVM_Interim_Response_to_Laurie_Rentas___Letter.pdf,7/3/08,Laurie Rentas   Letter,2008
FDA-2008-P-0404-0003_Final_Response_Letter_from_FDA_CDER_to_Strides_Arc.pdf,"July 14, 2008",FDA CDER to Strides Arc,2008
FDA-2008-P-0412-0003_FDA_CDER_Interim_Response_To_Foley___Lardner__LLP_.pdf,7/18/08,Foley   Lardner  LLP,2008
FDA-2008-P-0412-0006_FDA_CDER_Response_to_Foley___Lardner_LLP___Letter.pdf,"July 15, 2008",Foley   Lardner LLP   Letter,2008
FDA-2008-P-0421-0004_FDA_CDER_Response_to_Lachman_Consultant_Services__.pdf,"July 23, 2008",Lachman Consultant Services,2008
FDA-2008-P-0431-0004_FDA_CDER_to_Crixmor_LLC___Response_Letter.pdf,"July 25, 2008",Crixmor LLC   Response Letter,2008
FDA-2008-P-0442-0004_FDA_CDER_Interim_Response_to_Mutual_Pharmaceutical.pdf,8/7/08,Mutual Pharmaceutical,2008
FDA-2008-P-0443-0003_FDA_CDER_Interim_Response_to_PharmaForce__Inc____L.pdf,8/8/08,PharmaForce  Inc    L,2008
FDA-2008-P-0443-0005_FDA_CDER_Response_to_PharmaForce__Inc____Letter.pdf,8/8/08,PharmaForce  Inc    Letter,2008
FDA-2008-P-0444-0004_FDA_CDRH_Interim_Response_to_Codonics__Inc____Lett.pdf,11/7/08,Codonics  Inc    Lett,2008
FDA-2008-P-0452-0007_Interim_Response_Letter_from_FDA_CFSAN_to_The_West.pdf,8/14/08,FDA CFSAN to The West,2008
FDA-2008-P-0459-0004_FDA_CFSAN_Response_to_Deep_Seawater_International_.pdf,"August 8, 2008",Deep Seawater International,2008
FDA-2009-P-0003-0004_FDA_CFSAN_Response_to_Organic_Pastures_Dairy_Compa.pdf,1/9/09,Organic Pastures Dairy Compa,2009
FDA-2009-P-0004-0003_FDA_CDER_Interim_Response_to_Therapeutic_Proteins_.pdf,"January 7, 2009",Therapeutic Proteins,2009
FDA-2009-P-0038-0006_FDA_CDER_Response_to_Mayne_Pharma_International_Pt.pdf,"January 29, 2009",Mayne Pharma International Pt,2009
FDA-2009-P-0039-0007_FDA_CDER_Interim_Response_to_Parents_United_for_Ph.pdf,"January 30, 2009",Parents United for Ph,2009
FDA-2009-P-0059-0006_FDA_CDER_Response_to_Eurand_Pharmaceuticals__Inc__.pdf,"February 9, 2009",Eurand Pharmaceuticals  Inc,2009
FDA-2009-P-0077-0004_Response_Letter_from_FDA_CDER_to_Arent_Fox_LLP.pdf,02/13/2009,FDA CDER to Arent Fox LLP,2009
FDA-2009-P-0081-0004_FDA_CDER_Response_to_Medicis_Pharmaceuticals_Corpo.pdf,"January 29, 2009",Medicis Pharmaceuticals Corpo,2009
FDA-2009-P-0088-0003_FDA_CDER_Interim_Response_to_Lachman_Consultant_Se.pdf,"February 17, 2009",Lachman Consultant Se,2009
FDA-2009-P-0089-0003_FDA_CDER_Interim_Response_to_Novo_Nordisk___Letter.pdf,2/20/09,Novo Nordisk   Letter,2009
FDA-2009-P-0094-0003_Interim_Response_Letter_from_FDA_to_American_Assoc.pdf,"February 18, 2009",FDA to American Assoc,2009
FDA-2009-P-0094-0004_Final_Response_from_FDA_CDER_to_American_Associati.pdf,"May 26, 2022",FDA CDER to American Associati,2009
FDA-2009-P-0103-0003_FDA_CDER_Response_to_Hoffmann_LaRoche_Inc___and_Ro.pdf,"January 29, 2009",Hoffmann LaRoche Inc   and Ro,2009
FDA-2009-P-0105-0003_Interim_Response_to_Williams_Kherkher_Hart_Boundas.pdf,"February 17,2009",Williams Kherkher Hart Boundas,2009
FDA-2009-P-0107-0004_Approval_Letter_from_FDA_CDER_to_APP_Pharmaceutica.pdf,"February 23, 2009",FDA CDER to APP Pharmaceutica,2009
FDA-2009-P-0110-0003_FDA_CVM_Response_to_PetMedicus_Laboratories__Inc__.pdf,"February 24, 2009",PetMedicus Laboratories  Inc,2009
FDA-2009-P-0111-0003_FDA_CDRH_Interim_Response_to_Thomas_J__Quinn___Let.pdf,"August 27, 2009",Thomas J  Quinn   Let,2009
FDA-2009-P-0116-0003_FDA_CFSAN_Response_to_Vistaurum_Corporation___Elec.pdf,"April 16, 2009",Vistaurum Corporation   Elec,2009
FDA-2009-P-0116-0004_Vistaurum_Corporation_Response_to_FDA_CFSAN___Elec.pdf,"April 17, 2009",FDA CFSAN   Elec,2009
FDA-2009-P-0117-0003_Final_Response_Letter_from_FDA_CDRH_to_Kimberly_Cl.pdf,"October 16, 2017",FDA CDRH to Kimberly Cl,2009
FDA-2009-P-0120-0003_FDA_CDER_Response_to_Stiefel_Laboratories__Inc____.pdf,"January 29, 2009",Stiefel Laboratories  Inc,2009
FDA-2009-P-0122-0003_FDA_to_K__Paul_Stoller__MD__FACM___Interim_Respons.pdf,"February 27,2009",K  Paul Stoller  MD  FACM   Interim Respons,2009
FDA-2009-P-0123-0011_FDA_CDER_Response_to_Auxilium_Pharmaceuticals__Inc.pdf,"February 27, 2009",Auxilium Pharmaceuticals  Inc,2009
FDA-2010-P-0045-0038_Memo_and_Combined_Responses_to_Dr_Edlich_Citizen_P.pdf,"October 2, 
2008",Dr Edlich Citizen P,2010
FDA-2010-P-0050-0004_Interim_Response_to_Health_Research_Group_Public_C.pdf,"January 20, 2010",Health Research Group Public C,2010
FDA-2010-P-0052-0020_Memo_and_Combined_Responses_to_Dr_Edlich_Citizen_P.pdf,"October 2, 
2008",Dr Edlich Citizen P,2010
FDA-2010-P-0076-0006_Interim_Response_to_Roxane_Laboratories__Inc_.pdf,"February 3, 2010",Roxane Laboratories  Inc,2010
FDA-2010-P-0105-0032_Interim_Response_to_National_Chicken_Council__NCC_.pdf,"August 17,2010",National Chicken Council  NCC,2010
FDA-2010-P-0114-0007_FDA_CDER_Response_to_McGuff_Pharmaceuticals_Inc_Pe.pdf,"February 25, 2010",McGuff Pharmaceuticals Inc Pe,2010
FDA-2011-P-0022-0004_FDA_Interim_Response_to_Waxler_Regulatory_Consulta.pdf,1/14/11,Waxler Regulatory Consulta,2011
FDA-2011-P-0022-0013_Reconsideration_Denial_letter_from_the_FDA_to_Waxl.pdf,"July 31, 2014",the FDA to Waxl,2011
FDA-2011-P-0025-0003_FDA_CDER_Interim_Response_to_Olsson_Frank_Weeda_Te.pdf,1/14/11,Olsson Frank Weeda Te,2011
FDA-2011-P-0047-0012_FDA_CDER_Interim_Response_to_InvaGen_Pharmaceutica.pdf,"January 18, 2011",InvaGen Pharmaceutica,2011
FDA-2011-P-0047-0013_Response_Letter_from_FDA_CDER.pdf,2/8/11,FDA CDER,2011
FDA-2011-P-0055-0012_FDA_CDER_Interim_Response_to_C__Allen_Black__Ph_D_.pdf,"January 19, 2011",C  Allen Black  Ph D,2011
FDA-2011-P-0059-0003_Interim_Response_Letter_from_FDA_CDER_to_Hospira_I.pdf,"January 26, 2011",FDA CDER to Hospira I,2011
FDA-2011-P-0064-0034_Interim_Response_to_Barbara_L__Maw__P_C___Letter.pdf,"January 28, 2011",Barbara L  Maw  P C   Letter,2011
FDA-2011-P-0081-0011_Agency_Response_to_Armenpharm_Ltd.pdf,"February 8, 2011",Armenpharm Ltd,2011
FDA-2011-P-0081-0012_Notice_of_Approval_Suspension_for_ANDA_060851.pdf,"December 3, 2015",,2011
FDA-2011-P-0081-0014_Response_to_CDER_for_Suspension_of_ANDA_Approval_f.pdf,"December 17, 2015",CDER for Suspension of ANDA Approval f,2011
FDA-2011-P-0081-0021_Armenpharm__Ltd___Suspension_of_Approval_of_an_Abb.pdf,"September 21, 2016",,2011
FDA-2011-P-0083-0003_Interim_Response_Letter_from_FDA_CDRH_to_Pharmacis.pdf,"February 3, 2011",FDA CDRH to Pharmacis,2011
FDA-2011-P-0086-0011_Agency_Response_Letter_to_Risperidone_Staleness.pdf,2/23/11,Risperidone Staleness,2011
FDA-2011-P-0086-0012_Agency_Response_Letter_to_Risperidone.pdf,"June 15, 2022",Risperidone,2011
FDA-2011-P-0150-0003_Interim_Response_to_SureTek_Medical___Letter.pdf,4/11/11,SureTek Medical   Letter,2011
FDA-2011-P-0150-0004_Final_Response_from_FDA_CDRH_to_SureTek_Medical.pdf,4/11/11,FDA CDRH to SureTek Medical,2011
FDA-2011-P-0173-0003_Interim_Response_to_Hospira__Inc_.pdf,"March 18, 2011",Hospira  Inc,2011
FDA-2011-P-0173-0004_FDA_CDER_to_Hospira__Inc____Petiton_Approval.pdf,"January 25, 2011",Hospira  Inc    Petiton Approval,2011
FDA-2011-P-0213-0014_Interim_Response_to_CSL_Behring___Letter.pdf,"March 28, 2011",CSL Behring   Letter,2011
FDA-2011-P-0226-0003_Interim_Response_to_Hyman__Phelps___McNamara__P_C_.pdf,"March 30, 2011",Hyman  Phelps   McNamara  P C,2011
FDA-2011-P-0226-0004_FDA_CDER_response_to_Hyman__Phelps___McNamara__P_C.pdf,"March 30, 2011",Hyman  Phelps   McNamara  P C,2011
FDA-2011-P-0227-0003_FDA_CDER_Interim_Response_to_Intendis_Inc_Foley_an.pdf,"March 30, 2011",Intendis Inc Foley an,2011
FDA-2011-P-0227-0004_FDA_CDER_Interim_Response_to_Intendis_Inc_Foley_an.pdf,"March 30, 2011",Intendis Inc Foley an,2011
FDA-2011-P-0276-0005_Interim_Response_to_Environmental_Working_Group___.pdf,"September 6, 2011",Environmental Working Group,2011
FDA-2011-P-0291-0003_Interim_Response_to_Actavis_Inc____Letter.pdf,"April 21, 2011",Actavis Inc    Letter,2011
FDA-2011-P-0292-0003_Interim_Response_to_Actavis_Inc____Letter.pdf,OCT 17 2011,Actavis Inc    Letter,2011
FDA-2011-P-0297-0005_Interim_Response_to_Public_Citizen_s_Health_Resear.pdf,"April 25, 2011",Public Citizen s Health Resear,2011
FDA-2011-P-0297-0006_FDA_CDER_Response_to_Public_Citizens_Health_Resear.pdf,5/5/11,Public Citizens Health Resear,2011
FDA-2011-P-0331-0006_Interim_response_to_Citzen_Health_Research_Group__.pdf,"May 2,2011",Citzen Health Research Group,2011
FDA-2011-P-0331-0007_FDA_CDRH_final_response_to_Public_Citzen_Health_Re.pdf,"October 16, 2017",Public Citzen Health Re,2011
FDA-2011-P-0347-0004_FDA_CDER_Response_to_Lachman_Consultant_Services_I.pdf,"May 10, 2011",Lachman Consultant Services I,2011
FDA-2011-P-0355-0021_FDA_CDRH_to_Mela_Science_Inc__Response_Letter.pdf,"November 3,2011",Mela Science Inc  Response Letter,2011
FDA-2011-P-0356-0023_FDA_CTP_Interim_Response_to_the_Center_for_Tobacco.pdf,5/31/11,the Center for Tobacco,2011
FDA-2011-P-0407-0006_FDA_CFSAN_Interim_Response_to_the_Center_for_Scien.pdf,"November 22, 2011",the Center for Scien,2011
FDA-2011-P-0407-0007_FDA_CFSAN_Response_to_the_Center_for_Science_in_th.pdf,"March 19, 2012",the Center for Science in th,2011
FDA-2011-P-0438-0004_Interim_Response_to_Public_Citizen_Health_Research.pdf,"May 4,2011",Public Citizen Health Research,2011
FDA-2011-P-0438-0006_FDA_CDRH_Response_to_Public_Citizen_Health_Researc.pdf,6/2/11,Public Citizen Health Researc,2011
FDA-2011-P-0440-0003_Interim_Response_to_Patton_Boggs_LLP_National_Yogu.pdf,6/21/11,Patton Boggs LLP National Yogu,2011
FDA-2011-P-0440-0004_FDA_CFSAN_Response_to_Patton_Boggs__LLP__National_.pdf,"June 1, 2018",Patton Boggs  LLP  National,2011
FDA-2011-P-0448-0003_FDA_CVM_Interim_Response_to_Earthjustice_November_.pdf,"November 21,201",Earthjustice November,2011
FDA-2011-P-0450-0004_Interim_Response_to_MSMB_Capital_Management_LLC___.pdf,"June 7, 2011",MSMB Capital Management LLC,2011
FDA-2011-P-0455-0004_Interim_Response_to_Public_Citizen_s_Health_Resear.pdf,"June 7, 2011",Public Citizen s Health Resear,2011
FDA-2011-P-0458-0003_Interim_Response_to_Personal_Care_Products_Council.pdf,"June 8, 2011",Personal Care Products Council,2011
FDA-2011-P-0460-0004_Response_Letter_from_FDA_CDER_to_Lachman_Consultan.pdf,"June 8, 2011",FDA CDER to Lachman Consultan,2011
FDA-2011-P-0473-0004_Interim_Response_to_Varam_Inc__c_o__KVK_Tech_Inc__.pdf,"June 16, 2011",Varam Inc  c o  KVK Tech Inc,2011
FDA-2011-P-0474-0005_Interim_Response_to_Kalypto_Medical__Inc___DuVal__.pdf,"December 5, 2011",Kalypto Medical  Inc   DuVal,2011
FDA-2011-P-0479-0003_Interim_Response_Letter_from_FDA_CDRH_to_Dr__S__Al.pdf,"June 6, 2011",FDA CDRH to Dr  S  Al,2011
FDA-2011-P-0482-0003_FDA_CDER_Interim_Response_to_Novo_Nordisk_Inc.pdf,"June 17, 2011",Novo Nordisk Inc,2011
FDA-2011-P-0484-0004_Interim_Response_to_GotMercury__Turtle_Island_Rest.pdf,"June 20, 2011",GotMercury  Turtle Island Rest,2011
FDA-2011-P-0486-0003_Interim_Response_to_Winston___Strawn_LLP____Letter.pdf,"June 21, 2011",Winston   Strawn LLP    Letter,2011
FDA-2011-P-0488-0004_FDA_CDER_to_Sandoz__Inc____Response_Letter.pdf,7/18/11,Sandoz  Inc    Response Letter,2011
FDA-2011-P-0512-0005_Interim_Response_to_Ropes___Gray_LLPand_Sidley_Aus.pdf,"July 5,2011",Ropes   Gray LLPand Sidley Aus,2011
FDA-2011-P-0512-0014_Kalb_et_al_IU_Final_Rule_Response_3_26_18.pdf,"March 26, 2018",,2011
FDA-2011-P-0515-0003_Interim_Response_to_Pharmacists_Planning_Service__.pdf,"July 6, 2011",Pharmacists Planning Service,2011
FDA-2011-P-0537-0004_Interim_Response_to_Earthjustice_et_al__Letter.pdf,"July 5, 2011",Earthjustice et al  Letter,2011
FDA-2011-P-0537-0005_Denial_Letter_from_CFSAN_to_EARTHJUSTICE.pdf,"January 18, 2017",CFSAN to EARTHJUSTICE,2011
FDA-2011-P-0565-0003_FDA_2011_P_0565_CP_Response_final_.pdf,"August 15, 2011",,2011
FDA-2011-P-0573-0003_FDA_CTP_Interim_Response_to__J_Reynolds_Tobacco_Co.pdf,10/2/12,J Reynolds Tobacco Co,2011
FDA-2011-P-0580-0005_FDA_CDER_Response_to_Charles_Watson_Partial_Petiti.pdf,"August 2, 2011",Charles Watson Partial Petiti,2011
FDA-2011-P-0590-0003_Interim_Response_to_Kim_Witczak_and_William_Vaughn.pdf,"August 10, 2011",Kim Witczak and William Vaughn,2011
FDA-2011-P-0593-0003_FDA_2011_P_0593_CP_Response_final_.pdf,"August 15, 2011",,2011
FDA-2011-P-0596-0003_FDA_CDER_Interim_Response_to_Dr__Richard_M__Flemin.pdf,FEB 6 2012,Dr  Richard M  Flemin,2011
FDA-2011-P-0596-0009_FDA_CDER_Response_to_Dr_Richard_M_Fleming__Petitio.pdf,9/15/11,Dr Richard M Fleming  Petitio,2011
FDA-2011-P-0596-0015_Interim_Response_to_Dr_Richard_M__Fleming__Letter.pdf,9/15/11,Dr Richard M  Fleming  Letter,2011
FDA-2011-P-0604-0005_Interim_Response_to_Public_Citizen_s_Health_Resear.pdf,9/1/11,Public Citizen s Health Resear,2011
FDA-2011-P-0604-0006_Final_Response_from_FDA_CDER_to_Public_Citizen_s_H.pdf,"August 17, 2011",FDA CDER to Public Citizen s H,2011
FDA-2011-P-0606-0004_Interim_Response_to_Actavis__Inc____Letter.pdf,"August 18, 2011",Actavis  Inc    Letter,2011
FDA-2011-P-0610-0003_FDA_CDER_interim_response_to_Mayer_Brown_LLP__date.pdf,"August 19,2011",Mayer Brown LLP  date,2011
FDA-2011-P-0623-0003_FDA_CTP_Interim_Response_to_International_Premium_.pdf,9/2/11,International Premium,2011
FDA-2011-P-0637-0003_FDA_CDER_Interim_Response_to_Alliance_for_Natural_.pdf,9/12/11,Alliance for Natural,2011
FDA-2011-P-0637-0004_Response_Letter_to_Alliance_for_Natural_Health_fro.pdf,9/12/11,Alliance for Natural Health fro,2011
FDA-2011-P-0641-0005_FDA_CDRH_Interim_Response_to_Public_Citizen_Health.pdf,"February 10,2012",Public Citizen Health,2011
FDA-2011-P-0642-0003_Interim_Response_to_Center_for_Inquiry_and_the_Com.pdf,"August 29,2011",Center for Inquiry and the Com,2011
FDA-2011-P-0642-0016_Final_Response_from_FDA_CDER_to_Center_for_Inquiry.pdf,"August 26, 2011",FDA CDER to Center for Inquiry,2011
FDA-2011-P-0646-0003_Interim_Response_to_City_of_Philadephia_Department.pdf,"December 9, 2011",City of Philadephia Department,2011
FDA-2011-P-0646-0031_Interim_Response_Letter_from_FDA_CFSAN_to_Deparmen.pdf,"September 10,2015",FDA CFSAN to Deparmen,2011
FDA-2011-P-0657-0003_Interim_Response_Letter_from_FDA_CDER_to_National_.pdf,"September 2, 2011",FDA CDER to National,2011
FDA-2011-P-0660-0003_FDA_CDRH_interim_response_to_RegulatorPro_com.pdf,9/19/11,RegulatorPro com,2011
FDA-2011-P-0671-0004_Interim_Response_to_Beverly_Mikuriya__M_D___and_Wi.pdf,"September 9, 2011",Beverly Mikuriya  M D   and Wi,2011
FDA-2011-P-0671-0005_Final_Response_from_FDA_CDER_to_William_McPike__Es.pdf,"June 25, 1938",FDA CDER to William McPike  Es,2011
FDA-2011-P-0675-0006_Interim_Response_to_Public_Citizen_Health_Research.pdf,MAR 9 2012,Public Citizen Health Research,2011
FDA-2011-P-0675-0009_FDA_CDER_Response_to_Public_Citizen_Health_Researc.pdf,9/27/11,Public Citizen Health Researc,2011
FDA-2011-P-0696-0003_FDA_Office_of_Financial_Management_Interim_Respons.pdf,"September 20, 2011",,2011
FDA-2011-P-0696-0004_FDA_Response_to_Stat_Trade__Inc___Kleinfeld_Kaplan.pdf,"September 20,2011",Stat Trade  Inc   Kleinfeld Kaplan,2011
FDA-2011-P-0702-0003_FDA_CDER_Final_response_to_Warner_Chilcott__US___L.pdf,"September 23,2011",Warner Chilcott  US   L,2011
FDA-2011-P-0717-0003_Interim_Response_to_Cooley_LLP___Letter.pdf,"September 29, 2011",Cooley LLP   Letter,2011
FDA-2011-P-0725-0003_Interim_Response_to_Rush_University_Medical_Center.pdf,"October 4, 2011",Rush University Medical Center,2011
FDA-2011-P-0727-0004_Interim_Response_to_12TH_Man_Technologies___Letter.pdf,"October 6, 201",12TH Man Technologies   Letter,2011
FDA-2011-P-0741-0003_Interim_Response_to_Public_Citizens_Health_Researc.pdf,"October 11,2011",Public Citizens Health Researc,2011
FDA-2011-P-0744-0003_Interim_Response_to_Lachman_Consultant_Services_In.pdf,"October 12, 2011",Lachman Consultant Services In,2011
FDA-2011-P-0744-0004_Final_Response_letter_from_FDA_CDER_to_Lachman_Con.pdf,"October 12, 2011",FDA CDER to Lachman Con,2011
FDA-2011-P-0745-0004_FDA_CFSAN_Interim_Response_to_Natural_Resources_De.pdf,"June 25, 2012",Natural Resources De,2011
FDA-2011-P-0777-0003_Interim_Response_to_Institute_for_Health_Quality_a.pdf,"October 21,2011",Institute for Health Quality a,2011
FDA-2011-P-0777-0009_FDA_OC_Response_to__Institute_for_Health_Quality_a.pdf,10/31/11,Institute for Health Quality a,2011
FDA-2011-P-0798-0004_FDA_CDER_Interim_Response_to_Dr_S_Albert_Edwards_L.pdf,"November 1, 2011",Dr S Albert Edwards L,2011
FDA-2011-P-0820-0003_FDA_CDRH_Interim_Response_to_G_Scott_Crowther_PE_L.pdf,"November 8, 2011",G Scott Crowther PE L,2011
FDA-2011-P-0821-0005_Final_Response_Letter_from_FDA_CDER_to_Lachman_Con.pdf,"November 14, 2011",FDA CDER to Lachman Con,2011
FDA-2011-P-0823-0003_FDA_CDER_Response_to_AstraZeneca_Pharmaceuticals_L.pdf,"November 14,2011",AstraZeneca Pharmaceuticals L,2011
FDA-2011-P-0852-0003_FDA_CDER_Interim_Response_to_Dr__S_Albert_Edwards_.pdf,"November 21,2011",Dr  S Albert Edwards,2011
FDA-2011-P-0869-0004_FDA_CDER_Interim_Response_to_Hyman_Phelps_and_McNa.pdf,MAY 30 2012,Hyman Phelps and McNa,2011
FDA-2011-P-0869-0006_FDA_CDER_Response_to_Hyman_Phelps_and_McNamara_P_C.pdf,12/20/11,Hyman Phelps and McNamara P C,2011
FDA-2011-P-0923-0009_Interim_Response_to_Public_Citizen_Health_Research.pdf,"May 18,2012",Public Citizen Health Research,2011
FDA-2011-P-0923-0011_Public_Citizens_Health_Research_Group_Response_to_.pdf,"January 28, 2013",,2011
FDA-2011-P-0926-0004_Interim_Response_to_United_States_Pharmacopeial_Co.pdf,1/24/12,United States Pharmacopeial Co,2011
FDA-2011-P-0929-0003_FDA_CFSAN_Response_to_Caravan_Ingredients_Inc_Kell.pdf,"August 5, 2013",Caravan Ingredients Inc Kell,2011
FDA-2011-P-0931-0005_Upsher_Smith_Laboratories_re_Approval_Requirements.pdf,1/25/12,"Upsher-Smith Laboratories, Inc (Zuckerman Spaeder LLP)",2011
FDA-2012-P-0052-0003_Interim_Response_to_Lannett_Company__Inc____Letter.pdf,"January 12,2012",Lannett Company  Inc    Letter,2012
FDA-2012-P-0053-0004_Interim_Response_to_Alston_and_Bird_LLP_Letter.pdf,"January 12, 2012",Alston and Bird LLP Letter,2012
FDA-2012-P-0119-0006_Interim_Response_to_Mario_Morais_Letter.pdf,"February 3, 2012",Mario Morais Letter,2012
FDA-2012-P-0119-0008_Redacted_Partial_Approval_Partial_Denial_Response_.pdf,"December 5, 2011",,2012
FDA-2012-P-0119-0011_FDA_Response_to_joint_appeal_in_FDA_2012_P_0119_an.pdf,"January 19, 2017",joint appeal in FDA 2012 P 0119 an,2012
FDA-2012-P-0146-0005_Denial_letter_from_CFSAN_FDA_to_Center_for_Science.pdf,"February 9, 2012",CFSAN FDA to Center for Science,2012
FDA-2012-P-0189-0005_Interim_Response_to_Alston_and_Bird_LLP_Lannett_Co.pdf,"February 24, 2012",Alston and Bird LLP Lannett Co,2012
FDA-2012-P-0272-0006_Response_Letter_from_FDA_CDER_to_Actavis_Inc_.pdf,"March 15, 2012",FDA CDER to Actavis Inc,2012
FDA-2012-P-0292-0003_Interim_Response_to_Lachman_Consultant_Services_In.pdf,"March 22, 2012",Lachman Consultant Services In,2012
FDA-2012-P-0298-0012_Agency_Response_to_The_Joseph_Dedvukaj_Firm___P_C_.pdf,"March 27,2012",The Joseph Dedvukaj Firm   P C,2012
FDA-2012-P-0299-0006_Interim_Response_to_Schiff_Hardin_LLP_Range_Equine.pdf,3/30/12,Schiff Hardin LLP Range Equine,2012
FDA-2012-P-0317-0005_Interim_Response_to_Abbott_Laboratories_Covington_.pdf,5/8/12,Abbott Laboratories Covington,2012
FDA-2012-P-0379-0003_Interim_Response__to_David_Behar_MD_Letter.pdf,"April 16, 2012",David Behar MD Letter,2012
FDA-2012-P-0404-0004_Interim_Response_to_Public_Citizen_Health_Research.pdf,5/2/12,Public Citizen Health Research,2012
FDA-2012-P-0436-0003_FDA_CDER_Interim_Response_to_Lupin_Pharmaceuticals.pdf,"May 4, 2012",Lupin Pharmaceuticals,2012
FDA-2012-P-0436-0004_Response_Letter_from_FDA_CDER.pdf,5/8/12,FDA CDER,2012
FDA-2012-P-0468-0003_FDA_CDER_Interim_Response_to_Cadila_Pharmaceutical.pdf,"May 10, 2012",Cadila Pharmaceutical,2012
FDA-2012-P-0468-0004_Response_Letter_from_FDA_CDER.pdf,5/10/12,FDA CDER,2012
FDA-2012-P-0566-0004_Interim_Response_Letter_from_FDA_CDER_to_Empire_St.pdf,"June 6, 2012",FDA CDER to Empire St,2012
FDA-2012-P-0566-0006_Partial_Approval_and_Denial_Response_Letter_from_F.pdf,"June 6, 2012",F,2012
FDA-2012-P-0649-0003_Interim_Response_Letter_from_FDA_CDER_to_Lachman_C.pdf,6/21/12,FDA CDER to Lachman C,2012
FDA-2012-P-0649-0005_Response_Letter_from_FDA_CDER_to_Lachman_Consultan.pdf,6/21/12,FDA CDER to Lachman Consultan,2012
FDA-2012-P-0661-0003_Interim_Response_Letter_from_FDA_CDER_to_Sandoz__I.pdf,"June 20, 2012",FDA CDER to Sandoz  I,2012
FDA-2012-P-0661-0005_Interim_Response_Letter_from_FDA_CDER_to_Sandoz__I.pdf,"June 19, 2012",FDA CDER to Sandoz  I,2012
FDA-2012-P-0695-0009_Interim_Response_to_Lorillard_Tobacco_Company.pdf,6/28/12,Lorillard Tobacco Company,2012
FDA-2012-P-0695-0011_FDA_CTP_Response_to_Lorillard_Tobacco_Company_Peti.pdf,6/28/12,Lorillard Tobacco Company Peti,2012
FDA-2012-P-0747-0003_Interim_Response_to_Leroy_Leslie_Hamilton_PhD_Lett.pdf,"July 3, 2012",Leroy Leslie Hamilton PhD Lett,2012
FDA-2012-P-0754-0003_FDA_CFSAN_Interim_Response_to_North_American_Olive.pdf,"July 12, 2012",North American Olive,2012
FDA-2012-P-0818-0694_FDA_CDER_Interim_Response_to_Physicians_for_Respon.pdf,"July 25,2012",Physicians for Respon,2012
FDA-2012-P-0818-0793_FDA_CDER_Response_to_Physicians_for_Responsible_Op.pdf,7/30/12,Physicians for Responsible Op,2012
FDA-2012-P-0854-0003_FDA_CDER_Response_Letter_to_B_Braun_Medical_Inc_Pe.pdf,"August 2, 2012",B Braun Medical Inc Pe,2012
FDA-2012-P-0857-0036_FDACDER_Response_to_Sheller_P_C_Law_Offices_Letter.pdf,"August 2, 2012",Sheller P C Law Offices Letter,2012
FDA-2012-P-0857-0038_FDA_CDER_Response_to_Sheller_P_C_Law_Offices_Lette.pdf,"March 26, 2013",Sheller P C Law Offices Lette,2012
FDA-2012-P-0857-0039_FDA_CDER_Response_to_Sheller_P_C_Law_Offices_Lette.pdf,"July 2, 2013",Sheller P C Law Offices Lette,2012
FDA-2012-P-0857-0041_Response_from_Sheller_P_C_Law_Offices_to_FDA_CDER_.pdf,"July 2, 2013",Sheller P C Law Offices to FDA CDER,2012
FDA-2012-P-0872-0042_Interim_Response_to_Handcrafted_Soapmakers_Guild_I.pdf,"February 1,2013",Handcrafted Soapmakers Guild I,2012
FDA-2012-P-0872-0057_Response_Letter_to_Handcrafted_Soapmakers_Guild_In.pdf,8/10/12,Handcrafted Soapmakers Guild In,2012
FDA-2012-P-0895-0008_FDA_CDER_Interim_Response_to_Endo_Pharmaceuticals_.pdf,"August 13, 2012",Endo Pharmaceuticals,2012
FDA-2012-P-0895-0014_FDA_CDER_Final_Response_to_Endo_Pharmaceuticals_In.pdf,9/11/12,Endo Pharmaceuticals In,2012
FDA-2012-P-0904-0115_FDA_CFSAN_Response_to_Citizens_for_Health_Interim_.pdf,"August 15, 2012",Citizens for Health Interim,2012
FDA-2012-P-0906-0003_FDA_CDER_Response_to_Lachman_Consultant_Services_I.pdf,"August 16, 2012",Lachman Consultant Services I,2012
FDA-2012-P-0909-0003_Interim_response_to_Michael_D_Lorton_M_D_Letter.pdf,9/19/12,Michael D Lorton M D Letter,2012
FDA-2012-P-0916-0005_FDA_CDER_Response_to_Ei_Inc_Letter.pdf,"August 24, 2012",Ei Inc Letter,2012
FDA-2012-P-0963-0003_Interim_Response_to_Charles_J_Zimmerer_Letter_Reda.pdf,"August 31, 2012",Charles J Zimmerer Letter Reda,2012
FDA-2012-P-0963-0004_Final_Response_Letter_from_FDA_CDRH_to_Charles_J__.pdf,"November 26, 2024",FDA CDRH to Charles J,2012
FDA-2012-P-1000-0003_Interim_Response_to_CUSTOpharm_Inc_Letter.pdf,9/28/12,CUSTOpharm Inc Letter,2012
FDA-2012-P-1000-0005_FDA_CDER_to_CUSTOpharm_Inc___Agency_Response.pdf,9/28/12,CUSTOpharm Inc   Agency Response,2012
FDA-2012-P-1007-0004_Interim_Response_to_Public_Citizen_Litigation_Grou.pdf,9/26/12,Public Citizen Litigation Grou,2012
FDA-2012-P-1007-0005_Interim_Response_to_Public_Citizen_Litigation_Grou.pdf,"March 18, 2013",Public Citizen Litigation Grou,2012
FDA-2012-P-1009-0003_FDA_CDER_Response_Letter_to_Pfizer_Inc_Covington__.pdf,9/25/12,Pfizer Inc Covington,2012
FDA-2012-P-1034-0003_Interim_Response_to_Lachman_Consultant_Sevices_Inc.pdf,10/1/12,Lachman Consultant Sevices Inc,2012
FDA-2012-P-1052-0006_FDACDER_Interim_Response_to_James_Flory_MD_MSCE_et.pdf,"October 9, 2012",James Flory MD MSCE et,2012
FDA-2012-P-1053-0003_Interim_Response_from_FDA_CDER_to_Public_Citizen.pdf,10/11/12,FDA CDER to Public Citizen,2012
FDA-2012-P-1071-0004_FDA_CDER_Response_to_Law_Office_of_Alvin_J_Lorman_.pdf,"October 16, 2012",Law Office of Alvin J Lorman,2012
FDA-2012-P-1072-0003_FDA_CDER_Response_to_Boehringer_Ingelheim_Pharmace.pdf,"October 17, 2012",Boehringer Ingelheim Pharmace,2012
FDA-2012-P-1072-0006_Final_Response_from_FDA_CDER_to_Boehringer_Ingelhe.pdf,"October 17, 2012",FDA CDER to Boehringer Ingelhe,2012
FDA-2012-P-1095-0003_FDA_CDER_Interim_Response_to_Resveratrol_Partners_.pdf,"October 31, 2012",Resveratrol Partners,2012
FDA-2012-P-1107-0022_FDA_OC_Response_to_FzioMed_Inc_Hogan_Lovells_US_LL.pdf,11/21/12,FzioMed Inc Hogan Lovells US LL,2012
FDA-2012-P-1127-0003_FDA_CDER_Interim_Response_to_Onco_Therapies_Limite.pdf,"November 8, 2012",Onco Therapies Limite,2012
FDA-2012-P-1128-0006_FDA_CVM_Response_to_Dechra_Ltd_Approval_of_Petitio.pdf,"November 8, 2012",Dechra Ltd Approval of Petitio,2012
FDA-2012-P-1147-0003_Response_Letter_from_FDA_CDER_to_Foley___Lardner_L.pdf,"November 13, 2012",FDA CDER to Foley   Lardner L,2012
FDA-2012-P-1158-0003_FDA_CVM_Interim_Response_dated_May_16_2013__Respon.pdf,11/21/12,Milagros Demier,2012
FDA-2012-P-1160-0003_FDA_CDER_Interim_Response_to_Steven_A_Zecola_Redac.pdf,"November 20, 2012",Steven A Zecola Redac,2012
FDA-2012-P-1179-0009_Interim_Response_to_Jack_M__Saroyan__DDS__Letter.pdf,12/10/12,Jack M  Saroyan  DDS  Letter,2012
FDA-2012-P-1189-0003_Response_Letter_to_StarKist_Seafood_Company_from_F.pdf,"June 20, 2014",F,2012
FDA-2012-P-1252-0003_Interim_Response_to_the_Animal_Legal_Defense_Fund_.pdf,"February 28, 2025",the Animal Legal Defense Fund,2012
FDA-2012-P-1252-0006_Final_Response_Letter_from_FDA_CVM_to_Animal_Legal.pdf,"February 28, 2025",FDA CVM to Animal Legal,2012
FDA-2012-P-1265-0003_Interim_Response_to_Indicus_Pharma_LLC.pdf,12/31/12,Indicus Pharma LLC,2012
FDA-2012-P-1265-0004_Response_Letter_from_FDA_CDER.pdf,12/31/12,FDA CDER,2012
FDA-2013-P-0735-0006_FDA_Response_to_joint_appeal_in_FDA_2012_P_0119_an.pdf,"January 19, 2017",joint appeal in FDA 2012 P 0119 an,2013
FDA-2014-P-0038-0003_Interim_Response_Letter_from_FDA_CDRH_to_Riverain_.pdf,"December 18,2013",FDA CDRH to Riverain,2014
FDA-2014-P-0038-0004_Final_Response_letter_for_FDA_2017_P_3884_and_FDA_.pdf,"December 18, 2013",,2014
FDA-2014-P-0111-0003_Interim_Response_Letter_from_FDA_CDRH_to_LaMaitre_.pdf,"January 
9, 2014",FDA CDRH to LaMaitre,2014
FDA-2014-P-0111-0004_Response_Letter_from_FDA_CDRH_to_Xiang_Zhang.pdf,1/24/14,FDA CDRH to Xiang Zhang,2014
FDA-2014-P-0112-0004_Final_Response_Letter_from_FDA_CDRH_to_NadaChair_R.pdf,"March 1, 2024",FDA CDRH to NadaChair R,2014
FDA-2014-P-0143-0008_Interim_Response_from_FDA_CDRH_to_Gail_Gudmundsen_.pdf,"January 16, 2014",FDA CDRH to Gail Gudmundsen,2014
FDA-2014-P-0143-0009_Final_Response_from_FDA_CDRH_to_Gail_Gudmundsen_Re.pdf,"October 23, 2021",FDA CDRH to Gail Gudmundsen Re,2014
FDA-2014-P-0158-0003_Interim_Response_Letter_from_FDA_CDRH_to_H__Christ.pdf,"January 20, 2014",FDA CDRH to H  Christ,2014
FDA-2014-P-0158-0004_Interim_Response_from_FDA_CDRH_to_H__Christopher_S.pdf,"January 20,2014",FDA CDRH to H  Christopher S,2014
FDA-2014-P-0159-0005_Interim_Response_Letter_from_FDA_CDRH_to_Etymotic_.pdf,"July 22, 2014",FDA CDRH to Etymotic,2014
FDA-2014-P-0159-0006_Response_Letter_from_Etymotic_Research_Inc.pdf,"July 29, 2014",Etymotic Research Inc,2014
FDA-2014-P-0159-0012_Second_Interim_Response_from_FDA_CDRH_to_Etymotic_.pdf,"January 28, 2014",FDA CDRH to Etymotic,2014
FDA-2014-P-0159-0014_Final_Response_from_FDA_CDRH_to_Etymotic_Research_.pdf,"October 23, 2021",FDA CDRH to Etymotic Research,2014
FDA-2014-P-0245-0003_Interim_Response_Letter_from_FDA_CDER_to_Sugar_Ass.pdf,"March 5, 2014",FDA CDER to Sugar Ass,2014
FDA-2014-P-0259-0006_Interim_Response_from_FDA_CFSAN_to_Sabra_Dipping_C.pdf,"March 10, 2014",FDA CFSAN to Sabra Dipping C,2014
FDA-2014-P-0315-0004_Response_Letter_From_FDA_CDER_to_Lachman_Consultan.pdf,"March 18, 2014",FDA CDER to Lachman Consultan,2014
FDA-2014-P-0328-0003_Interim_Response_from_FDA_CDER_to_Hyman_Phelps_and.pdf,"March 19, 2014",FDA CDER to Hyman Phelps and,2014
FDA-2014-P-0367-0003_Interim_Response_Letter_from_FDA_CDER_to_Hyman_Phe.pdf,"March 28, 2014",FDA CDER to Hyman Phe,2014
FDA-2014-P-0377-0003_Interim_Response_Letter_from_FDA_CDER_to_Hyman_Phe.pdf,4/4/14,FDA CDER to Hyman Phe,2014
FDA-2014-P-0404-0004_Response_from_FDA_CDER_Partial_Approval_and_Denial.pdf,4/10/14,FDA CDER Partial Approval and Denial,2014
FDA-2014-P-0405-0003_Interim_Response_from_FDA_CDER_to_Ken_Surprenant_R.pdf,4/8/14,FDA CDER to Ken Surprenant R,2014
FDA-2014-P-0405-0012_Partial_Approval_Final_Response.pdf,"March 20, 2015",,2014
FDA-2014-P-0407-0007_Interim_Response_from_FDA_CDER_to_Almatica_Pharma_.pdf,4/3/14,"Almatica Pharma, Inc.",2014
FDA-2014-P-0446-0003_Final_Response_Letter_from_FDA_to_Pisani___Roll_LL.pdf,4/11/14,Starkist Company (Pisani And Roll Llp),2014
FDA-2014-P-0497-0003_Interim_Response_from_FDA_CDER_to_Ken_Surprenant_R.pdf,4/19/14,Ken Surprenant,2014
FDA-2014-P-0497-0009_Partial_Approval_Final_Response.pdf,4/19/14,Ken Surprenant,2014
FDA-2014-P-0511-0003_Interim_Response_from_FDA_CDER_to_Agila_Specialtie.pdf,4/21/14,Agila Specialties Inc.,2014
FDA-2014-P-0549-0004_Response_Letter_From_FDA_CDER_to_Emcure_Pharmaceut.pdf,"August 25, 2014",FDA CDER to Emcure Pharmaceut,2014
FDA-2014-P-0585-0003_Interim_Response_Letter_from_FDA_CFSAN_to_Capstone.pdf,5/1/14,A. Haggag (Capstone Law),2014
FDA-2014-P-0594-0010_Interim_Response_Letter_from_FDA_CDER_to_Hyman_Phe.pdf,5/5/14,Hyman Phelps Mcnamara P.C.,2014
FDA-2014-P-0628-0004_Interim_Response_From_CFSAN_to_Shauce_Co_.pdf,5/1/14,Shauce Company,2014
FDA-2014-P-0637-0005_Response_Letter_From_FDA_CDER_to_Lachman_Consultan.pdf,5/15/14,"Lachman Consultant Services, Inc.",2014
FDA-2014-P-0654-0010_Final_Response_Letter_from_FDA_CDRH_to_Edwards_Lif.pdf,5/6/14,Edwards Lifesciences Llc,2014
FDA-2014-P-0654-0011_Response_to_Request_for_Reconsideration_from_Edwar.pdf,5/6/14,Edwar,2014
FDA-2014-P-0654-0012_Variance_Approval_from_FDA_CDRH_to_Edwards_Lifesci.pdf,"June 10, 2014",FDA CDRH to Edwards Lifesci,2014
FDA-2014-P-0687-0007_Interim_Response_Letter_from_FDA_CDRH_to_Margaret_.pdf,5/20/14,Margaret Moline,2014
FDA-2014-P-0724-0013_Interim_Response_Letter_from_FDA_CDRH_to_Rocky_Mou.pdf,10/27/14,Barbara Spohn-Lillo,2014
FDA-2014-P-0802-0004_Second_Interim_Response_from_FDA_CDRH_to_Moon_T__K.pdf,1/22/14,Moon T. Kwon,2014
FDA-2014-P-0802-0005_Final_Response_from_FDA_CDRH_to_Moon_T_Kwon_Redact.pdf,1/22/14,Moon T. Kwon,2014
FDA-2014-P-0814-0007_Interim_Response_From_FDA_CDER_to_the_Center_for_R.pdf,6/18/14,The Center For Responsible Science,2014
FDA-2014-P-0823-0004_Interim_Response_Letter_from_FDA_CDER_to_Richard_D.pdf,6/12/14,Richard D. Burk,2014
FDA-2014-P-0823-0013_Agency_Response_Letter_From_FDA_CDER_to_Richard_D_.pdf,6/12/14,Richard D. Burk,2014
FDA-2014-P-0825-0006_Interim_Response_Letter_from_FDA_CDRH_to_Orthofix_.pdf,6/19/14,Orthofix Inc.,2014
FDA-2014-P-0830-0004_Interim_Response.pdf,6/19/14,"Merz North America (Buchanan, Ingersoll And Rooney Pc)",2014
FDA-2014-P-0830-0006_Denial_letter_from_FDA_CDER_to_Merz_North_America_.pdf,6/19/14,"Merz North America (Buchanan, Ingersoll And Rooney Pc)",2014
FDA-2014-P-0831-0007_Interim_Response_Letter_from_FDA_CDRH_to_Orthofix_.pdf,"December 17, 2014",FDA CDRH to Orthofix,2014
FDA-2014-P-0856-0007_Interim_Response_From_CDER_to_SONAR.pdf,6/18/14,The Southern Network On Adverse Reactions,2014
FDA-2014-P-0862-0003_Interim_Response_From_CDER_to_The_Alliance_for_Nat.pdf,6/23/14,The Alliance For Natural Health Usa,2014
FDA-2014-P-0862-0004_Final_Response_From_CDER_to_The_Alliance_for_Natur.pdf,6/23/14,The Alliance For Natural Health Usa,2014
FDA-2014-P-0908-0005_Denial_Response_Letter_from_FDA_CDRH_to_Mothers_Ag.pdf,"January 27, 2015",FDA CDRH to Mothers Ag,2014
FDA-2014-P-0919-0004_Interim_Response_from_CDRH_to_Daniel_Schumaier.pdf,"December 23,2014",CDRH to Daniel Schumaier,2014
FDA-2014-P-0919-0005_Interim_Response_Letter_from_FDA_CDRH_to_Daniel_Sc.pdf,"June 18, 2014",FDA CDRH to Daniel Sc,2014
FDA-2014-P-0919-0006_Final_Response_from_FDA_CDRH_to_Daniel_Schumaier_R.pdf,"October 23, 2021",FDA CDRH to Daniel Schumaier R,2014
FDA-2014-P-0935-0009_Interim_Response_from_FDA_CFSAN_to_Juice_Products_.pdf,"July 3, 2014",FDA CFSAN to Juice Products,2014
FDA-2014-P-0979-0005_Response_Letter_from_FDA_CDER_to_Emcure_Pharmaceut.pdf,"July 3, 2014",FDA CDER to Emcure Pharmaceut,2014
FDA-2014-P-1101-0004_Response_Letter_from_FDA_CDER_to_Lachman_Consultan.pdf,"July 25, 2014",FDA CDER to Lachman Consultan,2014
FDA-2014-P-1102-0004_Response_Letter_from_FDA_CDER_to_Lachman_Consultan.pdf,"July 25, 2014",FDA CDER to Lachman Consultan,2014
FDA-2014-P-1256-0003_Interim_Response_Letter_from_FDA_CDER_to_Public_Ci.pdf,"July 28, 2014",FDA CDER to Public Ci,2014
FDA-2014-P-1256-0004_Response_Letter_from_FDA_CDER_to_Public_Citizen_s_.pdf,"July 28, 2014",FDA CDER to Public Citizen s,2014
FDA-2014-P-1258-0003_Interim_Response_Letter_from_FDA_CDER_to_SoLRx_Glo.pdf,"August 13,2014",FDA CDER to SoLRx Glo,2014
FDA-2014-P-1281-0005_Interim_Response_Letter_from_FDA_CDER_to_Arnall_Go.pdf,"July 10, 2014",FDA CDER to Arnall Go,2014
FDA-2014-P-1353-0003_Denial_Response_from_FDA_CFSAN_to_the_Internationa.pdf,"September 5, 2014",FDA CFSAN to the Internationa,2014
FDA-2014-P-1429-0004_Interim_Response_Letter_from_FDA_CFSAN_to_Oliver_B.pdf,"March 4, 2015",FDA CFSAN to Oliver B,2014
FDA-2014-P-1562-0003_Interim_Response_from_FDA_CDER_to_the_Institute_fo.pdf,"October 8, 2014",FDA CDER to the Institute fo,2014
FDA-2014-P-1576-0005_Interim_Response_from_CDER_to_Gordon_Johnston_Regu.pdf,"October 9, 2014",CDER to Gordon Johnston Regu,2014
FDA-2014-P-1611-0003_Interim_Response_From_CDER_to_the_Southern_Network.pdf,10/15/14,CDER to the Southern Network,2014
FDA-2014-P-1611-0005_Partial_Approval_and_Partial_Denial_Response_From_.pdf,10/15/14,Southern Network On Adverse Reactions Sonar,2014
FDA-2014-P-1622-0012_Interim_Response_From_CDER_to_Genesee_Health_Syste.pdf,"September 10, 2014",CDER to Genesee Health Syste,2014
FDA-2014-P-1656-0007_Final_Response_Letter_from_FDA_to__Alaska_Seafood_.pdf,"November 16, 2017",FDA to  Alaska Seafood,2014
FDA-2014-P-1673-0003_Interim_Response_Letter_from_FDACDRH_to_Tia_Gonnel.pdf,"December 22, 2014",FDACDRH to Tia Gonnel,2014
FDA-2014-P-1685-0003_Interim_Response_from_CDER_to_Larry_R__Pilot.pdf,"September 22, 2014",CDER to Larry R  Pilot,2014
FDA-2014-P-1753-0006_Interim_Response_Letter_from_FDA_CDER_to_Angela_St.pdf,"October 28, 2014",FDA CDER to Angela St,2014
FDA-2014-P-1773-0003_Interim_Response_from_CDER_to_PPSI.pdf,"September 8, 2014",CDER to PPSI,2014
FDA-2014-P-1784-0005_Interim_Response_to_the_Wood_Burditt_Group.pdf,"August 15, 2014",the Wood Burditt Group,2014
FDA-2014-P-1796-0004_Interim_Response_Letter_from_FDA_CDER_to_Hogan_Lov.pdf,"October 31, 2014",FDA CDER to Hogan Lov,2014
FDA-2014-P-1844-0004_Interim_Response_Letter_from_FDA_CDER_to_Lachman_C.pdf,"November 5, 2014",FDA CDER to Lachman C,2014
FDA-2014-P-1882-0003_Final_Response_from_FDA_CFSAN_to_the_Isabella_Guaj.pdf,11/10/14,FDA CFSAN to the Isabella Guaj,2014
FDA-2014-P-1883-0006_Response_Letter_from_FDA_CDER_to_Lannett_Holdings_.pdf,"November 10, 2014",FDA CDER to Lannett Holdings,2014
FDA-2014-P-2035-0014_Interim_Response_Letter_from_FDA_CFSAN_to_Dr_Carla.pdf,"November 25, 2014",FDA CFSAN to Dr Carla,2014
FDA-2014-P-2035-0336_Final_Response_from_FDA_CFSAN_to_Texas_Children_s_.pdf,"November 06, 2023",FDA CFSAN to Texas Children s,2014
FDA-2014-P-2140-0008_Denial_letter_from_FDA_CDER_to_Lachman_Consultant_.pdf,"September 22, 2014",FDA CDER to Lachman Consultant,2014
FDA-2014-P-2276-0006_Interim_Response_Letter_from_FDA_CDER_to_Alan_Labo.pdf,"December 23, 2014",FDA CDER to Alan Labo,2014
FDA-2014-P-2301-0003_Interim_Response_Letter_from_FDA_CDER_to_Probiomed.pdf,"December 26, 2014",FDA CDER to Probiomed,2014
FDA-2015-P-0014-0003_Interim_Response_from_FDA_CDRH_to_Edward_L__Boshni.pdf,1/5/15,FDA CDRH to Edward L  Boshni,2015
FDA-2015-P-0014-0004_Interim_Response_from_FDA_CDRH_to_Richard_B__Smith.pdf,1/5/15,FDA CDRH to Richard B  Smith,2015
FDA-2015-P-0014-0005_Interim_Response_from_FDA_CDRH_to_Roger_D__Davis_R.pdf,1/5/15,FDA CDRH to Roger D  Davis R,2015
FDA-2015-P-0014-0006_Final_Response_from_FDA_CDER_to_Edward_L__Boshnick.pdf,"September 5, 2022",FDA CDRH to Edward L  Boshnick,2015
FDA-2015-P-0014-0006_Final_Response_from_FDA_CDRH_to_Edward_L__Boshnick.pdf,"September 5, 2022",FDA CDRH to Edward L  Boshnick,2015
FDA-2015-P-0051-0004_Inrange_Trade_Complaint_Response_Letter_Final.pdf,"March 2, 2015",,2015
FDA-2015-P-0059-0004_Interim_Response_Letter_from_FDA_CFSAN_to_CSPI.pdf,"December 9, 2014",FDA CFSAN to CSPI,2015
FDA-2015-P-0059-0013_Denial_response_letter_from_FDA_CFSAN_to_Center_fo.pdf,"April 16, 2018",FDA CFSAN to Center fo,2015
FDA-2015-P-0095-0009_Final_Response_Letter_from_FDA_CDRH_to_DuVal_and_A.pdf,1/9/15,FDA CDRH to DuVal and A,2015
FDA-2015-P-0233-0010_Interim_Response_Letter_from_FDA_CDER_to_the_Madis.pdf,"January 22, 2015",FDA CDER to the Madis,2015
FDA-2015-P-0403-0005_Interim_Response_Letter_from_FDA_CDER_to_Lachman_C.pdf,"February 5, 2015",FDA CDER to Lachman C,2015
FDA-2015-P-0464-0022_Interim_Response_Letter_from_FDA_CDER_to_Colgate_P.pdf,"February 11, 2015",FDA CDER to Colgate P,2015
FDA-2015-P-0464-0025_Response_Letter_from_FDA_CDER_to_Colgate_Palmolive.pdf,"February 11, 2015",FDA CDER to Colgate Palmolive,2015
FDA-2015-P-0543-0011_Interim_Response_Letter_from_FDA_CDER_to_Gland_Pha.pdf,"February 19, 2015",FDA CDER to Gland Pha,2015
FDA-2015-P-0543-0012_Final_Response_Letter_from_FDA_CDER_to_Gland_Pharm.pdf,"February 19, 2015",FDA CDER to Gland Pharm,2015
FDA-2015-P-0578-0004_Interim_Response_from_FDA_CDER_to_Public_Citizen_s.pdf,"February 24, 2015",FDA CDER to Public Citizen s,2015
FDA-2015-P-0613-0003_Interim_Response_Letter_from_FDA_CDER_to_Qilu_Phar.pdf,"February 25, 2015",FDA CDER to Qilu Phar,2015
FDA-2015-P-0613-0004_FDA_2015_P_0613___Final_CP_Response.pdf,"February 25, 2015",Qilu Pharma  Inc,2015
FDA-2015-P-0633-0003_Interim_Response_from_FDA_CDER_to_University_of_Ke.pdf,"February 27, 2015",FDA CDER to University of Ke,2015
FDA-2015-P-0633-0020_Final_Response_Letter_from_FDA_to_Jonathan_Smith.pdf,"February 27, 2015",FDA to Jonathan Smith,2015
FDA-2015-P-0711-0004_Interim_Response_Letter_from_FDA_CBER_to_Larry_Gar.pdf,"March 5, 2015",FDA CBER to Larry Gar,2015
FDA-2015-P-0732-0110_Interim_Response_Letter_from_FDA_CDER_to_Arnold_an.pdf,"March 9, 2015",FDA CDER to Arnold an,2015
FDA-2015-P-0732-0117_Response_Letter_to_Arnold___Porter_LLP_from_FDA_CD.pdf,"March 9, 2015",FDA CD,2015
FDA-2015-P-0762-0003_Interim_Response_from_FDA_CFSAN_to_Pharmacists_Pla.pdf,"September 24, 2015",FDA CFSAN to Pharmacists Pla,2015
FDA-2015-P-0840-0023_Interim_Response_Letter_from_FDA_CDER_to_Dr__Richa.pdf,"March 17, 2015",FDA CDER to Dr  Richa,2015
FDA-2015-P-0840-0026_Response_Letter_from_FDA_CDER_to_Dr__Richard_Sherm.pdf,"March 17, 2015",FDA CDER to Dr  Richard Sherm,2015
FDA-2015-P-0876-0003_Interim_Response_Letter_from_FDA_CDER_to_Escher_Fu.pdf,"March 19,2015",FDA CDER to Escher Fu,2015
FDA-2015-P-0876-0008_Response_Letter_from_FDA_CDER_to_Escher_Fund_for_A.pdf,"March 19, 2015",FDA CDER to Escher Fund for A,2015
FDA-2015-P-1090-0005_Interim_Response_Letter_from_FDA_CDER_to_Baker_Hos.pdf,8/18/15,FDA CDER to Baker Hos,2015
FDA-2015-P-1090-0006_Response_Letter_from_FDA_CDER_to_Baker___Hostetler.pdf,"November 30, 2023",FDA CDER to Baker   Hostetler,2015
FDA-2015-P-1103-0003_Interim_Response_Letter_from_FDA_CDER_to_Hyman__Ph.pdf,4/8/15,FDA CDER to Hyman  Ph,2015
FDA-2015-P-1153-0004_Interim_Response_Letter_from_FDA_CFSAN_to_Lachman_.pdf,4/10/15,FDA CFSAN to Lachman,2015
FDA-2015-P-1153-0006_Response_Letter_from_FDA_CDER_to_Lachman_Consultan.pdf,"April 8, 2015",FDA CDER to Lachman Consultan,2015
FDA-2015-P-1187-0003_Interim_Response_from_FDA_CFSAN_to_U_S__Right_to_K.pdf,"April 9, 2015",FDA CFSAN to U S  Right to K,2015
FDA-2015-P-1187-0004_Final_Response_Letter_from_FDA_to_U_S__Right_to_Kn.pdf,"October 26, 2017",FDA to U S  Right to Kn,2015
FDA-2015-P-1201-0011_Interim_Response_Letter_from_FDA_CFSAN_to_Tate___L.pdf,4/14/15,FDA CFSAN to Tate   L,2015
FDA-2015-P-1218-0004_Interim_Response_Letter_from_FDA_CDER_to_Hogan_Lov.pdf,"April 13, 2015",FDA CDER to Hogan Lov,2015
FDA-2015-P-1218-0005_Response_Letter_from_FDA_CDER_to_Hogan_Lovells_US_.pdf,"April 13, 
2015",FDA CDER to Hogan Lovells US,2015
FDA-2015-P-1279-0007_Interim_Response_Letter_from_FDA_CTP_to_Cigar_Righ.pdf,"April 16, 2015",FDA CTP to Cigar Righ,2015
FDA-2015-P-1279-0010_Interim_Response_from_FDA_CTP_to_Cigar_Rights_of_A.pdf,"April 20, 2016",FDA CTP to Cigar Rights of A,2015
FDA-2015-P-1279-0023_Final_Response_from_FDA_CDER_to_Cigar_Rights_of_Am.pdf,"October 25, 2016",FDA CDER to Cigar Rights of Am,2015
FDA-2015-P-1296-0022_Interim_Response_Letter_from_FDA_CDER_to_LeClairRy.pdf,4/22/15,FDA CDER to LeClairRy,2015
FDA-2015-P-1296-0025_Response_Letter_from_FDA_to_Jubilant_DraxImage.pdf,"April 17, 2015",FDA to Jubilant DraxImage,2015
FDA-2015-P-1431-0025_FDA_Final_Response_Denial_Letter.pdf,"March 20, 2008",,2015
FDA-2015-P-1433-0069_Interim_Response_Letter_from_FDA_CVM_to_Mr__Michae.pdf,"October 7, 2015",FDA CVM to Mr  Michae,2015
FDA-2015-P-1590-0004_Agency_Response_Letter_from_FDA_CDER_to_Qilu_Pharm.pdf,"May 6, 2015",FDA CDER to Qilu Pharm,2015
FDA-2015-P-1595-0004_Interim_Response_Letter_from_FDA_CDER_to_Cubist_Ph.pdf,"May 6, 2015",FDA CDER to Cubist Ph,2015
FDA-2015-P-1595-0005_Final_Response_Letter_from_FDA_CDER_to_Cubist_Phar.pdf,"May 7, 2015",FDA CDER to Cubist Phar,2015
FDA-2015-P-1669-0005_Interim_Response_from_FDA_CDER_to_RegCon_Solutions.pdf,"May 8, 2015",FDA CDER to RegCon Solutions,2015
FDA-2015-P-1674-0006_Interim_Response_Letter_from_FDA_CDRH_to_Globus_Me.pdf,"May 4, 2015",FDA CDRH to Globus Me,2015
FDA-2015-P-1752-0003_Interim_Response_Letter_from_FDA_CDER_to_Wiley_Rei.pdf,"May 15, 2015",FDA CDER to Wiley Rei,2015
FDA-2015-P-1899-0004_Interim_Response_Letter_from_FDA_CDER_to_Lachman_C.pdf,"May 27, 2015",FDA CDER to Lachman C,2015
FDA-2015-P-1900-0003_Interim_Response_Letter_from_FDA_CDER_to_Heidi_Jon.pdf,"May 27,2015",FDA CDER to Heidi Jon,2015
FDA-2015-P-1924-0006_Interim_Response_Letter_from_FDA_CDRH_to_Hunton___.pdf,"October 08, 2015",FDA CDRH to Hunton,2015
FDA-2015-P-1977-0235_Interim_Response_Letter_from_FDA_CDER_to_Gerald_St.pdf,6/5/15,FDA CDER to Gerald St,2015
FDA-2015-P-1977-0254_Response_Letter_from_FDA_CDER_to_Gerald_Steel_Reda.pdf,6/5/15,FDA CDER to Gerald Steel Reda,2015
FDA-2015-P-2000-0010_Interim_Response_from_FDA_CDER_to_AbbVie__Inc_.pdf,"June 2, 2015",FDA CDER to AbbVie  Inc,2015
FDA-2015-P-2141-0004_Interim_Response_Letter_from_FDA_CDER_to_Heritage_.pdf,"June 11,2015",FDA CDER to Heritage,2015
FDA-2015-P-2142-0005_Interim_Response_Letter_from_FDA_CDER_to_Public_Ci.pdf,"June 11,2015",FDA CDER to Public Ci,2015
FDA-2015-P-2142-0006_Response_Letter_from_FDA_CDER_to_Public_Citizen.pdf,6/15/15,FDA CDER to Public Citizen,2015
FDA-2015-P-2247-0006_Interim_Response_Letter_from_FDA_CFSAN_to_Tricia_S.pdf,"June 19, 2015",FDA CFSAN to Tricia S,2015
FDA-2015-P-2373-0006_Interim_Response_Letter_from_FDA_CDER_to_Dr__David.pdf,7/14/15,FDA CDER to Dr  David,2015
FDA-2015-P-2373-0008_Response_Letter_from_FDA_CDER_to_Dr__David_K__Cund.pdf,"September
28,2015",FDA CDER to Dr  David K  Cund,2015
FDA-2015-P-2375-0005_Interim_Response_Letter_from_FDA_CDRH_to_Public_Ci.pdf,"October 06, 2015",FDA CDRH to Public Ci,2015
FDA-2015-P-2375-0006_Public_Citizen_Seprafilm_Final_Response.pdf,"January 29, 2021",,2015
FDA-2015-P-2626-0003_Interim_Response_Letter_from_FDA_CDER_to_US_WorldM.pdf,"July 22, 2015",FDA CDER to US WorldM,2015
FDA-2015-P-2626-0004_Final_Response_Letter_from_FDA_CDER_to_US_WorldMed.pdf,"July 21, 2015",FDA CDER to US WorldMed,2015
FDA-2015-P-2678-0003_Interim_Response_Letter_from_FDA_CFSAN_to_Brian_C_.pdf,"July 27, 2015",FDA CFSAN to Brian C,2015
FDA-2015-P-2807-0004_Interim_Response_Letter_from_FDA_CDER_to_Lachman_C.pdf,"July 30,2015",FDA CDER to Lachman C,2015
FDA-2015-P-2820-0057_Interim_Response_from_FDA_CDRH_to_Alston___Bird__L.pdf,"July 31, 2015",FDA CDRH to Alston   Bird  L,2015
FDA-2015-P-2820-0077_Interim_Response_Letter_from_FDA__to__Alston_and_B.pdf,"July 31, 2015",FDA  to  Alston and B,2015
FDA-2015-P-2820-0078_Second_interim_response_from_FDA_OP_to_Center_for_.pdf,8/4/15,FDA OP to Center for,2015
FDA-2015-P-3009-0010_Interim_Response_Letter_from_FDA_CFSAN_to_Physicia.pdf,"August 14, 2015",FDA CFSAN to Physicia,2015
FDA-2015-P-3107-0003_Interim_Response_Letter_from_FDA_CDRH_to_DuVal___A.pdf,"August 20,2015",FDA CDRH to DuVal   A,2015
FDA-2015-P-3139-0003_Interim_Response_Letter_from_CFSAN_to_Kimberly_Kid.pdf,"August 26, 2015",CFSAN to Kimberly Kid,2015
FDA-2015-P-3299-0005_Interim_Response_Letter_from_FDA_CDER_to_Clinipace.pdf,"September 9, 2015",FDA CDER to Clinipace,2015
FDA-2015-P-3299-0007_Final_Agency_Response__Relisting_Letter___4_26_16_.pdf,"September 9, 2015",,2015
FDA-2015-P-3364-0003_Interim_Response_Letter_from_CDRH_to_Leory_Hamilto.pdf,"September 8, 2015",CDRH to Leory Hamilto,2015
FDA-2015-P-3365-0003_Response_Letter_from_FDA_CDRH_to_Inrange_Systems__.pdf,9/18/15,FDA CDRH to Inrange Systems,2015
FDA-2015-P-3391-0006_Denial_Letter_from_CFSAN_to_Ashley_Franz__Patricia.pdf,"September 16, 2015",CFSAN to Ashley Franz  Patricia,2015
FDA-2015-P-3400-0004_Interim_Response_Letter_from_FDA_CDER_to_Lupin_Pha.pdf,"September 18,2015",FDA CDER to Lupin Pha,2015
FDA-2015-P-3400-0005_Response_Letter_from_FDA_CDER.pdf,9/23/15,FDA CDER,2015
FDA-2015-P-3407-0004_Interim_Response_Letter_from_FDA_CDER_to_RegCon_So.pdf,"September 24, 2015",FDA CDER to RegCon So,2015
FDA-2015-P-3408-0004_Interim_Response_from_FDA_CDER_to_Dr__David_K__Cun.pdf,"September 25, 2015",FDA CDER to Dr  David K  Cun,2015
FDA-2015-P-3408-0006_Response_Letter_from_FDA_CDER_to_Dr__David_K__Cund.pdf,"September
28,2015",FDA CDER to Dr  David K  Cund,2015
FDA-2015-P-3410-0003_Interim_Response_from_FDA_CDER_to_David_K__Cundiff.pdf,"September 25, 2015",FDA CDER to David K  Cundiff,2015
FDA-2015-P-3410-0004_Response_Letter_from_FDA_CDER_to_Dr__David_K__Cund.pdf,"September
28,2015",FDA CDER to Dr  David K  Cund,2015
FDA-2015-P-3621-0006_Response_Letter_from_FDA_CDER_to_Hospira.pdf,"October 7, 2015",FDA CDER to Hospira,2015
FDA-2015-P-3739-0003_Interim_Response_Letter_from_FDA_CFSAN_to_Bryan_Ku.pdf,"October 15, 2015",FDA CFSAN to Bryan Ku,2015
FDA-2015-P-3778-0012_Interim_Response_to_Orthofix.pdf,"October 14, 2015",Orthofix,2015
FDA-2015-P-3794-0003_Interim_response_letter_to_Lawrence_Savage.pdf,"October 16, 2015",Lawrence Savage,2015
FDA-2015-P-3876-0009_Interim_Response_to_World_Alliance_for_Mercury_Fre.pdf,"October 10,2015",World Alliance for Mercury Fre,2015
FDA-2015-P-3876-0010_Final_Response_Letter_from_FDA_CDRH_to_Consumers_f.pdf,"May 26, 2022",FDA CDRH to Consumers f,2015
FDA-2015-P-3959-0012_Interim_Response_from_FDA_CDER_to_The_Weston_Firm.pdf,"October 27, 2015",FDA CDER to The Weston Firm,2015
FDA-2015-P-4019-0003_Interim_Response_Letter.pdf,"October 30,2015",,2015
FDA-2015-P-4131-0004_Interim_Response_FDA_2015_P_4131.pdf,"November 6, 2015",,2015
FDA-2015-P-4131-0016_Final_Response_Letter_from_FDA_CDER_to_the_Univers.pdf,"November 4, 2015",FDA CDER to the Univers,2015
FDA-2015-P-4224-0005_Interim_Response_Letter.pdf,"November 12,2015",,2015
FDA-2015-P-4231-0006_Final_Response_Letter_from_FDA_CDER_to_RegCon_Solu.pdf,"November 12, 2015",FDA CDER to RegCon Solu,2015
FDA-2015-P-4307-0004_Interim_Response_Letter_from_FDA_CFSAN_to_Guy_Alio.pdf,"November 18, 2015",FDA CFSAN to Guy Alio,2015
FDA-2015-P-4529-0011_Interim_Response_May_19_2016.pdf,"November 24, 2015",,2015
FDA-2015-P-4564-0017_Interim_Response_Letter_from_CFSAN_to_KIND_LLC.pdf,"December 2, 2015",CFSAN to KIND LLC,2015
FDA-2015-P-4566-0004_Interim_Response_from_FDA_CDER.pdf,"December 1, 2015",FDA CDER,2015
FDA-2015-P-4566-0005_Final_Response_from_FDA_CDER_to_Buchanan_Ingersoll.pdf,"October 21, 2013",FDA CDER to Buchanan Ingersoll,2015
FDA-2015-P-4582-0008_Interim_Response_May_18_2016.pdf,"November 20, 2015",,2015
FDA-2015-P-4600-0003_Interim_Response_Letter_from_CDER_to_Bayer_HealthC.pdf,"December 4, 2015",CDER to Bayer HealthC,2015
FDA-2015-P-4601-0004_Interim_Response_re__FDA_2015_P_4601.pdf,"December 4, 2015",,2015
FDA-2015-P-4664-0031_Interim_Response_05_19_2016.pdf,"May 19, 2016",,2015
FDA-2015-P-4770-0004_Response_Letter_from_FDA_CDER_to_Epic_Pharma__LLC.pdf,"December 11, 2015",FDA CDER to Epic Pharma  LLC,2015
FDA-2015-P-4916-0004_Interim_Response_June_13_2016.pdf,"December 16, 2015",,2015
FDA-2015-P-4935-0006_Interim_Response_Letter_from_FDA_CDER_to_AbbVie_In.pdf,"December 17, 2015",FDA CDER to AbbVie In,2015
FDA-2015-P-4945-0003_Interim_Response_Letter_from_FDA_CDRH_to_Mr__Rysza.pdf,"March 14, 2016",FDA CDRH to Mr  Rysza,2015
FDA-2015-P-5022-0007_Interim_Response_from_FDA_CDER_to_PRMA.pdf,"December 22, 2015",FDA CDER to PRMA,2015
FDA-2015-P-5081-0021_Interim_Response_FDA_2015_P_5081.pdf,"December 24, 2015",,2015
FDA-2015-P-5081-0080_Final_Response_Letter_from_FDA_to_Meghan_O__Hara__.pdf,"December 24, 2015",FDA to Meghan O  Hara,2015
FDA-2016-P-0031-0004_Interim_Response.pdf,"December 30, 2015",,2016
FDA-2016-P-0135-0003_Interim_Response_from_FDA_CDER.pdf,"January 11, 2016",FDA CDER,2016
FDA-2016-P-0147-0007_Interim_Response_from_FDA_CFSAN_to_Bumble_Bee_Food.pdf,"January 15, 2016",FDA CFSAN to Bumble Bee Food,2016
FDA-2016-P-0159-0006_Denial_letter_from_the_FDA_CDRH_to_Biorex_Labs_LLC.pdf,"June 29, 2016",the FDA CDRH to Biorex Labs LLC,2016
FDA-2016-P-0214-0007_Interim_Response_from_CBER_to_Rosalind_Advisosrs_I.pdf,"January 19,2016",CBER to Rosalind Advisosrs I,2016
FDA-2016-P-0214-0008_Denial_Response_from_FDA_CBER_to_Public_Citizen.pdf,"January 16, 2016",FDA CBER to Public Citizen,2016
FDA-2016-P-0378-0004_Final_Response_Letter_June_2_2016.pdf,"January 28, 2016",,2016
FDA-2016-P-0618-0003_Interim_Response_Letter_from_FDA_CFSAN_to_Emily_Co.pdf,MAY 112016,FDA CFSAN to Emily Co,2016
FDA-2016-P-0644-0006_Final_Response_from_FDA_CDER_to__Gordon_Johnston_R.pdf,"February 22, 2016",FDA CDER to  Gordon Johnston R,2016
FDA-2016-P-0645-0012_CDER_Interim_Response_Letter_to_Pharmaceutical_Man.pdf,"February 22, 2016",Pharmaceutical Man,2016
FDA-2016-P-0645-0015_CDER_Response_Letter_to_Pharmaceutical_Manufacturi.pdf,2/26/16,Pharmaceutical Manufacturi,2016
FDA-2016-P-0656-0004_Interim_response_redacted.pdf,"February 19,2016",,2016
FDA-2016-P-0689-0003_Response_letter_from_FDA_CDER_to_the_Commissioner_.pdf,"February 24, 2016",FDA CDER to the Commissioner,2016
FDA-2016-P-0769-0003_Interim_Response_Letter_from_FDA_CDER_to_Empire_St.pdf,"February 28, 2016",FDA CDER to Empire St,2016
FDA-2016-P-0769-0007_Final_Response_Letter_from_FDA_to_Empire_State_Con.pdf,"February 26, 2016",FDA to Empire State Con,2016
FDA-2016-P-0770-0004_Interim_Response_from_FDA_CDER.pdf,"November 19, 2016",FDA CDER,2016
FDA-2016-P-1085-0004_Agency_Response_from_FDA_CDER_to_Beijing_Health_Li.pdf,"March 23, 2016",FDA CDER to Beijing Health Li,2016
FDA-2016-P-1088-0008_Agency_Response_Letter_from_FDA_CDER_to_ABHAI_LLP_.pdf,"March 23, 2016",FDA CDER to ABHAI LLP,2016
FDA-2016-P-1090-0020_Interim_Response_to_Lachman_Consulting_Services__I.pdf,"March 25,2016",Lachman Consulting Services  I,2016
FDA-2016-P-1108-0005_Response_letter_from_FDA_to_Gordon_Johnston_Regula.pdf,"April 1, 2016",FDA to Gordon Johnston Regula,2016
FDA-2016-P-1115-0051_Interim_Response_from_CDRH_to_Mostyn_Law_Firm.pdf,"March 31, 2016",CDRH to Mostyn Law Firm,2016
FDA-2016-P-1115-0054_Response_from_FDA_CDRH_to_Mostyn_Law_Firm___redact.pdf,"February 13, 2024",FDA CDRH to Mostyn Law Firm   redact,2016
FDA-2016-P-1133-0003_Denial_Response_to_Fox_Rothschild_LLP.pdf,"September 14, 2016",Fox Rothschild LLP,2016
FDA-2016-P-1163-0097_Response_Letter_from_FDA_CDER_to_Foley_Hoag_LLP.pdf,"April 15, 2016",FDA CDER to Foley Hoag LLP,2016
FDA-2016-P-1163-0100_Response_Letter_from_FDA_CDER_to_Sidley_Austin_LLP.pdf,"June 25, 2021",FDA CDER to Sidley Austin LLP,2016
FDA-2016-P-1169-0015_Reconsideration_Denial_Letter.pdf,"September 20, 2018",,2016
FDA-2016-P-1171-0004_Interim_Response_Letter_from_FDA_CFSAN_to_Breast_C.pdf,4/19/2016,FDA CFSAN to Breast C,2016
FDA-2016-P-1171-0017_Final_Response_Letter_from_FDA_CFSAN_to_Earthjusti.pdf,"July 21, 2023",FDA CFSAN to Earthjusti,2016
FDA-2016-P-1180-0029_Interim_Response_Letter_from_CFSAN_to_Top_Health_I.pdf,8/30/17,CFSAN to Top Health I,2016
FDA-2016-P-1246-0007_Response_Letter_from_FDA_DDM_to_the_Working_Group_.pdf,"May 12, 
2016",FDA DDM to the Working Group,2016
FDA-2016-P-1247-0003_Interim_response_from_CDER_to_KVK_Tech__Inc.pdf,"May 4, 2016",CDER to KVK Tech  Inc,2016
FDA-2016-P-1250-0005_Interim_response_from_CDER_to_PTS_Consulting_LLC.pdf,"May 4, 2016",CDER to PTS Consulting LLC,2016
FDA-2016-P-1251-0006_Agency_Response_from_FDA_CDER_to_Lachman_Consultan.pdf,"May 9, 2016",FDA CDER to Lachman Consultan,2016
FDA-2016-P-1285-0007_Interim_Response_Letter_from_FDA_CDER_to_Mylan_Pha.pdf,"May 12, 2016",FDA CDER to Mylan Pha,2016
FDA-2016-P-1286-0006_Response_from_Lachman_Consultant_Services.pdf,"September 22, 2020",Lachman Consultant Services,2016
FDA-2016-P-1287-0007_Approval_Letter_from_FDA_CDER_to_Lachman_Consultan.pdf,"May 13, 2016",FDA CDER to Lachman Consultan,2016
FDA-2016-P-1303-0015_Interim_Response_Letter_from_CDRH_to_Consumers_for.pdf,"May 17, 2016",CDRH to Consumers for,2016
FDA-2016-P-1303-0016_Final_Response_Letter_from_FDA_CDRH_to_Consumers_f.pdf,"May 26, 2022",FDA CDRH to Consumers f,2016
FDA-2016-P-1314-0004_Interim_Response_from_FDA_CDER_to_Center_for_Respo.pdf,"May 9, 2016",FDA CDER to Center for Respo,2016
FDA-2016-P-1314-0005_Final_Response_from_FDA_CDER_to_Center_for_Respons.pdf,"May 9, 2016",FDA CDER to Center for Respons,2016
FDA-2016-P-1319-0006_Final_Response_Letter_from_FDA_CDER_to__Florek___E.pdf,"May 23, 2016",FDA CDER to  Florek   E,2016
FDA-2016-P-1363-0004_Interim_Response_Letter_from_CDER_to_Gordon_Johnst.pdf,"May 25, 2016",CDER to Gordon Johnst,2016
FDA-2016-P-1398-0003_Interim_Response_Letter_from_CDRH_to_Dr__Hooman_No.pdf,"May 31, 2016",CDRH to Dr  Hooman No,2016
FDA-2016-P-1547-0005_Approval_letter_from_CDER_FDA_to_Baxter_Healthcare.pdf,"June 8, 2016",CDER FDA to Baxter Healthcare,2016
FDA-2016-P-1650-0004_Interim_Response_Letter.pdf,"June 14, 2016",,2016
FDA-2016-P-1667-0005_Interim_Response_Letter_from_CDER_to_Zydus_Pharmac.pdf,"June 15, 2016",CDER to Zydus Pharmac,2016
FDA-2016-P-1667-0006_Response_Letter_from_FDA_CDER.pdf,"June 16, 2016",FDA CDER,2016
FDA-2016-P-1674-0007_Interim_Response_Letter_from_CFSAN_to_Tate___Lyle_.pdf,"June 16, 2016",CFSAN to Tate   Lyle,2016
FDA-2016-P-1674-0008_FDA_2016_P_1674_TateLyle_Granting_Response.pdf,"June 13, 2018",,2016
FDA-2016-P-1676-0005_Interim_Response_Letter_to_JR_Rapoza_Associates__I.pdf,"June 16, 2016",JR Rapoza Associates  I,2016
FDA-2016-P-1676-0006_Final_Response_Letter_to_JR_Rapoza_Associates__Inc.pdf,"June 16,2016",JR Rapoza Associates  Inc,2016
FDA-2016-P-1725-0003_Interim_Response_from_FDA_CDER_to_Lachman_Consulta.pdf,"June 20,2016",FDA CDER to Lachman Consulta,2016
FDA-2016-P-1825-0005_Interim_Response_Letter_from_FDA_CDER_to_Lachman_C.pdf,"June 24, 2016",FDA CDER to Lachman C,2016
FDA-2016-P-1825-0006_Final_Response_Letter_from_FDA_to_Lachman_Consulta.pdf,"June 24, 2016",FDA to Lachman Consulta,2016
FDA-2016-P-1852-0059_Interim_Response_Letter_from_CFSAN_to_Organic_Past.pdf,"June 22, 2016",CFSAN to Organic Past,2016
FDA-2016-P-1852-0060_Response_Request_Letter_from_Farm_to_Consumer_Lega.pdf,"August 2, 2019",Farm to Consumer Lega,2016
FDA-2016-P-1874-0005_Interim_Response_Letter_from_CDER_to_Public_Citize.pdf,"June 29, 2016",CDER to Public Citize,2016
FDA-2016-P-1874-0007_Denial_Response_Letter_from_FDA_CDER_to_Public_Cit.pdf,"June 29, 2016",FDA CDER to Public Cit,2016
FDA-2016-P-1946-0008_CP_Denial_Letter_from_FDA_CDER_to_Hyman__Phelps___.pdf,"July 1, 2016",FDA CDER to Hyman  Phelps,2016
FDA-2016-P-1952-0005_Response_letter_from_FDA_CDER_to_Fresenius_Kabi_US.pdf,"July 5, 2016",FDA CDER to Fresenius Kabi US,2016
FDA-2016-P-1962-0003_Interim_Response_Letter_from_FDA_CDER_to_Hyman__Ph.pdf,"July 6, 2016",FDA CDER to Hyman  Ph,2016
FDA-2016-P-1962-0005_FDA_2016_P_1962_Response_to_Comments.pdf,"July 13, 2018",Comments,2016
FDA-2016-P-2030-0011_Interim_Response_Letter_from_CFSAN_to_The_Food_Law.pdf,"July 13,2016",CFSAN to The Food Law,2016
FDA-2016-P-2072-0005_Part_approval_and_denial_letter_from_CDER_FDA_to_P.pdf,"July 11, 2016",CDER FDA to P,2016
FDA-2016-P-2091-0005_Response_letter_from_FDA_CDER_to_ANDA_Consultants.pdf,"July 14, 2016",FDA CDER to ANDA Consultants,2016
FDA-2016-P-2375-0004_Interim_Response_Letter_from_CDER_to_Akorn_Pharmac.pdf,"July 27, 2016",CDER to Akorn Pharmac,2016
FDA-2016-P-2377-0010_Interim_Response_Letter_from_CFSAN_to_Archer_Danie.pdf,"July 22, 2016",CFSAN to Archer Danie,2016
FDA-2016-P-2497-0005_Interim_Response_Letter_from_CDRH_to_Clinical_Deci.pdf,"August 16,2016",CDRH to Clinical Deci,2016
FDA-2016-P-2532-0003_Response_letter_from_FDA_to_David_K__Cundiff__M_D_.pdf,"August 25, 2016",FDA to David K  Cundiff  M D,2016
FDA-2016-P-2532-0004_30_Day_Response_Letter_from_FDA_CFSAN__to_Dr__Cund.pdf,"August 25, 2016",FDA CFSAN  to Dr  Cund,2016
FDA-2016-P-2533-0003_Interim_Response_Letter_from_CVM_to_American_Feed_.pdf,"March 10, 2017",CVM to American Feed,2016
FDA-2016-P-2533-0004_Final_Response_from_FDA_CVM_to_American_Feed_Indus.pdf,"November 9, 2022",FDA CVM to American Feed Indus,2016
FDA-2016-P-2558-0018_Interim_Response_Letter_from_CDER_to_Similasan_Cor.pdf,"August 25, 2016",CDER to Similasan Cor,2016
FDA-2016-P-2558-0019_Agency_Response_Letter_from_CDER_to_Similasan_Corp.pdf,"August 29, 2016",CDER to Similasan Corp,2016
FDA-2016-P-2559-0026_Interim_Response_Letter_from_CDRH_to_Emord_and_Ass.pdf,"August 25, 2016",CDRH to Emord and Ass,2016
FDA-2016-P-2674-0004_FDA_CDER_Response_to_Heritage_Pharma_Labs__Inc_.pdf,"August 31, 2016",Heritage Pharma Labs  Inc,2016
FDA-2016-P-2675-0004_Interim_response_from_FDA_CDER_to_Foley___Lardner_.pdf,"September 7, 2016",FDA CDER to Foley   Lardner,2016
FDA-2016-P-2676-0004_Interim_Response_Letter_from_CFSAN_to_Joshua_Schro.pdf,"August 31,2016",CFSAN to Joshua Schro,2016
FDA-2016-P-2736-0076_Interim_Response_Letter_from_CFSAN_to_Hyman__Phelp.pdf,"September 14, 2016",CFSAN to Hyman  Phelp,2016
FDA-2016-P-2736-0077_FDA_2016_P_2736_Hyman_Phelps___Granting_Response.pdf,"June 13, 2018",,2016
FDA-2016-P-2737-0125_Interim_Response_Letter_from_CVM_to_Natural_Resour.pdf,"March 10, 2017",CVM to Natural Resour,2016
FDA-2016-P-2737-0144_Final_Response_Letter_to_Natural_Resources_Defense.pdf,"February 25, 2021",Natural Resources Defense,2016
FDA-2016-P-2738-0003_Interim_Response_Letter_from_FDA_CDER_to_Metabolic.pdf,"September 14, 2016",FDA CDER to Metabolic,2016
FDA-2016-P-2860-0005_Interim_Response_Letter_from_CFSAN_to_General_Mill.pdf,"September 22, 2016",CFSAN to General Mill,2016
FDA-2016-P-2955-0053_Interim_Response_fromCBER_to_Nicholas_Isel___redac.pdf,"September 27, 2016",Nicholas Isel   redac,2016
FDA-2016-P-2955-0088_Response_from_FDA_CBER_to_Nicholas_Isel_Redacted.pdf,"September 15, 2016",FDA CBER to Nicholas Isel Redacted,2016
FDA-2016-P-2955-0136_Interim_Response_Letter_from_FDA_CBER_to_Rozovics_.pdf,"September 10, 2018",FDA CBER to Rozovics,2016
FDA-2016-P-3070-0010_Interim_Response_Letter_from_CFSAN_to_DuPont_Nutri.pdf,"September 30, 
2016",CFSAN to DuPont Nutri,2016
FDA-2016-P-3082-0014_Interim_Response_Letter_from_FDA_CDER_to__Ropes___.pdf,"September 30, 2016",FDA CDER to  Ropes,2016
FDA-2016-P-3112-0003_Interim_Response_Letter_from_FDA_OC_to_Mr__Mario_M.pdf,"January 19, 2017",FDA OC to Mr  Mario M,2016
FDA-2016-P-3195-0004_Denial_Letter_from_CDRH__to_Wood__Herron___Evans__.pdf,"October 6, 2016",CDRH  to Wood  Herron   Evans,2016
FDA-2016-P-3311-0012_Interim_Response_Letter_fromCFSAN_to_Tate___Lyle_I.pdf,"October 12,2016",Tate   Lyle I,2016
FDA-2016-P-3313-0004_CP_Response_from_FDA_CDER_to_Kleinfeld__Kaplan_and.pdf,"October 12, 2016",FDA CDER to Kleinfeld  Kaplan and,2016
FDA-2016-P-3356-0018_CP_Response_from_FDA_CDER_to_Sandoz_Inc_.pdf,"October 13, 2016",FDA CDER to Sandoz Inc,2016
FDA-2016-P-3578-0003_Interim_Response_Letter_from_CVM_to_TruthinPetFood.pdf,"October 27,2016",CVM to TruthinPetFood,2016
FDA-2016-P-3578-0006_Final_Response___Letter_from_FDA_CVM_to_Associatio.pdf,"April 30, 2019",FDA CVM to Associatio,2016
FDA-2016-P-3578-0838_Final_Response_Letter_from_FDA_CVM_to_Association_.pdf,"April 30, 2019",FDA CVM to Association,2016
FDA-2016-P-3598-0004_Interim_Response_from_FDA_to_Axinn_Veltrop___Harkr.pdf,"October 27, 2016",FDA to Axinn Veltrop   Harkr,2016
FDA-2016-P-3598-0005_Final_Response_Letter_from_FDA_to_Axinn__Veltrop__.pdf,"October 27, 2016",FDA to Axinn  Veltrop,2016
FDA-2016-P-3620-0010_Interim_Response_Letter_from_CFSAN_to_MGP_Ingredie.pdf,"October 31, 2016",CFSAN to MGP Ingredie,2016
FDA-2016-P-3674-0023_Interim_Response_Letter_from_CDRH_to_Consumers_for.pdf,"November 1, 2016",CDRH to Consumers for,2016
FDA-2016-P-3674-0024_Final_Response_Letter_from_FDA_CDRH_to_Consumers_f.pdf,"May 26, 2022",FDA CDRH to Consumers f,2016
FDA-2016-P-3753-0006_Interim_Response_Letter_from_FDA_CDER_to_MacLeods_.pdf,"November 7, 2016",FDA CDER to MacLeods,2016
FDA-2016-P-3823-0003_Agency_Response_Letter_from_FDA_CFSAN_to_Jennifer_.pdf,"October 13, 
2016",FDA CFSAN to Jennifer,2016
FDA-2016-P-3968-0136_Interim_Response_from_FDA_to_International_Probiot.pdf,"February 2, 2018",FDA to International Probiot,2016
FDA-2016-P-4047-0003_Interim_Response_Letter_from_CDER_to_Mayne_Pharma_.pdf,"November 22, 2016",CDER to Mayne Pharma,2016
FDA-2016-P-4047-0005_Final_Response_Letter_from_CDER_to_Mayne_Pharma_ln.pdf,"November 22,2016",CDER to Mayne Pharma ln,2016
FDA-2016-P-4094-0003_Response_Letter_from_FDA_CDER_to_Adapt_Pharma_Oper.pdf,"November 23, 2016",FDA CDER to Adapt Pharma Oper,2016
FDA-2016-P-4095-0005_Final_Response_from_FDA_CDER_to_Mapi_USA__Inc_.pdf,"November 24, 2016",FDA CDER to Mapi USA  Inc,2016
FDA-2016-P-4141-0003_Interim_Response_Letter_from_CDER_to_Hyman__Phelps.pdf,MAY 17 2017,CDER to Hyman  Phelps,2016
FDA-2016-P-4141-0004_Response_Letter_from_CDER_to_Hyman__Phelps___McNam.pdf,MAY 17 2017,CDER to Hyman  Phelps   McNam,2016
FDA-2016-P-4164-0006_Response_for_Information_Request_from_Lachman_Cons.pdf,"September 3, 2020",Lachman Cons,2016
FDA-2016-P-4186-0003_Interim_Response_from_FDA_CDER_to_Lachman_Consulta.pdf,"December 1, 2016",FDA CDER to Lachman Consulta,2016
FDA-2016-P-4186-0004_Response_Letter_from_FDA_CDER_to_Lachman_Consultan.pdf,"December 1, 2016",FDA CDER to Lachman Consultan,2016
FDA-2016-P-4233-0008_CFSAN_Interim_Response_Letter_to_KFSU_Ltd_Sugarcan.pdf,"December 6, 
2016",KFSU Ltd Sugarcan,2016
FDA-2016-P-4233-0009_FDA_2016_P_4233___KFSU_Granting_Response_Letter.pdf,"June 13, 2018",,2016
FDA-2016-P-4275-0055_CFSAN_Interim_Response_Letter__to_BioNeutra_North_.pdf,"December 8, 
2016",BioNeutra North,2016
FDA-2016-P-4388-0009_Interim_Response_Letter_from_FDA_CDER_to_Dr__S__Va.pdf,"December 21, 2016",FDA CDER to Dr  S  Va,2016
FDA-2016-P-4388-0013_Response_Letter_from_FDA_CDER_to_Dr__S__Varghese.pdf,"June 7, 2016",FDA CDER to Dr  S  Varghese,2016
FDA-2016-P-4584-0012_Response_letter_from_FDA_CDER_to_Public_Citizen_s_.pdf,"December 28, 2016",FDA CDER to Public Citizen s,2016
FDA-2017-P-0052-0150_Interim_Response_from_CBER_to_Donor_Sibling_Regist.pdf,"January 3, 2017",CBER to Donor Sibling Regist,2017
FDA-2017-P-0052-0203_Response_letter_from_FDA_CBER_to_Donor_Sibling_Reg.pdf,"January 3, 2017",FDA CBER to Donor Sibling Reg,2017
FDA-2017-P-0137-0005_Interim_Response_Letter_to_Macleods_Pharmaceutical.pdf,"January 9, 2017",Macleods Pharmaceutical,2017
FDA-2017-P-0176-0003_Interim_Response_from_FDA_to_American_Herbal_Produ.pdf,"February 2, 2018",FDA to American Herbal Produ,2017
FDA-2017-P-0495-0003_Interim_Response_Letter_from_FDA_CDER_to_Lachman_C.pdf,"January 25, 2017",FDA CDER to Lachman C,2017
FDA-2017-P-0508-0040_Interim_Response_Letter_from_CFSAN_to_Union_of_Con.pdf,"January 25, 2017",CFSAN to Union of Con,2017
FDA-2017-P-0840-0003_Interim_Response_Letter_from_CDER_to_The_Weinberg_.pdf,"February 8, 2017",CDER to The Weinberg,2017
FDA-2017-P-0840-0005_Final_Response_Letter_from_CDER_to_The_Weinberg_Gr.pdf,"February 8, 2017",CDER to The Weinberg Gr,2017
FDA-2017-P-0864-0003_Interim_Response_Letter_from_CDER_to_Hyman__Phelps.pdf,"February 8, 2017",CDER to Hyman  Phelps,2017
FDA-2017-P-0866-0003_Interim_Response_Letter_from_CDER_to_Hyman__Phelps.pdf,"February 8, 2017",CDER to Hyman  Phelps,2017
FDA-2017-P-0866-0004_Response_Letter_from_CDER_to_Hyman__Phelps___McNam.pdf,"February 8, 2017",CDER to Hyman  Phelps   McNam,2017
FDA-2017-P-0867-0103_Interim_Response_from_CBER_to_Public_Citizen_2.pdf,"July 25, 2017",CBER to Public Citizen 2,2017
FDA-2017-P-0867-0107_Final_Response_Letter_from_FDA_CBER_to_Public_Citi.pdf,"July 7, 2021",FDA CBER to Public Citi,2017
FDA-2017-P-0970-0006_Interim_response_letter_from_FDA_CFSAN_to_RiceBran.pdf,"February 14, 
2017",FDA CFSAN to RiceBran,2017
FDA-2017-P-0970-0007_FDA_2017_P_0970_RiceBran_Granting_Response.pdf,"June 13, 2018",,2017
FDA-2017-P-1002-0003_Denial_Response_from_FDA_CDRH_to_INRange_Systems__.pdf,"February 13, 2017",FDA CDRH to INRange Systems,2017
FDA-2017-P-1077-0003_Interim_Response_Letter_from_CDER_to_Recordati_Rar.pdf,"March 2, 2017",CDER to Recordati Rar,2017
FDA-2017-P-1077-0004_Response_Letter_from_CDER_to_Recordati_Rare_Diseas.pdf,"March 2, 2017",CDER to Recordati Rare Diseas,2017
FDA-2017-P-1096-0003_Interim_Response_Letter_from_CDER_to_Hyman__Phelps.pdf,"February 17,2017",CDER to Hyman  Phelps,2017
FDA-2017-P-1096-0004_Response_Letter_from_FDA_CDER_to_Hyman__Phelps___M.pdf,8/16/17,FDA CDER to Hyman  Phelps   M,2017
FDA-2017-P-1104-0007_Interim_Response_Letter_from_CDER_to_Gator_Pharmac.pdf,10/10/19,CDER to Gator Pharmac,2017
FDA-2017-P-1108-0005_Response_Letter_from_FDA_to_Orbicular_Pharmaceutic.pdf,"February 22, 2017",FDA to Orbicular Pharmaceutic,2017
FDA-2017-P-1226-0004_Denial_Response_from_FDA_CDRH_to_INRange_Systems_I.pdf,"February 24, 2017",FDA CDRH to INRange Systems I,2017
FDA-2017-P-1230-0004_Interim_Response_from_FDA_CDER_to_RegCon_Solutions.pdf,"February 27, 2017",FDA CDER to RegCon Solutions,2017
FDA-2017-P-1230-0006_Final_Response_from_FDA_CDER_to_RegCon_Solutions.pdf,"February 27, 2017",FDA CDER to RegCon Solutions,2017
FDA-2017-P-1251-0003_Tentative_Response_from_FDA_CVM_to_NGFA.pdf,"August 22, 2017",FDA CVM to NGFA,2017
FDA-2017-P-1251-0004_Final_Response_from_FDA_CVM_to_American_Feed_Indus.pdf,"November 9, 2022",FDA CVM to American Feed Indus,2017
FDA-2017-P-1252-0003_Interim_Response_Letter_from_FDA_CDER_to_Xiromed_L.pdf,"February 27, 2017",FDA CDER to Xiromed L,2017
FDA-2017-P-1252-0004_Response_Letter_from_FDA_CDER_to__VKT_Pharma_Priva.pdf,"May 4, 2017",FDA CDER to  VKT Pharma Priva,2017
FDA-2017-P-1297-0006_Interim_Response_Letter_from_FDA_CDER_to_Regcon_So.pdf,"March 1, 2017",FDA CDER to Regcon So,2017
FDA-2017-P-1298-0091_Interim_Response_Letter_from_FDA_CFSAN_to_The_Good.pdf,"March 2, 2017",FDA CFSAN to The Good,2017
FDA-2017-P-1359-0026_Interim_Response_Letter_from_FDA_CDER_to_Pharmaceu.pdf,"March 6, 2017",FDA CDER to Pharmaceu,2017
FDA-2017-P-1460-0003_Interim_Response_Letter_from_FDA_CDER_to_Covington.pdf,"March 8, 2017",FDA CDER to Covington,2017
FDA-2017-P-1461-0004_Response_Letter_from_FDA_CDER_to_Foley___Lardner_L.pdf,"March 8, 2017",FDA CDER to Foley   Lardner L,2017
FDA-2017-P-1573-0002_Prior_approval_supplemental_letter_from_CDER_to_Pa.pdf,"January 8, 2016",CDER to Pa,2017
FDA-2017-P-1990-0016_Interim_Response_Letter_from_FDA_to_AIDP.pdf,"March 30, 2017",FDA to AIDP,2017
FDA-2017-P-2043-0005_Interim_Response_Letter_to_Yiling_Pharmaceutical__.pdf,"March 31, 2017",Yiling Pharmaceutical,2017
FDA-2017-P-2043-0006_Response_Letter_from_FDA_to_Yiling_Pharmaceuticals.pdf,"March 31, 2017",FDA to Yiling Pharmaceuticals,2017
FDA-2017-P-2044-0017_Final_Determination_Response_to_Nirsum_Pharmaceuti.pdf,"March 31, 2017",Nirsum Pharmaceuti,2017
FDA-2017-P-2092-0018_Interim_Response_Letter_from_CDER_to_Wilson_Sonsin.pdf,"April 3, 2017",CDER to Wilson Sonsin,2017
FDA-2017-P-2092-0019_Response_Letter_from_FDA_CDER_to_Wilson_Sonsini_Go.pdf,"April 3, 2017",FDA CDER to Wilson Sonsini Go,2017
FDA-2017-P-2164-0005_Interim_Response_Letter_to_Steptoe___Johnson_LLP_d.pdf,"December 1, 2014",Steptoe   Johnson LLP d,2017
FDA-2017-P-2229-0013_Interim_Response_Letter_from_CFSAN_to_Covington___.pdf,"April 7, 2017",CFSAN to Covington,2017
FDA-2017-P-2229-0014_Interim_Response_Letter_from_CFSAN_to_American_Bak.pdf,"April 7, 2017",CFSAN to American Bak,2017
FDA-2017-P-2233-0052_Interim_Response_from_FDA_to_Consumers_for_Dental_.pdf,"April 7, 2017",FDA to Consumers for Dental,2017
FDA-2017-P-2233-0053_Final_Response_Letter_from_FDA_CDRH_to_Consumers_f.pdf,"May 26, 2022",FDA CDRH to Consumers f,2017
FDA-2017-P-2245-0004_Interim_Response_Letter_from_CDER_to_Fresenius_Kab.pdf,"April 7, 2017",CDER to Fresenius Kab,2017
FDA-2017-P-2365-0005_Interim_Response_Letter_from_CFSAN_to_Senators_Sch.pdf,"April 14, 2017",CFSAN to Senators Sch,2017
FDA-2017-P-2365-0006_Final_Response_Letter_from_FDA_to_The_Office_of_Se.pdf,"December 19, 2017",FDA to The Office of Se,2017
FDA-2017-P-2530-0004_Final_Response_Letter_from_FDA_to_Lachman_Consulta.pdf,"April 21, 2017",FDA to Lachman Consulta,2017
FDA-2017-P-2563-0042_Interim_Response_from_FDA_to_The_Tatia_Oden_French.pdf,"April 24, 2017",FDA to The Tatia Oden French,2017
FDA-2017-P-2626-0003_Interim_Response_Letter_from_FDA_CFSAN_to_Emord___.pdf,"October 17, 2017",FDA CFSAN to Emord,2017
FDA-2017-P-2626-0007_Response_letter_from_FDA__CFSAN_Emord_and_Associat.pdf,"April 26, 2017",FDA  CFSAN Emord and Associat,2017
FDA-2017-P-2659-0004_Interim_Response_from_FDA_to_Jubilant_Generics.pdf,"April 27,2017",FDA to Jubilant Generics,2017
FDA-2017-P-2659-0005_Final_Response_Letter_from_FDA_to_Jubilant_Generic.pdf,"April 27, 2017",FDA to Jubilant Generic,2017
FDA-2017-P-2660-0004_Interim_Response_from_FDA_CDER_to_Jubilant_Generic.pdf,"October 27, 2017",FDA CDER to Jubilant Generic,2017
FDA-2017-P-2660-0006_Final_Response_from_FDA_CDER_to_Jubilant_Generics.pdf,"April 27, 2017",FDA CDER to Jubilant Generics,2017
FDA-2017-P-2733-0004_Interim_Response_Letter_from_FDA_CDER_to_Esophagea.pdf,"May 1, 2017",FDA CDER to Esophagea,2017
FDA-2017-P-2733-0006_Response_Letter_from_FDA_CDER_to_Esophageal_Cancer.pdf,"May 1, 2017",FDA CDER to Esophageal Cancer,2017
FDA-2017-P-2836-0003_Interim_Response_Letter_from_FDA_CDER_to_VKT_Pharm.pdf,"May 4, 2017",FDA CDER to VKT Pharm,2017
FDA-2017-P-2836-0004_Response_Letter_from_FDA_CDER_to__VKT_Pharma_Priva.pdf,"May 4, 2017",FDA CDER to  VKT Pharma Priva,2017
FDA-2017-P-2967-0007_Final_Response_Letter_from_FDA_CDER_to_Lachman_Con.pdf,"May 9, 2017",FDA CDER to Lachman Con,2017
FDA-2017-P-3092-0010_Response_Letter_from_FDA_to___AstraZeneca_Global_M.pdf,"May 15, 2017",FDA to   AstraZeneca Global M,2017
FDA-2017-P-3196-0071_Response_Letter_from_CFSAN_to_Philip_Spiller__et__.pdf,"October 13, 2017",CFSAN to Philip Spiller  et,2017
FDA-2017-P-3196-0074_Reconsideration_Denial_CP_Response_to_Philip_Spill.pdf,"November 13, 2017",Philip Spill,2017
FDA-2017-P-3329-0003_Interim_Response_from_FDA_to_Hyman__Phelps___McNam.pdf,"May 25, 2017",FDA to Hyman  Phelps   McNam,2017
FDA-2017-P-3329-0004_Response_from_FDA_CDERto_Hyman__Phelps___McNamara_.pdf,"May 25, 2017",FDA CDERto Hyman  Phelps   McNamara,2017
FDA-2017-P-3330-0005_Interim_Response_from_FDA_redacted.pdf,"November 17, 2017",FDA redacted,2017
FDA-2017-P-3330-0006_Dental_Laser_CP_Final_Response.pdf,"January 28, 2020",,2017
FDA-2017-P-3405-0003_Interim_response__from_FDA_CDRH__to__Michael_Boggi.pdf,"May 30, 2017",FDA CDRH  to  Michael Boggi,2017
FDA-2017-P-3468-0004_Interim_Response_from_FDA_to_Teligent_Pharma__Inc.pdf,"June 1, 2017",FDA to Teligent Pharma  Inc,2017
FDA-2017-P-3484-0003_Interim_Response_Letter_from_FDA_CDER_to_Glasshous.pdf,"June 2, 2017",FDA CDER to Glasshous,2017
FDA-2017-P-3486-0013_Interim_Response_to_BioMedEcon__LLC_from_FDA_CDER.pdf,"June 2, 2017",FDA CDER,2017
FDA-2017-P-3581-0005_Response_from_FDA_CDER_to_Alembic_Pharmaceuticals.pdf,"June 7, 2017",FDA CDER to Alembic Pharmaceuticals,2017
FDA-2017-P-3672-0022_Response_Letter_from_FDA_to_Millennium_Pharmaceuti.pdf,"June 9, 2017",FDA to Millennium Pharmaceuti,2017
FDA-2017-P-3675-0004_Interim_Response_Letter_from_FDA_CDER_to_Teligent_.pdf,"June 9, 2017",FDA CDER to Teligent,2017
FDA-2017-P-3684-0004_Final_Response_Letter_from_FDA_to_Goodwin_Procter_.pdf,"June 9, 201",FDA to Goodwin Procter,2017
FDA-2017-P-3832-0003_Interim_Response_from_FDA_to_Porzio__Bromberg___Ne.pdf,"June 20, 2017",FDA to Porzio  Bromberg   Ne,2017
FDA-2017-P-3832-0004_FDA_2017_P_3832___NPA_Response_Letter.pdf,"June 13, 2018",,2017
FDA-2017-P-3884-0003_Final_Response_letter_for_FDA_2017_P_3884_and_FDA_.pdf,"December 18, 2013",,2017
FDA-2017-P-3950-0003_Interim_Response_from_FDA_to_Amin_Talati_Upadhye_L.pdf,"June 23, 2017",FDA to Amin Talati Upadhye L,2017
FDA-2017-P-4039-0003_Interim_Response_Letter_from_FDA_CDER_to_Center_fo.pdf,"July 3, 2017",FDA CDER to Center fo,2017
FDA-2017-P-4233-0007_Final_Response_Letter_from_FDA_CDER_to_Lachman_Con.pdf,"July 13, 2017",FDA CDER to Lachman Con,2017
FDA-2017-P-4245-0003_Interim_Response_from_FDA_to_Jubilant_Generics.pdf,"July 13, 2017",FDA to Jubilant Generics,2017
FDA-2017-P-4334-0042_Response_Letter_from_FDA_to_Sidley_Austin_LLP.pdf,"July 12, 2017",FDA to Sidley Austin LLP,2017
FDA-2017-P-4335-0003_Interim_response_from_FDA_CDRH_to_William_Bonifici.pdf,"July 11, 2017",FDA CDRH to William Bonifici,2017
FDA-2017-P-4335-0004_Response_Letter_from_FDA_CDRH_to_William_Bonificio.pdf,"May 26, 2021",FDA CDRH to William Bonificio,2017
FDA-2017-P-4389-0003_Interim_Response_Letter.pdf,"July 21, 2017",,2017
FDA-2017-P-4409-0004_Response__from__Synergy_Pharmaceuticals_to_CDER.pdf,"October 11,2017",Synergy Pharmaceuticals to CDER,2017
FDA-2017-P-4409-0006_Interim_Response_Letter_from_FDA_CDER_to_Hyman__Ph.pdf,"July 24, 2017",FDA CDER to Hyman  Ph,2017
FDA-2017-P-4409-0007_Response_Letter_from_FDA_CDER_to_Hyman__Phelps___M.pdf,"July 24, 2017",FDA CDER to Hyman  Phelps   M,2017
FDA-2017-P-4500-1796_Final_Response_Letter_from_FDA_CBER_to_Kent_Hecken.pdf,"December 2, 2022",FDA CBER to Kent Hecken,2017
FDA-2017-P-4575-0003_Interim_Response_Letter_from_CSFAN_to_Unilever.pdf,"August 4, 2017",CSFAN to Unilever,2017
FDA-2017-P-4575-0195_Response_Letter_to_Unilever_for_a_1_year_Extension.pdf,"August 24, 2018",Unilever for a 1 year Extension,2017
FDA-2017-P-4575-0196_Response_Letter_to_Unilever_for_a_1_year_Extension.pdf,"February 24, 2021",Unilever for a 1 year Extension,2017
FDA-2017-P-4575-0198_Response_Letter_to_Unilever_for_a_1_year_Extension.pdf,"February 23, 2022",Unilever for a 1 year Extension,2017
FDA-2017-P-4575-0200_Response_Letter_to_Unilever_for_a_1_year_Extension.pdf,"February 23, 2023",Unilever for a 1 year Extension,2017
FDA-2017-P-4575-0202_Response_Letter_to_Unilever_for_a_1_year_Extension.pdf,"February 23, 2024",Unilever for a 1 year Extension,2017
FDA-2017-P-4670-0008_Interim_Response_from_FDA_to_Baxter_Healthcare_Cor.pdf,"August 2, 2017",FDA to Baxter Healthcare Cor,2017
FDA-2017-P-4736-0003_Interim_Response_from_FDA_CDER_to_the_Americal_Den.pdf,"August 4, 2017",FDA CDER to the Americal Den,2017
FDA-2017-P-4791-0004_Interim_Response_Letter_from_CDER_to_Hyman__Phelps.pdf,"August 8, 2017",CDER to Hyman  Phelps,2017
FDA-2017-P-4939-0005_Interim_Response_Letter_to_Dr__Chul_Hi_Park.pdf,"August 14, 2017",Dr  Chul Hi Park,2017
FDA-2017-P-5027-0010_Response_Letter_from_FDA_CDER_to_Wilson_Disease_As.pdf,"August 17, 2017",FDA CDER to Wilson Disease As,2017
FDA-2017-P-5080-0003_Interim_Response_Letter_from_FDA_CDER_to_Quagen_Ph.pdf,"August 17, 2017",FDA CDER to Quagen Ph,2017
FDA-2017-P-5081-0004_Interim_Response_Letter_from_FDA_CDER_to_Pfizer__I.pdf,"August 18, 2017",FDA CDER to Pfizer  I,2017
FDA-2017-P-5081-0005_Response_from_FDA_CDER_to_Pfizer_Essential_Health_.pdf,"August 17, 2017",FDA CDER to Pfizer Essential Health,2017
FDA-2017-P-5082-0014_Interim_Response_Letter_from_FDA_CFSAN_to_ChromaDe.pdf,"February 15, 2018",FDA CFSAN to ChromaDe,2017
FDA-2017-P-5090-0003_Interim_Response_Letter_from_CDER_to_Macleods_Phar.pdf,"August 18, 2017",CDER to Macleods Phar,2017
FDA-2017-P-5090-0004_Response_Letter_from_CDER_to_Macleods_Pharmaceutic.pdf,"August 18, 2017",CDER to Macleods Pharmaceutic,2017
FDA-2017-P-5118-1369_Interim_Response_Letter_from_FDA_CFSAN_to_Gluten_F.pdf,"August 18, 2017",FDA CFSAN to Gluten F,2017
FDA-2017-P-5124-0004_Final_Response_Letter_from_FDA_to_Hyman__Phelps___.pdf,"January 31, 2018",FDA to Hyman  Phelps,2017
FDA-2017-P-5205-0003_Interim_Response_Letter_from_FDA_CDER_to_Xiromed__.pdf,"August 24, 2017",FDA CDER to Xiromed,2017
FDA-2017-P-5370-0011_Interim_Response_from_FDA_to_Dennis_Ryll_Redacted.pdf,"August 31, 2017",FDA to Dennis Ryll Redacted,2017
FDA-2017-P-5396-1001_Interim_Response_from_FDA_to_Physicians_for_Respon.pdf,"September 1, 2017",FDA to Physicians for Respon,2017
FDA-2017-P-5592-0005_Interim_Response_from_FDA_to_International_Isotope.pdf,"September 11, 2017",FDA to International Isotope,2017
FDA-2017-P-5787-0221_Interim_Response_from_FDA_to_Post_Finasteride_Synd.pdf,"September 18, 2017",FDA to Post Finasteride Synd,2017
FDA-2017-P-5787-0242_Final_Response_Letter_from_FDA_CDER_to_Post_Finast.pdf,"September 18, 2017",FDA CDER to Post Finast,2017
FDA-2017-P-5799-0004_Interim_Response_Letter_From_FDA_CDER_to_Granules_.pdf,"September 19, 2017",FDA CDER to Granules,2017
FDA-2017-P-5799-0005_Response_Letter_From_FDA_CDER_to_Granules_Pharmace.pdf,"September 18, 2017",FDA CDER to Granules Pharmace,2017
FDA-2017-P-5845-0003_Interim_Response__Letter_from_FDA_CDER_to_B_H_Cons.pdf,"September 20, 2017",FDA CDER to B H Cons,2017
FDA-2017-P-5946-0004_Response_Letter_from_FDA_to_Goodwin_Procter_LLP.pdf,"September 26, 2017",FDA to Goodwin Procter LLP,2017
FDA-2017-P-5947-0004_Interim_Response_Letter_from_FDA_CDER_to_Teligent_.pdf,"September 26, 2017",FDA CDER to Teligent,2017
FDA-2017-P-5954-0005_Interim_Response__Letter_from_FDA_CDER_to_Elite_La.pdf,"September 27, 2017",FDA CDER to Elite La,2017
FDA-2017-P-5978-0005_Interim_Response_Letter_from_FDA_CDER_to_JR_Rapoza.pdf,"September 28, 2017",FDA CDER to JR Rapoza,2017
FDA-2017-P-6020-0006_Final_Response_Letter_from_FDA_CDER_to_Axinn__Velt.pdf,"October 3, 2017",FDA CDER to Axinn  Velt,2017
FDA-2017-P-6027-0006_Approval_Letter_from_FDA_CDER_to_Axinn__Veltrop___.pdf,"October 3, 2017",FDA CDER to Axinn  Veltrop,2017
FDA-2017-P-6028-0009_Response_Letter_from_FDA_CDER_to_Axinn__Veltrop___.pdf,"October 3, 2017",FDA CDER to Axinn  Veltrop,2017
FDA-2017-P-6029-0022_Response_Letter_from_FDA_CDER_to_Novo_Nordisk__Inc.pdf,"October 2, 2017",FDA CDER to Novo Nordisk  Inc,2017
FDA-2017-P-6101-0004_Interim_Response_Letter_from_FDA_CDER_to_Strides_P.pdf,"October 10, 2017",FDA CDER to Strides P,2017
FDA-2017-P-6101-0005_Agency_Response_Letter_from_FDA_CDER_to_Strides_Ph.pdf,"October 10, 2017",FDA CDER to Strides Ph,2017
FDA-2017-P-6116-0006_Final_Response_Letter_from_FDA_CDER_to_King___Spal.pdf,"October 11, 2017",FDA CDER to King   Spal,2017
FDA-2017-P-6136-0004_Interim_response_from_FDA_CDER_to_Foley___Lardner_.pdf,"October 12, 2017",FDA CDER to Foley   Lardner,2017
FDA-2017-P-6136-0005_Denial_Letter_from_FDA__CDER_to_Foley___Lardner_LL.pdf,"October 12, 2017",FDA  CDER to Foley   Lardner LL,2017
FDA-2017-P-6208-0004_Interim_Response_Letter.pdf,"October 19,2017",,2017
FDA-2017-P-6211-0012_Interim_Response_Ltr_for_FDA_2017_P_6211_to_Hugh_C.pdf,"October 19, 2017",Hugh C,2017
FDA-2017-P-6214-0003_Interim_Response_Letter_from_FDA_CDER_to_Yabao_Pha.pdf,"September 25, 2017",FDA CDER to Yabao Pha,2017
FDA-2017-P-6214-0004_Interim_Response_Letter_from_FDA_CDER_to_Esophagea.pdf,"October 19, 2017",FDA CDER to Esophagea,2017
FDA-2017-P-6245-0009_Interim_response_letter_from_FDA_CFSAN_to_ViGuard_.pdf,"October 23, 2017",FDA CFSAN to ViGuard,2017
FDA-2017-P-6248-0007_Final_Response_Letter_from_FDA_CDER_to_Lachman_Con.pdf,"October 23, 2017",FDA CDER to Lachman Con,2017
FDA-2017-P-6274-0007_Response_Letter_from_FDA_CDER_to_Amneal_Pharmaceut.pdf,"October 26, 2017",FDA CDER to Amneal Pharmaceut,2017
FDA-2017-P-6291-0003_Interim_Response_Letter_from_FDA_CDER_to_Lachman_C.pdf,"October 26, 2017",FDA CDER to Lachman C,2017
FDA-2017-P-6307-0004_Interim_Response_Letter_from_FDA_CDER_to_Aurolife_.pdf,"October 27, 2017",FDA CDER to Aurolife,2017
FDA-2017-P-6307-0007_Response_Letter_from_FDA_CDER_to_Aurolife_Pharma_L.pdf,"October 26, 2017",FDA CDER to Aurolife Pharma L,2017
FDA-2017-P-6316-0009_Interim_Response_from_FDA_CDER_to_Provepharm__SAS.pdf,"October 30, 2017",FDA CDER to Provepharm  SAS,2017
FDA-2017-P-6316-0010_Response_Letter_from_FDA_CDER_to_Kleinfeld__Kaplan.pdf,"October 30, 2017",FDA CDER to Kleinfeld  Kaplan,2017
FDA-2017-P-6451-0006_Approval_Letter_from_FDA_CDER_to_Locke_Lord_LLP.pdf,"November 8, 2017",FDA CDER to Locke Lord LLP,2017
FDA-2017-P-6479-0004_Interim_Response_from_FDA_CDER_to_Teligent_Pharma_.pdf,"November 13, 2017",FDA CDER to Teligent Pharma,2017
FDA-2017-P-6513-0015_Interim_Response_from_FDA_CDER_to_Public_Citizen.pdf,"November 15, 2017",FDA CDER to Public Citizen,2017
FDA-2017-P-6663-0014_Letter_of_Denial_from_FDA_CDRH_to_Dr___Albert_Edwa.pdf,"May 25, 2020",FDA CDRH to Dr   Albert Edwa,2017
FDA-2017-P-6689-0004_Interim_response_from_FDA_CDER_to_Muthusamy_Shanmu.pdf,"November 29, 2017",FDA CDER to Muthusamy Shanmu,2017
FDA-2017-P-6692-0040_Interim_Response_from_FDA_CDER_to_Drug_Watch_Int_.pdf,"November 29, 2017",FDA CDER to Drug Watch Int,2017
FDA-2017-P-6745-0009_Interim_Response_Letter_from_FDA_CDER_to_Foley_Hoa.pdf,"December 5, 2017",FDA CDER to Foley Hoa,2017
FDA-2017-P-6745-0010_Response_Letter_from_FDA_CDER_to_Foley_Hoag_LLP.pdf,"May 4, 2018",FDA CDER to Foley Hoag LLP,2017
FDA-2017-P-6751-0012_180_Day_Interim_Response_Letter_from_FDA_CFSAN_to_.pdf,"December 5, 2017",FDA CFSAN to,2017
FDA-2017-P-6758-0003_Interim_Response_from_FDA_CDER_to_Public_Citizen.pdf,"December 6, 2017",FDA CDER to Public Citizen,2017
FDA-2017-P-6777-0003_Interim_Response_Letter_from_FDA_CDER_to_Hyman__Ph.pdf,"December 6, 2017",FDA CDER to Hyman  Ph,2017
FDA-2017-P-6805-0003_Interim_Response_Letter_from_FDA_CDER_to_Bracco_Di.pdf,"December 8, 2017",FDA CDER to Bracco Di,2017
FDA-2017-P-6809-0003_Interim_Response_Letter_from_FDA_CDER_to_Freyr_Inc.pdf,"December 8, 2017",FDA CDER to Freyr Inc,2017
FDA-2017-P-6809-0004_Final_Response_Letter_from_FDA_CDER_to_Freyr_Inc__.pdf,"December 8, 2017",FDA CDER to Freyr Inc,2017
FDA-2017-P-6918-0022_Response_Letter_from_FDA_CDER_to_St__Jude_Children.pdf,"June 29, 2020",FDA CDER to St  Jude Children,2017
FDA-2017-P-6968-0005_Response_Letter_from_FDA_to_Ceva_Animal_Health__LL.pdf,"December 21, 2017",FDA to Ceva Animal Health  LL,2017
FDA-2017-P-7033-0007_Response_Letter_from_FDA_CDER_to_Jubilant_Generics.pdf,"December 29, 2017",FDA CDER to Jubilant Generics,2017
FDA-2018-P-0034-0004_Interim_Response_Letter_from_FDA_CDER_to_Hyman__Ph.pdf,"January 2, 2018",FDA CDER to Hyman  Ph,2018
FDA-2018-P-0034-0005_Agency_Response_Letter_from_FDA_CDER_to_Strides_Ph.pdf,"October 10, 2017",FDA CDER to Strides Ph,2018
FDA-2018-P-0097-0003_Interim_Response_from_FDA_CDER.pdf,"January 5, 2018",FDA CDER,2018
FDA-2018-P-0098-0007_Final_Response_Letter_from_FDA_CDER_to_Lachman_Con.pdf,"January 8, 2018",FDA CDER to Lachman Con,2018
FDA-2018-P-0130-0007_Response_Letter_from_FDA_CDER_to_Lachman_Consultan.pdf,"January 8, 2018",FDA CDER to Lachman Consultan,2018
FDA-2018-P-0131-0007_Final_Response_Letter_from_FDA_CDER_to_Lachman_Con.pdf,"January 8, 2018",FDA CDER to Lachman Con,2018
FDA-2018-P-0266-0003_Response_Letter_from_FDA_CDER_to_Arent_Fox_LLP.pdf,"January 17, 2018",FDA CDER to Arent Fox LLP,2018
FDA-2018-P-0268-0003_Response_Letter_from_FDA_CDER_to_Arent_Fox_LLP.pdf,"January 17, 2018",FDA CDER to Arent Fox LLP,2018
FDA-2018-P-0269-0003_Response_Letter_from_FDA_CDER_to_Arent_Fox_LLP.pdf,"January 17, 2018",FDA CDER to Arent Fox LLP,2018
FDA-2018-P-0322-0004_Final_Response_from_FDA_CTP.pdf,"February 4, 2022",FDA CTP,2018
FDA-2018-P-0345-0006_Interim_Response_Letter_from_FDA_CDER_to_Macleods_.pdf,"January 23, 2018",FDA CDER to Macleods,2018
FDA-2018-P-0564-0006_Interim_Response_Letter_from_FDA_CFSAN_to_Panera__.pdf,"January 18, 2018",FDA CFSAN to Panera,2018
FDA-2018-P-0564-0007_Final_Response_Letter_from_FDA_CFSAN_to_Panera__LL.pdf,"March 29, 2022",FDA CFSAN to Panera  LL,2018
FDA-2018-P-0597-0004_Interim_Response_from_FDA_CDER_re_FDA_2018_P_0597.pdf,"February 7, 2018",FDA CDER re FDA 2018 P 0597,2018
FDA-2018-P-0599-0018_Interim_Response_from_FDA_OC_to_National_Pediculos.pdf,"February 6, 2018",FDA OC to National Pediculos,2018
FDA-2018-P-0599-0020_Final_Response_from_FDA_OC_to_National_Pediculosis.pdf,9/26/18,FDA OC to National Pediculosis,2018
FDA-2018-P-0614-0003_Interim_response_from_FDA_DDM_to__GeneYork_Pharmac.pdf,"February 7, 2018",FDA DDM to  GeneYork Pharmac,2018
FDA-2018-P-0625-0007_Interim_Response_from_FDA_CDER_to_Made_in_the_USA_.pdf,"February 8, 2018",FDA CDER to Made in the USA,2018
FDA-2018-P-0664-0003_Interim_response_from_FDA_CDER_to_Prinston_Pharmac.pdf,"February 9, 2018",FDA CDER to Prinston Pharmac,2018
FDA-2018-P-0670-0008_Interim_Response_Letter_FDA_2018_P_0670.pdf,"January 24, 2018",,2018
FDA-2018-P-0673-0009_Interim_Response_from_FDA_CDER_to_Justice_for_Jake.pdf,"February 9, 2018",FDA CDER to Justice for Jake,2018
FDA-2018-P-0673-0011_Response_Letter_from_FDA_CDER_to_Justice_for_Jake.pdf,"February 9, 2018",FDA CDER to Justice for Jake,2018
FDA-2018-P-0674-0007_Final_Response_Letter_from_FDA_CDER_to_Medtech_Pro.pdf,"February 12, 2018",FDA CDER to Medtech Pro,2018
FDA-2018-P-0870-0007_Final_Response_Letter_from_FDA_CDER_to_Lachman_Con.pdf,"February 26, 2018",FDA CDER to Lachman Con,2018
FDA-2018-P-0874-0049_Interim_Response_Letter_from_FDA_CFSAN_to_Bonumose.pdf,"February 22, 2018",FDA CFSAN to Bonumose,2018
FDA-2018-P-0874-0051_Interim_Response_Letter_from_FDA_CFSAN_to_Bonumose.pdf,"February 22, 2018",FDA CFSAN to Bonumose,2018
FDA-2018-P-0874-0055_Supplemental_Response_Letter_from_CFSAN_to_Bonumos.pdf,"November 29, 2023",CFSAN to Bonumos,2018
FDA-2018-P-0876-0006_Response_Letter_from_FDA_CDER_to_Hyman__Phelps___M.pdf,"February 23, 2018",FDA CDER to Hyman  Phelps   M,2018
FDA-2018-P-0877-0005_The_Food_Lawyers_Interim_Respons.pdf,"June 13, 2018",,2018
FDA-2018-P-0878-0006_Approval_Letter_from_FDA_CDER_to_Hyman__Phelps___M.pdf,"February 26, 2018",FDA CDER to Hyman  Phelps   M,2018
FDA-2018-P-0884-0004_Interim_Response_Letter_from_FDA_CDER_to_Buchanan_.pdf,"February 26, 2018",FDA CDER to Buchanan,2018
FDA-2018-P-0884-0005_Response_Letter_from_FDA_CDER_to_Buchanan_Ingersol.pdf,"February 26, 2018",FDA CDER to Buchanan Ingersol,2018
FDA-2018-P-0945-0010_Interim_Response_Letter_from_FDA_CBER_to_Scott_Bea.pdf,"February 21, 2018",FDA CBER to Scott Bea,2018
FDA-2018-P-0945-0012_Agency_Response_Letter_from_FDA_CBER_to_Scott_Beac.pdf,"February 21, 2018",FDA CBER to Scott Beac,2018
FDA-2018-P-0964-0005_Agency_Response_Letter_from_FDA_CDER_to_Fresenius_.pdf,"March 2, 2018",FDA CDER to Fresenius,2018
FDA-2018-P-0967-0005_Agency_Response_Letter_from_FDA_CDER_to_Fresenius_.pdf,"March 2, 2018",FDA CDER to Fresenius,2018
FDA-2018-P-1173-0034_Interim_Response_Letter_from_FDA_CDER_to_Alliance_.pdf,"March 15, 2018",FDA CDER to Alliance,2018
FDA-2018-P-1173-0036_Response_Letter_from_FDA_OC_to_Alliance_for_Natura.pdf,"December 13, 2022",FDA OC to Alliance for Natura,2018
FDA-2018-P-1174-0006_Final_Response_Letter_from_FDA_CDER_to_Pharma_Regu.pdf,"March 16, 2018",FDA CDER to Pharma Regu,2018
FDA-2018-P-1195-0006_Interim_Response_Letter_from_FDA_CDER_to_Kurt_Kars.pdf,"March 19, 2018",FDA CDER to Kurt Kars,2018
FDA-2018-P-1195-0007_Interim_Response_from_FDA_CDER_to_Hyman__Phelps___.pdf,"March 19, 2018",FDA CDER to Hyman  Phelps,2018
FDA-2018-P-1197-0003_Interim_Response_from_FDA_CDER_to_Exela_Pharma_Sci.pdf,"March 19, 2018",FDA CDER to Exela Pharma Sci,2018
FDA-2018-P-1263-0005_Interim_Response_Letter_from_FDA_CDER_to_Kratz___B.pdf,"March 26, 2018",FDA CDER to Kratz   B,2018
FDA-2018-P-1335-0004_Agency_Response_Letter_from_FDA_CDER_to_Hyman__Phe.pdf,"March 30, 2018",FDA CDER to Hyman  Phe,2018
FDA-2018-P-1351-0006_Agency_Response_Letter_from_FDA_CVM_to_Schafer_Vet.pdf,"March 19, 2018",FDA CVM to Schafer Vet,2018
FDA-2018-P-1352-0006_Agency_Response_Letter_from_FDA_CVM_to_Schafer_Vet.pdf,"March 19, 2018",FDA CVM to Schafer Vet,2018
FDA-2018-P-1361-0004_Agency_Response_Letter_from_FDA_CDER_to_Ajanta_Pha.pdf,"March 30, 2018",FDA CDER to Ajanta Pha,2018
FDA-2018-P-1441-0009_Response_Letter_from_FDA_CDER_to_Mr__Antell_and_Mr.pdf,"April 9, 2018",FDA CDER to Mr  Antell and Mr,2018
FDA-2018-P-1453-0019_Response_from_FDA_CDER_to_Spear_Pharmaceuticals__I.pdf,"April 9, 2018",FDA CDER to Spear Pharmaceuticals  I,2018
FDA-2018-P-1469-0007_Final_Response_Letter_from_FDA_CDRH_to_Epstein_Bec.pdf,"July 29, 2024",FDA CDRH to Epstein Bec,2018
FDA-2018-P-1484-0007_Interim_Response_from_FDA_CDER__to_Macleods_Pharma.pdf,"April 12, 2018",FDA CDER  to Macleods Pharma,2018
FDA-2018-P-1484-0008_Approval_Response_from_CDER_to_Macleods_Pharmaceut.pdf,10/5/18,CDER to Macleods Pharmaceut,2018
FDA-2018-P-1484-0009_Updated_Response_Letter_from_CDER_to_Macleods_Phar.pdf,10/5/18,CDER to Macleods Phar,2018
FDA-2018-P-1531-0008_Denial_Letter_from_CDER_to_King___Spalding_LLP.pdf,"April 16, 2018",CDER to King   Spalding LLP,2018
FDA-2018-P-1593-0051_Interim_Response_Letter_from_FDA_CFSAN_to_Pete_and.pdf,"April 23, 2018",FDA CFSAN to Pete and,2018
FDA-2018-P-1678-0006_Agency_Response_Letter_from_FDA_CDER_to__Mapi_USA_.pdf,"April 27, 2018",FDA CDER to  Mapi USA,2018
FDA-2018-P-1740-0006_Suitability_Response_Letter_from_FDA_CVM_to_Provet.pdf,"May 3, 2018",FDA CVM to Provet,2018
FDA-2018-P-1751-0004_Interim_Response_Letter_from_FDA_CDER_to_RegCon_So.pdf,"May 4, 2018",FDA CDER to RegCon So,2018
FDA-2018-P-1751-0005_Response_Letter_from_FDA__CDER_RegCon_Solutions_LL.pdf,"May 4, 2018",FDA  CDER RegCon Solutions LL,2018
FDA-2018-P-1780-0004_Interim_Response_Letter_from_FDA_CDER_to_Pacira_Ph.pdf,"May 8, 2018",FDA CDER to Pacira Ph,2018
FDA-2018-P-1780-0005_Response_Letter_from_FDA_CDER_to_Pacira_Pharmaceut.pdf,"May 8, 2018",FDA CDER to Pacira Pharmaceut,2018
FDA-2018-P-1846-0092_Interim_Response_Letter_from_FDA_DDM_to_Data_Based.pdf,"May 10, 2018",FDA DDM to Data Based,2018
FDA-2018-P-1853-0003_Interim_Response_Letter_from_FDA_CDER_to_Aurobindo.pdf,"May 10, 2018",FDA CDER to Aurobindo,2018
FDA-2018-P-1869-0008_Interim_Response_Letter_from_FDA_CDER_to_Aurobindo.pdf,"May 14, 2018",FDA CDER to Aurobindo,2018
FDA-2018-P-1880-0005_Response_Letter_from_FDA_CDER_to_Louis_Morris_Aled.pdf,"May 14, 2018",FDA CDER to Louis Morris Aled,2018
FDA-2018-P-1892-0003_Interim_response__from_FDA_CDER_to__Aurobindo_Phar.pdf,"May 15, 2018",FDA CDER to  Aurobindo Phar,2018
FDA-2018-P-1966-0006_Response_Letter_from_FDA_CDER_to_McNeely__Hare___W.pdf,"May 21, 2018",FDA CDER to McNeely  Hare   W,2018
FDA-2018-P-2025-0013_Interim_Response_from_FDA_CDER_to_Center_for_Biolo.pdf,"May 31, 2018",FDA CDER to Center for Biolo,2018
FDA-2018-P-2050-0005_Response_Letter_from_FDA_CDER_to_SS_Formulations__.pdf,"May 29, 2018",FDA CDER to SS Formulations,2018
FDA-2018-P-2073-0003_Interim_Response_Letter_from_FDA_CDRH_to_LMS_Direc.pdf,"May 16, 2018",FDA CDRH to LMS Direc,2018
FDA-2018-P-2073-0005_Response_Letter_from_FDA_to_LMS_Direc.pdf,"December 30, 2020",FDA to LMS Direc,2018
FDA-2018-P-2361-0005_Interim_Response_Letter_from_FDA_CDER_to_BF_Innova.pdf,"June 12, 
2018",FDA CDER to BF Innova,2018
FDA-2018-P-2408-0022_Agency_Response_Letter_fro_FDA_CDER_to_Public_Citi.pdf,"June 21, 2018",Public Citi,2018
FDA-2018-P-2658-0003_Interim_response_from_FDA_CDER_to__Hyman__Phelps__.pdf,"July 10, 2018",FDA CDER to  Hyman  Phelps,2018
FDA-2018-P-2658-0004_Response_Letter_from_FDA_to_Hyman__Phelps__and_McN.pdf,"July 10, 2018",FDA to Hyman  Phelps  and McN,2018
FDA-2018-P-2720-0003_Interim_response_from_FDA_CDER_to_Hyman__Phelps___.pdf,"July 13, 2018",FDA CDER to Hyman  Phelps,2018
FDA-2018-P-2749-0003_Interim_response_from_FDA_CDER_to_Anne_A__Shirinia.pdf,"July 13, 2018",FDA CDER to Anne A  Shirinia,2018
FDA-2018-P-2754-0004_Interim_response_from_FDA_CDER_to_Ascend_Laborator.pdf,"July 18, 2018",FDA CDER to Ascend Laborator,2018
FDA-2018-P-2755-0007_Interim_response_from_FDA_CDER_to_Ascend_Laborator.pdf,"July 18, 2018",FDA CDER to Ascend Laborator,2018
FDA-2018-P-2755-0008_Response_Letter_from_FDA_to_Hyman__Phelps__and_McN.pdf,"July 18, 2018",FDA to Hyman  Phelps  and McN,2018
FDA-2018-P-2838-0011_Final_Response_Letter_from_FDA_CFSAN_to_Public_Cit.pdf,"July 23, 2018",FDA CFSAN to Public Cit,2018
FDA-2018-P-2862-0007_Interim_response_from_FDA_CDER_to__Lupin_Pharmaceu.pdf,"July 24, 2018",FDA CDER to  Lupin Pharmaceu,2018
FDA-2018-P-2901-0003_Interim_response_from_FDA_CDER_to_Yiling_Pharmaceu.pdf,"July 26, 2018",FDA CDER to Yiling Pharmaceu,2018
FDA-2018-P-2997-0006_Interim_Response_from_FDA_OP_to_New_Civil_Libertie.pdf,"August 1, 2018",FDA OP to New Civil Libertie,2018
FDA-2018-P-3076-0003_Interim_Response_Letter_from_FDA_CDER_to_Dr__Josep.pdf,"August 6, 2018",FDA CDER to Dr  Josep,2018
FDA-2018-P-3176-0004_Agency_Interim_Response_Letter_from_FDA_CDRH_to_Me.pdf,"August 15, 2018",FDA CDRH to Me,2018
FDA-2018-P-3176-0005_Final_Response_Letter_from_FDA_CDER_to_Medefil__In.pdf,"August 15, 2018",FDA CDER to Medefil  In,2018
FDA-2018-P-3266-0006_Interim_Response_Letter_from_FDA_CDER_to_Haynes_an.pdf,"August 23, 2018",FDA CDER to Haynes an,2018
FDA-2018-P-3266-0007_Final_Response_Letter_from_FDA_to_Haynes_and_Boone.pdf,"August 23, 2018",FDA to Haynes and Boone,2018
FDA-2018-P-3281-0013_Final_Response_Letter_from_FDA_CDER_to_Pfizer_Esse.pdf,"August 27, 2018",FDA CDER to Pfizer Esse,2018
FDA-2018-P-3284-0022_Response_Letter_from_FDA_CDER_to__Keryx_Biopharmac.pdf,"February 21, 2019",FDA CDER to  Keryx Biopharmac,2018
FDA-2018-P-3355-0017_Interim_Response_from_FDA_CDER.pdf,"August13,2018",FDA CDER,2018
FDA-2018-P-3355-0020_Final_Response_from_FDA_CDER_to_AllCare_Health.pdf,"September 4, 2018",FDA CDER to AllCare Health,2018
FDA-2018-P-3372-0008_Final_response_from_FDA_CDRH_to_Ohio_State_Univers.pdf,"April 21, 2021",FDA CDRH to Ohio State Univers,2018
FDA-2018-P-3401-0010_Agency_Response_Letter_from_FDA_CDER_to_Novo_Nordi.pdf,"September 05, 2018",FDA CDER to Novo Nordi,2018
FDA-2018-P-3426-0004_Response_Letter_from_FDA_CDER_to_Pharmax_Group__In.pdf,"September 7, 2018",FDA CDER to Pharmax Group  In,2018
FDA-2018-P-3616-0011_Response_Letter_from_FDA_CDER_to_Suven_Life_Scienc.pdf,"September 26, 2018",FDA CDER to Suven Life Scienc,2018
FDA-2018-P-3640-0008_180_Day_Interim_Response_Letter_from_FDA_CFSAN_to_.pdf,"September 25, 2018",FDA CFSAN to,2018
FDA-2018-P-3640-0009_Interim_Response_Letter_from_FDA_CFSAN_to_Informat.pdf,"September 25, 2018",FDA CFSAN to Informat,2018
FDA-2018-P-3666-0004_Denial_Response_Letter_from_FDA_CDER_to_Fresenius_.pdf,"September 25, 2018",FDA CDER to Fresenius,2018
FDA-2018-P-3709-0011_Interim_Response_Letter_from_FDA_CDRH_to_Jennifer_.pdf,"March 4, 2019",FDA CDRH to Jennifer,2018
FDA-2018-P-3709-0014_Final_Response_Letter_from_FDA_CDRH_to_Jennifer_Ne.pdf,"July 12, 2022",FDA CDRH to Jennifer Ne,2018
FDA-2018-P-3742-0005_Final_Response_from_FDA_CDER_to_Pharmacmechanics.pdf,"October 1, 2018",FDA CDER to Pharmacmechanics,2018
FDA-2018-P-3786-0006_Response_Letter_from_FDA_CDER_to_Hyman__Phelps___M.pdf,"October 3, 2018",FDA CDER to Hyman  Phelps   M,2018
FDA-2018-P-3806-0004_Response_letter_from_FDA_CDER_to_Greg_Grillo.pdf,"October 4, 2018",FDA CDER to Greg Grillo,2018
FDA-2018-P-3825-0004_180_Day_Interim_Response_Letter_from_FDA_CFSAN_to_.pdf,"October 9, 2018",FDA CFSAN to,2018
FDA-2018-P-3896-0005_Interim_Response_from_FDA_CDRH_to_Chul_Hi_Park_Red.pdf,"April 11,2019",FDA CDRH to Chul Hi Park Red,2018
FDA-2018-P-3933-0003_Response_Letter_from_FDA_CDER_to_Fresenius_Kabi_US.pdf,"October 17, 2018",FDA CDER to Fresenius Kabi US,2018
FDA-2018-P-3951-0004_Interim_Response_Letter_from_FDA_CDRH_Redacted.pdf,"October 18, 2018",FDA CDRH Redacted,2018
FDA-2018-P-4281-0006_Response_Letter_from_FDA_CDER_to_Fresenius_Kabi_US.pdf,"November 7, 2018",FDA CDER to Fresenius Kabi US,2018
FDA-2018-P-4306-0037_Interim_Response_from_FDA_CDER__re_Citizen_Petitio.pdf,"November 9, 2018",FDA CDER  re Citizen Petitio,2018
FDA-2018-P-4306-0050_Response_Letter_from_FDA_CDER_to_Jill_H__Osborne_R.pdf,"November 8, 2018",FDA CDER to Jill H  Osborne R,2018
FDA-2018-P-4338-0025_Agency_Response_Letter_from_FDA_CDER_to_PMRS.pdf,"November 13, 2018",FDA CDER to PMRS,2018
FDA-2018-P-4454-0011_Final_Response_Letter_from_FDA_CFSAN_to_Bonumose_L.pdf,"November 19, 2018",FDA CFSAN to Bonumose L,2018
FDA-2018-P-4549-0007_Interim_Response_Letter_for_FDA_2018_P_4549.pdf,"November 29, 2018",FDA DDM to Unichem Phar,2018
FDA-2018-P-4549-0009_Response_Letter_from_FDA_CDER_to_Unichem_Pharmaceu.pdf,"November 28, 2018",FDA CDER to Unichem Pharmaceu,2018
FDA-2018-P-4591-0003_Interim_Response_Letter_from_FDA_CFSAN_to_Internat.pdf,"November 30, 2018",FDA CFSAN to Internat,2018
FDA-2018-P-4642-0005_Agency_Response_Letter_from_FDA_CVM_to_Provetica_A.pdf,"December 6, 
2018",FDA CVM to Provetica A,2018
FDA-2018-P-4832-0004_Interim_Response_Letter_from_FDA_CDER_to_Goodwin_P.pdf,"December 21, 2018",FDA CDER to Goodwin P,2018
FDA-2018-P-4832-0005_Final_Response_Letter_from_FDA_CDER_to_Goodwin_Pro.pdf,"December 21, 2018",FDA CDER to Goodwin Pro,2018
FDA-2019-P-0076-0008_Response_Letter_from_FDA_CDER_to_Unichem_Pharmaceu.pdf,1/7/19,FDA CDER to Unichem Pharmaceu,2019
FDA-2019-P-0198-0006_Response_Letter_from_FDA_to_Lachman_Consultant_Ser.pdf,1/14/19,FDA to Lachman Consultant Ser,2019
FDA-2019-P-0417-0013_Response_Letter_from_FDA_CDER_to_Scilex_Pharmaceut.pdf,"December 31, 2018",FDA CDER to Scilex Pharmaceut,2019
FDA-2019-P-0537-0004_Response_Letter_from_FDA_CDER_to_Kulkarni_Law_Firm.pdf,2/4/19,FDA CDER to Kulkarni Law Firm,2019
FDA-2019-P-0726-0007_Final_Response_Letter_from_FDA_CDER_to_Sunny_Pharm.pdf,"February 13, 2019",FDA CDER to Sunny Pharm,2019
FDA-2019-P-0913-0009_Interim_Response_Letter_from_FDA_CFSAN_to_Independ.pdf,3/20/19,FDA CFSAN to Independ,2019
FDA-2019-P-0916-0005_Response_Letter_from_FDA_to_Felix_Pharmaceuticals_.pdf,"February 25, 2019",FDA to Felix Pharmaceuticals,2019
FDA-2019-P-1130-0006_Final_Response_Letter_from_FDA_CBER_to_Kent_Hecken.pdf,"December 2, 2022",FDA CBER to Kent Hecken,2019
FDA-2019-P-1198-0009_Interim_Response_Letter_from_FDA_CFSAN_to_KIND_LLC.pdf,"March 13, 
2019",FDA CFSAN to KIND LLC,2019
FDA-2019-P-1236-0006_Interim_Response_Letter_from_FDA_CDER_to_Sarfaraz_.pdf,3/15/19,FDA CDER to Sarfaraz,2019
FDA-2019-P-1351-0351_Interim_Response_Letter_from_FDA_CDER_to_Law_Offic.pdf,3/21/19,FDA CDER to Law Offic,2019
FDA-2019-P-1525-0005_Interim_Response_Letter_from_FDA_CDER_to_Baxter_He.pdf,4/30/19,FDA CDER to Baxter He,2019
FDA-2019-P-1525-0007_Final_Response_Letter_from_FDA_CDER_to_Baxter_Heal.pdf,4/30/19,FDA CDER to Baxter Heal,2019
FDA-2019-P-1534-0014_Interim_Response_Letter_from_FDA_CDER_to_American_.pdf,4/1/19,FDA CDER to American,2019
FDA-2019-P-1534-0016_Response_Letter_from_FDA_CDER_to_American_Associat.pdf,"March 29, 2019",FDA CDER to American Associat,2019
FDA-2019-P-1560-0003_Interim_Response_Letter_from_FDA_CDER_to_Hyman__Ph.pdf,4/3/19,FDA CDER to Hyman  Ph,2019
FDA-2019-P-1607-0003_Response_Letter_from_FDA_to_Aurobindo_Pharma_USA__.pdf,4/4/19,FDA to Aurobindo Pharma USA,2019
FDA-2019-P-1636-0006_Interim_Response_Letter_from_FDA_CDER_to_Nexsen_Pr.pdf,4/5/19,FDA CDER to Nexsen Pr,2019
FDA-2019-P-1640-0008_Interim_Response_Letter_from_FDA_CFSAN_to_Top_Heal.pdf,4/5/19,FDA CFSAN to Top Heal,2019
FDA-2019-P-1640-0010_Final_Response_Letter_from_FDA_CFSAN_to_Top_Health.pdf,"January 9, 2020",FDA CFSAN to Top Health,2019
FDA-2019-P-1678-0003_Interim_Response_Letter_from_FDA_CDER_to_Exela_Pha.pdf,4/8/19,FDA CDER to Exela Pha,2019
FDA-2019-P-1679-0077_Interim_Response_from_FDA_Office_of_Orphan_Product.pdf,"April 8, 2019",FDA Office of Orphan Product,2019
FDA-2019-P-1679-0079_Response_Letter_from_FDA_to_Lassman_Law___Policy.pdf,"April 5, 2019",FDA to Lassman Law   Policy,2019
FDA-2019-P-1783-0005_Response_Letter___Denial__from_FDA_CDER_to_Public_.pdf,4/16/19,FDA CDER to Public,2019
FDA-2019-P-1800-0006_Denial_Response_from_FDA_CDRH_to_Boditech_Med_Inc_.pdf,"April 16, 2019",FDA CDRH to Boditech Med Inc,2019
FDA-2019-P-1818-0007_Interim_Response_from_FDA_CDER_to_Public_Citizen_s.pdf,4/17/19,FDA CDER to Public Citizen s,2019
FDA-2019-P-1818-0008_Agency_Response_Letter_from_FDA_CDER_to_Public_Cit.pdf,"April 16, 2019",FDA CDER to Public Cit,2019
FDA-2019-P-1893-0008_Interim_Response_Letter_from_FDA_CDER_to_Novartis_.pdf,4/19/19,FDA CDER to Novartis,2019
FDA-2019-P-1893-0010_Final_Response_Letter_from_FDA_CDER_to_Novartis_Ph.pdf,"April 18, 2019",FDA CDER to Novartis Ph,2019
FDA-2019-P-1911-0007_Interim_Response_Letter_from_FDA_CFSAN_to_Keller_a.pdf,4/22/19,FDA CFSAN to Keller a,2019
FDA-2019-P-1911-0008_Final_Response_Letter_from_FDA_CFSAN_to_Keller_and.pdf,4/22/19,FDA CFSAN to Keller and,2019
FDA-2019-P-1980-0006_Interim_Response_Letter_from_FDA_CDER_to_Novitium_.pdf,4/25/19,FDA CDER to Novitium,2019
FDA-2019-P-2074-0003_Interim_Response_from_FDA_CDER_to_Encube_Ethicals_.pdf,5/10/19,FDA CDER to Encube Ethicals,2019
FDA-2019-P-2074-0004_Final_Response_from_FDA_CDER_to_Encube_Ethicals_Pr.pdf,"April 30, 2019",FDA CDER to Encube Ethicals Pr,2019
FDA-2019-P-2088-0003_Interim_Response_Letter_from_FDA_CDER_to_Summit_He.pdf,5/2/19,FDA CDER to Summit He,2019
FDA-2019-P-2123-0004_Agency_Response_Letter_from_FDA_CDER_to_Lachman_Co.pdf,5/2/19,FDA CDER to Lachman Co,2019
FDA-2019-P-2142-0006_Interim_Response_Letter_from_FDA_to_Archer_Daniels.pdf,5/3/19,FDA to Archer Daniels,2019
FDA-2019-P-2239-0008_Interim_Response_Letter_from_FDA_to_BioNeutra_Nort.pdf,5/10/19,FDA to BioNeutra Nort,2019
FDA-2019-P-2239-0009_Final_Response_Letter_from_FDA_to_BioNeutra_North_.pdf,"January 9, 2020",FDA to BioNeutra North,2019
FDA-2019-P-2240-0010_Response_Letter_from_FDA_CDER_to_Axinn.pdf,5/9/19,FDA CDER to Axinn,2019
FDA-2019-P-2289-0183_Partial_Response_from_FDA_CDER_to_Contraceptive_St.pdf,"May 9, 2019",FDA CDER to Contraceptive St,2019
FDA-2019-P-2370-0004_Response_Letter_from_FDA_CDER_to_Alembic_Pharmaceu.pdf,5/23/19,FDA CDER to Alembic Pharmaceu,2019
FDA-2019-P-2537-0005_Interim_Response_from_FDA_to_Allergan_Holdings_Unl.pdf,5/24/19,FDA to Allergan Holdings Unl,2019
FDA-2019-P-2590-0003_Interim_Response_Letter_from_FDA_to_Fresenius_Kabi.pdf,5/29/19,FDA to Fresenius Kabi,2019
FDA-2019-P-2853-0003_Interim_Response_Letter_from_FDA_to_Fresenius_Medi.pdf,6/13/19,FDA to Fresenius Medi,2019
FDA-2019-P-2853-0004_Final_Response_from_FDA_CDER_to_Fresenius_Medical_.pdf,"June 11, 2019",FDA CDER to Fresenius Medical,2019
FDA-2019-P-2869-0006_Interim_Response_Letter_from_FDA_CDER_to_Valisure_.pdf,6/13/19,FDA CDER to Valisure,2019
FDA-2019-P-2945-0062_FDA_Interim_Reponse_Redacted.pdf,6/25/19,Jesse J LeBlanc III,2019
FDA-2019-P-2982-0004_Agency_Response_Letter_from_FDA_CDER_to_Hetero_Lab.pdf,6/20/19,FDA CDER to Hetero Lab,2019
FDA-2019-P-2998-0006_Interim_Response_Letter_from_FDA_CDER_to_SONAR.pdf,6/21/19,FDA CDER to SONAR,2019
FDA-2019-P-2998-0104_Final_Response_Letter_from_FDA_CDER_to_Southern_Ne.pdf,"June 20, 
2019",FDA CDER to Southern Ne,2019
FDA-2019-P-3022-0008_Approval_Letter_from_FDA_CDER_to_Foley___Lardner_L.pdf,"June 24, 2019",FDA CDER to Foley   Lardner L,2019
FDA-2019-P-3082-0004_Interim_Response_Letter_from_FDA_CDER_to_Andarix_P.pdf,6/26/19,FDA CDER to Andarix P,2019
FDA-2019-P-3109-0006_Approval_Letter_from_FDA_CVM_to_Noble_Pharma__LLC.pdf,"June 24, 2019",FDA CVM to Noble Pharma  LLC,2019
FDA-2019-P-3232-0004_Interim_Response_Letter_from_FDA_CDER_to_Lachman_C.pdf,7/5/19,FDA CDER to Lachman C,2019
FDA-2019-P-3232-0006_Response_Letter_from_FDA_CDER_to_Lachman_Consultan.pdf,"July 2, 2019",FDA CDER to Lachman Consultan,2019
FDA-2019-P-3266-0014_Interim_Response_letter_to__Medical_Research_Colla.pdf,7/8/19,Medical Research Colla,2019
FDA-2019-P-3424-0003_Response_Letter_from_FDA_CDER_to_Medical_Research_.pdf,7/17/19,FDA CDER to Medical Research,2019
FDA-2019-P-3545-0008_Response_Letter_from_FDA_CDER_to_Axinn__Veltrop___.pdf,7/26/19,FDA CDER to Axinn  Veltrop,2019
FDA-2019-P-3803-0003_Interim_Response_Letter_from_FDA_CDER_to_Hyman__Ph.pdf,8/13/19,FDA CDER to Hyman  Ph,2019
FDA-2019-P-3809-0003_Final_Response_Letter_from_FDA_CDER_to_Lachman_Con.pdf,8/13/19,FDA CDER to Lachman Con,2019
FDA-2019-P-3877-0004_Response_Letter_to_Harman_Finochem_Limited_Updated.pdf,8/20/19,Harman Finochem Limited Updated,2019
FDA-2019-P-3903-0003_Interim_Response_Letter_from_FDA_CDER_to_Hyman__Ph.pdf,"August 16, 2019",FDA CDER to Hyman  Ph,2019
FDA-2019-P-3903-0004_Approval_Letter_from_FDA_CDER_to_Hyman__Phelps___M.pdf,"August 16, 2019",FDA CDER to Hyman  Phelps   M,2019
FDA-2019-P-3907-0003_Interim_Response_Letter_from_FDA_CDER_to_Novitium_.pdf,"August 16, 2019",FDA CDER to Novitium,2019
FDA-2019-P-3937-0003_Interim_Response_Letter_from_FDA_CDER_to_Teva_Phar.pdf,8/21/19,FDA CDER to Teva Phar,2019
FDA-2019-P-4003-0010_Denial_Response_from_FDA_CDER_to_Lisa_Myslinski_Re.pdf,8/26/19,FDA CDER to Lisa Myslinski Re,2019
FDA-2019-P-4006-0007_Interim_Response_Letter_from_FDA_CFSAN_to_Tate___L.pdf,8/26/19,FDA CFSAN to Tate   L,2019
FDA-2019-P-4140-0016_Response_Letter_from_FDA_CDER_to_Persion_Pharmaceu.pdf,9/5/19,FDA CDER to Persion Pharmaceu,2019
FDA-2019-P-4155-0003_Interim_Response_Letter_from_FDA_CDER_to_Teva_Phar.pdf,9/6/19,FDA CDER to Teva Phar,2019
FDA-2019-P-4261-0003_Interim_Response_Letter_from_FDA_CDER_to_Hyman__Ph.pdf,9/12/19,FDA CDER to Hyman  Ph,2019
FDA-2019-P-4261-0004_Approval_Letter_from_FDA_CDER_to_Hyman__Phelps___M.pdf,"May 14, 2020",FDA CDER to Hyman  Phelps   M,2019
FDA-2019-P-4281-0007_Interim_Response_Letter_from_FDA_CDER_to_Valisure_.pdf,"September 13, 2019",FDA CDER to Valisure,2019
FDA-2019-P-4281-0008_Final_Response_Letter_from_FDA_CDER_to_Valisure__L.pdf,"April 1, 2020",FDA CDER to Valisure  L,2019
FDA-2019-P-4424-0003_Interim_Response_Letter_from_FDA_CDER_to_Hibrow_He.pdf,"September 23, 2019",FDA CDER to Hibrow He,2019
FDA-2019-P-4424-0004_Response_letter_from_FDA__CDER_to_Hibrow_Healthcar.pdf,"May 7, 2020",FDA  CDER to Hibrow Healthcar,2019
FDA-2019-P-4448-0004_Interim_Response_Letter_from_FDA_CFSAN_to_Samuel_A.pdf,"September 24, 2019",FDA CFSAN to Samuel A,2019
FDA-2019-P-4481-0007_Interim_Response_Letter_from_FDA_CDER_to_Macleods_.pdf,"April 29, 2020",FDA CDER to Macleods,2019
FDA-2019-P-4515-0004_Interim_Response_from_Foley___Lardner_LLP_to_FDA_C.pdf,"September 26, 2019",Foley   Lardner LLP to FDA C,2019
FDA-2019-P-4643-0014_Final_response_from_FDA_CFSAN_to_Physicians_Commit.pdf,10/4/19,FDA CFSAN to Physicians Commit,2019
FDA-2019-P-4669-0003_Interim_Response_Letter_from_FDA_CFSAN_to_RdR_Solu.pdf,10/8/19,FDA CFSAN to RdR Solu,2019
FDA-2019-P-4670-0005_Interim_Response_Letter_from_FDA_CFSAN_to_Lonza_In.pdf,10/8/19,FDA CFSAN to Lonza In,2019
FDA-2019-P-4670-0008_Response_Letter_from_FDA_CFSAN_to_Lonza_Inc.pdf,"February 24, 2022",FDA CFSAN to Lonza Inc,2019
FDA-2019-P-4683-0007_Interim_Response_Letter_from_FDA_CDER_to_Public_Ci.pdf,"October 8, 2019",FDA CDER to Public Ci,2019
FDA-2019-P-4683-0008_Response_Letter_from_FDA__to_Public_Citizen_s_Heal.pdf,"October 8, 2019",FDA  to Public Citizen s Heal,2019
FDA-2019-P-4830-0014_Interim_Response_Letter_from_FDA_CDER_to_Ipsen_Bio.pdf,10/17/19,FDA CDER to Ipsen Bio,2019
FDA-2019-P-4830-0016_Response_Letter_from_FDA_CDER_to_Ipsen_Biopharmace.pdf,"October 15, 2019",FDA CDER to Ipsen Biopharmace,2019
FDA-2019-P-4879-0004_Interim_Response_from_FDA_CDER_to_Lachman_Consulta.pdf,"October 18, 2019",FDA CDER to Lachman Consulta,2019
FDA-2019-P-4962-0003_Interim_Response_Letter_from_FDA_CDER_to_Fresenius.pdf,"October 24, 2019",FDA CDER to Fresenius,2019
FDA-2019-P-4962-0005_Interim_Response_Letter_from_FDA_CDER_to_Fresenius.pdf,"January 15, 2021",FDA CDER to Fresenius,2019
FDA-2019-P-5048-0005_Interim_Response_Letter_from_FDA_CDRH_to_Epstein_B.pdf,"April 27, 2020",FDA CDRH to Epstein B,2019
FDA-2019-P-5048-0006_Final_Response_Letter_from_FDA_CDRH_to_Epstein_Bec.pdf,"July 29, 2024",FDA CDRH to Epstein Bec,2019
FDA-2019-P-5069-0004_Interim_Response_Letter_from_FDA_CFSAN_to_Ontario_.pdf,"April 6, 2020",FDA CFSAN to Ontario,2019
FDA-2019-P-5069-0005_Final_Response_letter_from_FDA_CFSAN_to_Ms__Rebecc.pdf,"June 30, 2020",FDA CFSAN to Ms  Rebecc,2019
FDA-2019-P-5151-0069_Response_Letter_from_FDA_OSPOP_ORA_to_Robert_K__Je.pdf,"February 21, 2020",FDA OSPOP ORA to Robert K  Je,2019
FDA-2019-P-5151-0077_Interim_Response_Letter_from_FDA_CDER_to_GlaxoSmit.pdf,"November 1, 2019",FDA CDER to GlaxoSmit,2019
FDA-2019-P-5151-0080_Response_Letter_to_GlaxoSmithKline_from_CDER.pdf,"November 1, 2019",CDER,2019
FDA-2019-P-5191-0017_Interim_response_letter_from_FDA_CFSAN.pdf,11/6/19,FDA CFSAN,2019
FDA-2019-P-5237-0004_Interim_Response_Letter_from_FDA_CDER_to_US_Agent_.pdf,"November 5, 2019",FDA CDER to US Agent,2019
FDA-2019-P-5266-0003_Interim_Response_from_FDA_to_James_Grote.pdf,"May 6, 2020",FDA to James Grote,2019
FDA-2019-P-5268-0015_Interim_Response_Letter_from_FDA_CDER_to_Public_Ci.pdf,"May 4, 2020",FDA CDER to Public Ci,2019
FDA-2019-P-5268-0017_Final_Response_Letter_from_FDA_CDER_to_Public_Citi.pdf,"November 6, 2019",FDA CDER to Public Citi,2019
FDA-2019-P-5394-0003_Interim_Response_Letter_from_FDA_CFSAN_to_Consumer.pdf,"June 16, 2020",FDA CFSAN to Consumer,2019
FDA-2019-P-5394-0004_Response_Letter_from_FDA_CFSAN_to_Consumer_Healthc.pdf,"January 26, 2023",FDA CFSAN to Consumer Healthc,2019
FDA-2019-P-5403-0007_Interim_Response_from_FDA_CDER_to_Husch_Blackwell_.pdf,"May 6, 2020",FDA CDER to Husch Blackwell,2019
FDA-2019-P-5440-0003_Interim_response_letter_from_FDA_CDER_to_Diane_Kra.pdf,"November 18, 2019",FDA CDER to Diane Kra,2019
FDA-2019-P-5441-0004_Interim_Response_from_FDA_to_Hyman__Phelps___McNam.pdf,"May 11, 2020",FDA to Hyman  Phelps   McNam,2019
FDA-2019-P-5593-0006_Final_Response_from_FDA_CDER_to_Hyman__Phelps___Mc.pdf,"November 25, 2019",FDA CDER to Hyman  Phelps   Mc,2019
FDA-2019-P-5759-0007_Cover_letter__Response.pdf,"May 3, 2021",,2019
FDA-2019-P-5759-0008_Final_Response_Letter_from_FDA_CDER_to_Aavis_Pharm.pdf,"December 6, 2019",FDA CDER to Aavis Pharm,2019
FDA-2019-P-5760-0007_Response_Letter_from_FDA_CDER_to_Sun_Pharmaceutica.pdf,"December 6, 2019",FDA CDER to Sun Pharmaceutica,2019
FDA-2019-P-5791-0007_Final_Response_from_FDA_CDER_to_Guvam_Pharma_LLC.pdf,"December 8, 2019",FDA CDER to Guvam Pharma LLC,2019
FDA-2019-P-5800-0003_Interim_response_to_Verax_from_FDA_CBER.pdf,"December 10, 2019",FDA CBER,2019
FDA-2019-P-5887-0005_Agency_Response_Letter_from_FDA_CFSAN_to_Upfield_U.pdf,"June 7, 2022",FDA CFSAN to Upfield U,2019
FDA-2019-P-5887-0006_Final_Response_from_FDA_CFSAN_to_Upfield_US_Inc.pdf,12/13/19,FDA CFSAN to Upfield US Inc,2019
FDA-2019-P-5922-0013_Interim_Response_Letter_from_FDA__CTP_to_Respira_T.pdf,"May 5, 2020",FDA  CTP to Respira T,2019
FDA-2019-P-5943-0007_Response_Letter_from_FDA_CDER_to_Hyman__Phelps___M.pdf,"December 16, 2019",FDA CDER to Hyman  Phelps   M,2019
FDA-2019-P-5970-0005_Response_Letter_from_FDA_CDER_to_IQVIA_RDS_In.pdf,12/18/19,FDA CDER to IQVIA RDS In,2019
FDA-2019-P-6044-0006_Agency_Response_Letter_from_FDA_CDER_to_Latham_and.pdf,12/26/19,FDA CDER to Latham and,2019
FDA-2019-P-6045-0019_180_day_Interim_Response_to_the_Wacker_Chemical_Co.pdf,"June 19,2020",the Wacker Chemical Co,2019
FDA-2019-P-6045-0021_Final_Response_Letter_from_FDA_CFSAN_to_Hyman_Phel.pdf,"April 25, 2022",FDA CFSAN to Hyman Phel,2019
FDA-2019-P-6049-0030_Response_Letter_from_FDA_CDER_to_US_WorldMeds__LLC.pdf,"December 23, 2019",FDA CDER to US WorldMeds  LLC,2019
FDA-2019-P-6099-0004_Interim_Response_from_FDA_CBER_to_Public_Citizen.pdf,"December 30, 2019",FDA CBER to Public Citizen,2019
FDA-2019-P-6099-0005_Final_Response_from_FDA_CBER_to_Patients_for_Acces.pdf,"December 30, 2019",FDA CBER to Patients for Acces,2019
FDA-2019-P-6100-0031_Interim_Response_Letter_from_FDA_CBER_to_American_.pdf,"December 31, 
2019",FDA CBER to American,2019
FDA-2019-P-6100-0034_Response_Leter_from_CBER_to_American_Association_o.pdf,"June 8, 2020",CBER to American Association o,2019
FDA-2019-P-6100-0036_Response_Letter_from_CBER_to_American_Association_.pdf,"August 25, 2022",CBER to American Association,2019
FDA-2020-P-0102-0004_Interim_response_from_FDA_CDER_to_Linda_Valentine.pdf,"July 13, 2020",FDA CDER to Linda Valentine,2020
FDA-2020-P-0421-0008_Response_Letter_from_FDA_CDER_to_Cooley_s_Anemia_F.pdf,"January 24, 2020",FDA CDER to Cooley s Anemia F,2020
FDA-2020-P-0511-0006_Interim_Response_letter_from_FDA_CDER_to_Novitium_.pdf,"July 31, 2020",FDA CDER to Novitium,2020
FDA-2020-P-0599-0004_Response_letter_from_FDA_CDER_to_Romark_Laboratori.pdf,"February 4, 
2020",FDA CDER to Romark Laboratori,2020
FDA-2020-P-0725-0011_Interim_Response_letter_from_FDA_CDRH_to_GBUK_Grou.pdf,"July 18, 2020",FDA CDRH to GBUK Grou,2020
FDA-2020-P-0734-0020_Interim_Response_letter_from_FDA_CDRH_to_GBUK_Grou.pdf,"July 18, 2020",FDA CDRH to GBUK Grou,2020
FDA-2020-P-0763-0005_Response_Letter_from_FDA_CDER_to_Clark_Anderson.pdf,"February 12, 2020",FDA CDER to Clark Anderson,2020
FDA-2020-P-0893-0010_Interim_Response_letter_from_FDA_CDRH_to_Kelly_Rom.pdf,2/21/20,FDA CDRH to Kelly Rom,2020
FDA-2020-P-0945-0013_Interim_Response_letter_from_FDA_CDRH_to_Dr__Ernes.pdf,"July 18, 2020",FDA CDRH to Dr  Ernes,2020
FDA-2020-P-0947-0003_Interim_Response_from_FDA_CDER_to_Hyman__Phelps__M.pdf,"February 26, 2020",FDA CDER to Hyman  Phelps  M,2020
FDA-2020-P-0978-0007_Partial_Response_Letter_from_FDA_CDER_to_Valisure_.pdf,"May 28, 2020",FDA CDER to Valisure,2020
FDA-2020-P-0978-0009_Response_Letter_from_FDA_CDER_to_Valisure__LLC.pdf,"June 12, 2020",FDA CDER to Valisure  LLC,2020
FDA-2020-P-0983-0004_Final_Response_from_FDA_CDER_to_grBiosystems_Inc_.pdf,"February 27, 2020",FDA CDER to grBiosystems Inc,2020
FDA-2020-P-1016-0009_Interim_response_from_FDA_CDER_to_CellTrion__Inc_.pdf,"August 26, 2020",FDA CDER to CellTrion  Inc,2020
FDA-2020-P-1052-0004_Tentative_Response_from_FDA_CTP_to_National_Tobacc.pdf,"August 17, 2020",FDA CTP to National Tobacc,2020
FDA-2020-P-1072-0005_Response_Letter_from_FDA_CDER_to_Yiling_Pharmaceut.pdf,"March 10, 2020",FDA CDER to Yiling Pharmaceut,2020
FDA-2020-P-1166-0005_Agency_Response__Letter_from_FDA_CDRH_to_Eckert_Se.pdf,"March 27, 2020",FDA CDRH to Eckert Se,2020
FDA-2020-P-1166-0006_Agency_Response_Letter_from_FDA_CDRH_to_Eckert_Sea.pdf,"June 11, 2022",FDA CDRH to Eckert Sea,2020
FDA-2020-P-1246-0004_Response_Letter_from_FDA_CDER_to_Fresenius_Kabi_US.pdf,"April 2, 2020",FDA CDER to Fresenius Kabi US,2020
FDA-2020-P-1247-0005_Interim_Response_Letter_from_FDA_CDER_to_Belcher_P.pdf,"April 2, 2020",FDA CDER to Belcher P,2020
FDA-2020-P-1247-0006_Final_Response_Letter_from_FDA_CDER_to_Belcher_Pha.pdf,"April 2, 2020",FDA CDER to Belcher Pha,2020
FDA-2020-P-1334-0034_Interim_Response_from_FDA_CDER_to_TherapeuticsMD__.pdf,"May 1, 2020",FDA CDER to TherapeuticsMD,2020
FDA-2020-P-1344-0007_Response_Letter_from_FDA_CDER_to_Lachman_Consultan.pdf,"October 12, 2023",FDA CDER to Lachman Consultan,2020
FDA-2020-P-1369-0003_Interim_Response_Letter_from_FDA_CDER_to_Hyman__Ph.pdf,"May 8, 2020",FDA CDER to Hyman  Ph,2020
FDA-2020-P-1423-0061_Interim_response_letter_from_FDA_CFSAN.pdf,5/26/20,FDA CFSAN,2020
FDA-2020-P-1506-0009_Partial_Interim_Response_from_FDA_CVM_to_Daniel_Wa(1).pdf,"December 17, 2020",FDA CVM to Daniel Wa(1),2020
FDA-2020-P-1506-0009_Partial_Interim_Response_from_FDA_CVM_to_Daniel_Wa.pdf,"December 17, 2020",FDA CVM to Daniel Wa(1),2020
FDA-2020-P-1506-0010_Final_Response_Letter_from_FDA_CVM_to_Animal_Legal.pdf,"February 28, 2025",FDA CVM to Animal Legal,2020
FDA-2020-P-1511-0009_Interim_Response_Letter_from_FDA_CDER_to_Annora_Ph.pdf,"June 5, 2020",FDA CDER to Annora Ph,2020
FDA-2020-P-1511-0011_Final_Response_Letter_from_FDA_CDER_to_Annora_Phar.pdf,"June 6, 2020",FDA CDER to Annora Phar,2020
FDA-2020-P-1523-0003_Response_Letter_from_FDA_CFSAN_to_Wine_America.pdf,6/9/20,FDA CFSAN to Wine America,2020
FDA-2020-P-1540-0003_Interim_Response_to_Alliance_For_Natural_Health_US.pdf,"June 10, 2020",Alliance For Natural Health US,2020
FDA-2020-P-1540-0005_Final_Response_Letter_from_FDA_CDER_to_Alliance_fo.pdf,"June 10, 2020",FDA CDER to Alliance fo,2020
FDA-2020-P-1549-0007_Final_Response_Letter_from_FDA_CDER_to_Windels_Mar.pdf,"June 10, 2020",FDA CDER to Windels Mar,2020
FDA-2020-P-1582-0004_180_Day_Interim_Response_Letter_to_the_Council_for.pdf,"November 17, 2020",the Council for,2020
FDA-2020-P-1582-0005_Response_Letter_from_FDA_CFSAN_to_The_Council_for_.pdf,"January 26, 2023",FDA CFSAN to The Council for,2020
FDA-2020-P-1601-0069_Denial_Letter_from_FDA_CBER_to_Siri___Glimstad_LLP.pdf,"December 11, 2020",FDA CBER to Siri   Glimstad LLP,2020
FDA-2020-P-1601-0071_Response_to_Siri___Glimstad_LLP_form_FDA_CBER.pdf,"June 18, 2021",Siri   Glimstad LLP form FDA CBER,2020
FDA-2020-P-1611-0016_Interim_Response_letter_from_FDA_CDER_to_Public_Ci.pdf,"June 24, 2020",FDA CDER to Public Ci,2020
FDA-2020-P-1617-0004_Interim_Response_letter_from_FDA_CDER_to_E4_Consul.pdf,"June 24, 2020",FDA CDER to E4 Consul,2020
FDA-2020-P-1674-0022_Response_Letter_from_FDA_CDER_to_Putting_Rare_Dise.pdf,"July 15, 2020",FDA CDER to Putting Rare Dise,2020
FDA-2020-P-1689-0012_Interim_Response_from_FDA_CBER_to_Lassman_Law___Po.pdf,"July 20, 2020",FDA CBER to Lassman Law   Po,2020
FDA-2020-P-1768-0048_Interim_Response_Letter_from_FDA_CBER_to_Siri___Gl.pdf,"October 16, 2020",FDA CBER to Siri   Gl,2020
FDA-2020-P-1768-0049_Final_Response_Letter_from_FDA_CBER_to_Siri___Glim.pdf,"July 18, 2023",FDA CBER to Siri   Glim,2020
FDA-2020-P-1831-0039_Response_Letter_from_FDA_CDER_to_Meenal_Kheterpal_.pdf,,FDA CDER to Meenal Kheterpal,2020
FDA-2020-P-1859-0006_Denial_Letter_Final_response_for_Suitability_Petit.pdf,"September 8, 2020",,2020
FDA-2020-P-1864-0004_Response_Letter_from_FDA_CDRH_to_Kambiz_Tajkarimi_.pdf,"May 9, 2023",FDA CDRH to Kambiz Tajkarimi,2020
FDA-2020-P-1991-0003_Interim_Response_Letter_from_FDA_CDER_to_Hyman__Ph.pdf,"September 21, 2020",FDA CDER to Hyman  Ph,2020
FDA-2020-P-2003-0455_180_Day_Interim_Response_Letter_from_FDA_CFSAN_to_.pdf,"March 15, 2021",FDA CFSAN to,2020
FDA-2020-P-2005-0006_Approval_letter_from_FDA_CDER_to_Hyman__Phelps___M.pdf,"September 23, 2020",FDA CDER to Hyman  Phelps   M,2020
FDA-2020-P-2008-0007_Response_Letter_from_FDA_CDRH_to_Andy_Zeltwanger.pdf,9/24/20,FDA CDRH to Andy Zeltwanger,2020
FDA-2020-P-2010-0007_Interim_Response_Letter_from_FDA_CDRH_to_Philips_R.pdf,"September 22, 2020",FDA CDRH to Philips R,2020
FDA-2020-P-2033-0005_Interim_Response_Letter_from_FDA_DMS_to_Kentucky_D.pdf,"March 29, 2021",FDA DMS to Kentucky D,2020
FDA-2020-P-2048-0004_Interim_Response_Letter_from_FDA_CDER_to_Fresenius.pdf,"October 4, 2020",FDA CDER to Fresenius,2020
FDA-2020-P-2048-0006_Response_Letter_from_FDA_CDER_to_Fresenius_Kabi_US.pdf,"October 4, 2020",FDA CDER to Fresenius Kabi US,2020
FDA-2020-P-2060-0003_Interim_Response_from_FDA_CDRH_to_Penn_Avenue_Law_.pdf,"October 7, 2020",FDA CDRH to Penn Avenue Law,2020
FDA-2020-P-2060-0005_Final_Response_Letter_from_FDA_CDRH_to_Christine_B.pdf,10/8/20,FDA CDRH to Christine B,2020
FDA-2020-P-2067-0006_Final_Response_Letter_from_FDA_CDER_to_Hyman__Phel.pdf,"October 12, 2020",FDA CDER to Hyman  Phel,2020
FDA-2020-P-2102-0005_Approval_Letter.pdf,"October 19, 2020",,2020
FDA-2020-P-2133-0003_Interim_Response_Letter_from_FDA_CDER_to_Fresenius(1).pdf,"October 26, 2020",FDA CDER to Fresenius(1),2020
FDA-2020-P-2133-0003_Interim_Response_Letter_from_FDA_CDER_to_Fresenius.pdf,"October 26, 2020",FDA CDER to Fresenius(1),2020
FDA-2020-P-2133-0004_Response_Letter_from_FDA_CDER_to_Fresenius_Kabi_US.pdf,"October 26, 2020",FDA CDER to Fresenius Kabi US,2020
FDA-2020-P-2134-0003_Interim_Response_Letter_from_FDA_CFSAN_to_Natural_.pdf,10/27/20,FDA CFSAN to Natural,2020
FDA-2020-P-2136-0005_Interim_Response_from_FDA_CBER_to_Siri___Glimstad_.pdf,"October 28, 2020",FDA CBER to Siri   Glimstad,2020
FDA-2020-P-2136-0006_Final_Response_from_FDA_CBER_to_Siri___Glimstad__L.pdf,"September 5, 2023",FDA CBER to Siri   Glimstad  L,2020
FDA-2020-P-2180-0070_Denial_Letter_from_FDA_CBER_to_Siri___Glimstad_LLP.pdf,"December 11, 2020",FDA CBER to Siri   Glimstad LLP,2020
FDA-2020-P-2212-0051_Interim_response_from_FDA_CDER_to_Encore_Dermatolo.pdf,"November 13, 2020",FDA CDER to Encore Dermatolo,2020
FDA-2020-P-2213-0031_Interim_Response_Letter_from_FDA_CDER_to_Kenneth_E.pdf,"November 17, 2020",FDA CDER to Kenneth E,2020
FDA-2020-P-2213-0045_Final_Response_from_FDA_CDER_to_Kenneth_Surprenant.pdf,"July 29, 2016",FDA CDER to Kenneth Surprenant,2020
FDA-2020-P-2225-0008_SOA_Denial_Letter_from_FDA_CBER__to_Siri___Glimsta.pdf,"December 11, 2020",FDA CBER  to Siri   Glimsta,2020
FDA-2020-P-2236-0003_Response_Letter_from_FDA_CDER_to_Covington___Burli.pdf,"November 25, 2020",FDA CDER to Covington   Burli,2020
FDA-2020-P-2236-0004_Final_Response_to_Covington___Burling_LLP_from_FDA.pdf,"November 25, 2020",FDA,2020
FDA-2020-P-2244-0010_Response_Letter_from_FDA_CDER_to_Camargo_Pharmaceu.pdf,"December 1, 2020",FDA CDER to Camargo Pharmaceu,2020
FDA-2020-P-2276-0011_Interim_Response_Letter_from_FDA_CFSAN_to_Environm.pdf,"December 9, 2020",FDA CFSAN to Environm,2020
FDA-2020-P-2289-0005_Response_Letter_from_FDA_CDRH_to_James_N__Czaban__.pdf,"December 5, 2022",FDA CDRH to James N  Czaban,2020
FDA-2020-P-2296-0025_Interim_Response_Letter_from_FDA_CDER_to_Parentera.pdf,"December 1, 2020",FDA CDER to Parentera,2020
FDA-2020-P-2296-0026_Interim_response_from_FDA_CDER_to_Parenteral_Techn.pdf,"January 25, 2023",FDA CDER to Parenteral Techn,2020
FDA-2020-P-2301-0004_Response_Letter_from_FDA_CDER_to_Alpha_Cognition_U.pdf,"December 10, 2020",FDA CDER to Alpha Cognition U,2020
FDA-2020-P-2312-0004_Tentative_Response_Letter_from_FDA_CVM_to_Covingto.pdf,"May 18, 2021",FDA CVM to Covingto,2020
FDA-2020-P-2312-0005_Final_Response_Letter_from_FDA_CVM_to_Covington___.pdf,"November 2, 2023",FDA CVM to Covington,2020
FDA-2020-P-2313-0004_Tentative_Response_Letter_from_FDA_CVM_to_Covingto.pdf,"May 18, 2021",FDA CVM to Covingto,2020
FDA-2020-P-2313-0005_Final_Response_Letter_from_FDA_CVM_to_Covington___.pdf,"November 3, 2023",FDA CVM to Covington,2020
FDA-2020-P-2317-0004_Response_Letter_from_FDA_CDER_to_Baxter_Healthcare.pdf,"December 21, 2020",FDA CDER to Baxter Healthcare,2020
FDA-2020-P-2322-0003_Interim_Response_to_Covington___Burling_LLP_from_F.pdf,"December 17, 2020",F,2020
FDA-2020-P-2360-0068_Response_Letter_from_FDA_CVM_to_Pet_Schooled.pdf,"June 30, 2021",FDA CVM to Pet Schooled,2020
FDA-2021-P-0434-0003_Interim_Response_from_FDA_CDER_to_Braintree.pdf,"May 4, 2021",FDA CDER to Braintree,2021
FDA-2021-P-0523-0006_Response_Letter_from_FDA_CFSAN_to_Council_for_Resp.pdf,"November 24, 2021",FDA CFSAN to Council for Resp,2021
FDA-2021-P-0530-0086_Interim_Response_from_CDER_to_OptiNose_US_Inc.pdf,"June 1, 2021",CDER to OptiNose US Inc,2021
FDA-2021-P-0533-0017_Interim_Response_from_FDA_CDER_to_RVL_Pharmaceutic.pdf,"June 2, 2021",FDA CDER to RVL Pharmaceutic,2021
FDA-2021-P-0550-0044_Interim_Response_Letter_from_FDM_CDER_to_Baker___H.pdf,"June 16, 2021",FDM CDER to Baker   H,2021
FDA-2021-P-0581-0007_Interim_Response_Letter_from_FDA_CDER_to_Intertek_.pdf,"June 17, 2021",FDA CDER to Intertek,2021
FDA-2021-P-0582-0006_Response_Letter_from_FDA_CDRH_to_James_McKim_Redac.pdf,"August 28, 2021",FDA CDRH to James McKim Redac,2021
FDA-2021-P-0674-0006_Agency_Response_Letter_FDA_CDER_to_Hyman__Phelps__.pdf,"July 2, 2021",Hyman  Phelps,2021
FDA-2021-P-0680-0020_Response_Letter_from_FDA_CDER_to_Joe_DiNardo_and_C.pdf,7/9/21,FDA CDER to Joe DiNardo and C,2021
FDA-2021-P-0700-0003_Response_Letter_from_FDA_CVM_to_Eric_Nault_Redacte.pdf,"January 5, 2022",FDA CVM to Eric Nault Redacte,2021
FDA-2021-P-0700-0004_Final_Response_Letter_from_FDA_CVM_to_Eric_Nault__.pdf,"August 2, 2024",FDA CVM to Eric Nault,2021
FDA-2021-P-0705-0003_Interim_Response_Letter_from_FDA_CDER_to_Catalyst_.pdf,"July 8, 2021",FDA CDER to Catalyst,2021
FDA-2021-P-0882-0003_Tentative_Response_Letter_from_FDA_CVM_to_Chelsea_.pdf,"February 2, 2022",FDA CVM to Chelsea,2021
FDA-2021-P-0885-0006_Response_Letter_from_FDA_CDER_to_Zydus_Pharmaceuti.pdf,"August 10, 2021",FDA CDER to Zydus Pharmaceuti,2021
FDA-2021-P-0893-0077_Interim_Response_Letter_from_FDA_CDER_to_Sidley_Au.pdf,4/1/2022,FDA CDER to Sidley Au,2021
FDA-2022-P-0032-0005_Interim_Response_Letter_from_Cristina_Maria_Rosa_R.pdf,"June 29, 2022",Cristina Maria Rosa R,2022
FDA-2022-P-0058-0003_Final_Response_from_FDA_CVM_to__Donavan_Melton_Red.pdf,1/11/22,FDA CVM to  Donavan Melton Red,2022
FDA-2022-P-0063-0003_Tentative_Response_Letter_from_FDA_CVM_to_Krysta_F.pdf,1/11/22,FDA CVM to Krysta F,2022
FDA-2022-P-0063-0004_Final_Response_Letter_from_FDA_CVM_to_Krysta_Fox__.pdf,"August 2, 2024",FDA CVM to Krysta Fox,2022
FDA-2022-P-0068-0003_Interim_Response_from_FDA_CDER_to_HYMAN__PHELPS___.pdf,"January 11, 2022",FDA CDER to HYMAN  PHELPS,2022
FDA-2022-P-0069-0005_Response_Letter_from_FDA_CDER_to_Aurobindo_Pharma_.pdf,"January 11, 2022",FDA CDER to Aurobindo Pharma,2022
FDA-2022-P-0077-0004_Response_Letter_from_FDA_CDER_to_Aurobindo_Pharma_.pdf,"January 14, 2022",FDA CDER to Aurobindo Pharma,2022
FDA-2022-P-0088-0003_180_day_Interim_response_from_FDA_CFSAN_to_Tufts_U.pdf,"July 22, 2022",FDA CFSAN to Tufts U,2022
FDA-2022-P-0095-0004_Final_Response_from_FDA_CVM_to_HARRY_DUTY_Redacted.pdf,1/26/22,FDA CVM to HARRY DUTY Redacted,2022
FDA-2022-P-0107-0004_Final_Response_from_FDA_CVM_to_Pet_Schooled__Redac.pdf,1/28/22,FDA CVM to Pet Schooled  Redac,2022
FDA-2022-P-0110-0005_180_Day_Response_Letter_from_FDA_CFSAN_to_Center_f.pdf,"July 18, 2022",FDA CFSAN to Center f,2022
FDA-2022-P-0115-0004_Agency_Response_Letter_from_FDA_CDER_to_Baxter_Hea.pdf,"February 2, 2022",FDA CDER to Baxter Hea,2022
FDA-2022-P-0120-0004_Final_Response_Letter_from_FDA_CVM_to_Chelsea_Kent.pdf,2/4/22,FDA CVM to Chelsea Kent,2022
FDA-2022-P-0121-0003_Final_Response_from_FDA_CVM_to__Pet_Schooled_Redac.pdf,2/4/22,FDA CVM to  Pet Schooled Redac,2022
FDA-2022-P-0122-0004_Agency_Response_Letter_from_FDA_CBER_to_Jianqing_W.pdf,2/7/22,FDA CBER to Jianqing W,2022
FDA-2022-P-0126-0003_Final_Response_Letter_from_FDA_CVM_to_Harry_Duty_R.pdf,"April 6, 2022",FDA CVM to Harry Duty R,2022
FDA-2022-P-0144-0030_Interim_response_from_FDA_CDER_to_Axinn__Veltrop__.pdf,"February 8, 2022",FDA CDER to Axinn  Veltrop,2022
FDA-2022-P-0144-0032_Final_Response_from_FDA_CDER_to_Axinn_Veltrop_and_.pdf,"February 8, 2022",FDA CDER to Axinn Veltrop and,2022
FDA-2022-P-0149-0013_Interim_response_from_FDA_CDER_to_Public_Citizen_s.pdf,"February 8, 2022",FDA CDER to Public Citizen s,2022
FDA-2022-P-0149-0014_Response_Letter_from_FDA_CDER_to_Public_Citizen_s_.pdf,"February 8, 2022",FDA CDER to Public Citizen s,2022
FDA-2022-P-0151-0006_Approval_Letter_from_FDA_CDER_to_Ascend_Laboratori.pdf,"February 9, 2022",FDA CDER to Ascend Laboratori,2022
FDA-2022-P-0152-0003_Final_Response_Letter_from_FDA_CDER_to_Qilu_Pharma.pdf,"February 10, 2022",FDA CDER to Qilu Pharma,2022
FDA-2022-P-0155-0006_Final_Response_Letter_from_FDA_CDER_to_Kleinfeld_K.pdf,"February 10, 2022",FDA CDER to Kleinfeld K,2022
FDA-2022-P-0160-0012_Interim_response_from_FDA_CDER_to_Ferring_Pharmace.pdf,"February 10, 2022",FDA CDER to Ferring Pharmace,2022
FDA-2022-P-0172-0004_Final_Response_from_FDA_CVM_to_Ronald_Brock___Reda.pdf,2/14/22,FDA CVM to Ronald Brock   Reda,2022
FDA-2022-P-0174-0004_Final_Response_Final_Response_from_FDA_CVM_to_Rona.pdf,2/14/22,FDA CVM to Rona,2022
FDA-2022-P-0182-0003_Interim_response_from_FDA_CFSAN_to_Center_for_Food.pdf,"August 11, 2022",FDA CFSAN to Center for Food,2022
FDA-2022-P-0195-0004_180_day_Response_Letter_from_FDA_CFSAN_to_Connor_C.pdf,"December 8, 2023",FDA CFSAN to Connor C,2022
FDA-2022-P-0200-0006_Final_Response_Letter_from_FDA_CDER_to_Lachman_Con.pdf,"February 18, 2022",FDA CDER to Lachman Con,2022
FDA-2022-P-0208-0003_Final_Response_from_FDA_ORA_to_Harry_Duty_REDACTED.pdf,2/22/22,FDA ORA to Harry Duty REDACTED,2022
FDA-2022-P-0209-0004_Tentative_Response_Letter_from_FDA_CVM_to_Harry_Du.pdf,"September 19, 2022",FDA CVM to Harry Du,2022
FDA-2022-P-0209-0005_Final_Response_Letter_from_FDA_CVM_to_Harry_Duty_R.pdf,2/22/22,FDA CVM to Harry Duty R,2022
FDA-2022-P-0213-0004_Final_Response_Letter_from_FDA_CVM_to_Leslie_Novos.pdf,"August 2, 2024",FDA CVM to Leslie Novos,2022
FDA-2022-P-0215-0019_Final_Response_Letter_from_FDA_CDER_to_Jonathan_H_.pdf,"February 24, 2022",FDA CDER to Jonathan H,2022
FDA-2022-P-0220-0003_Interim_Response_Letter_from_FDA_CVM_to_Pet_School.pdf,"August 17, 2022",FDA CVM to Pet School,2022
FDA-2022-P-0234-0005_Final_Response_from_FDA_CDRH_to_Pink_Concussions.pdf,"November 6, 2022",FDA CDRH to Pink Concussions,2022
FDA-2022-P-0237-0003_Agency_Response_Letter_from_FDA_OP_to_Only_Orphans.pdf,"August 23, 2022",FDA OP to Only Orphans,2022
FDA-2022-P-0253-0004_Final_Response_Letter_from_FDA_CVM_to_Tyler_Burch_.pdf,"August 2, 2024",FDA CVM to Tyler Burch,2022
FDA-2022-P-0256-0004_Interim_Response_from_FDA_CFSAN_to_Center_for_Scie.pdf,"September 2, 2022",FDA CFSAN to Center for Scie,2022
FDA-2022-P-0270-0003_Interim_Response_Letter_from_FDA_CBER_to_Sanofi_Pa.pdf,"March 2, 2022",FDA CBER to Sanofi Pa,2022
FDA-2022-P-0287-0003_Interim_Response_letter_from_FDA_CDER_to_Kabi_USA_.pdf,"March 3, 2022",FDA CDER to Kabi USA,2022
FDA-2022-P-0290-0004_Interim_Response_Letter_from_FDA_CDER_to_Fresenius.pdf,"March 4, 2022",FDA CDER to Fresenius,2022
FDA-2022-P-0293-0004_180_day_Interim_Response_Letter_from_FDA_CFSAN_to_.pdf,"August 30, 2022",FDA CFSAN to,2022
FDA-2022-P-0299-0003_Tentative_Response_Letter_from_FDA_CVM_to_Donavan_.pdf,"August 31, 2022",FDA CVM to Donavan,2022
FDA-2022-P-0299-0004_Final_Response_Letter_from_FDA_CVM_to_Donavan_Melt.pdf,3/8/22,FDA CVM to Donavan Melt,2022
FDA-2022-P-0306-0003_Tentative_Response_Letter_from_FDA_CVM_to_Donavan_.pdf,"August 31, 2022",FDA CVM to Donavan,2022
FDA-2022-P-0306-0004_Final_Response_Letter_from_FDA_CVM_to_Donavan_Melt.pdf,3/9/22,FDA CVM to Donavan Melt,2022
FDA-2022-P-0307-0004_Tentative_Response_Letter_from_FDA_CVM_to_Chelsea_.pdf,"August 31, 2022",FDA CVM to Chelsea,2022
FDA-2022-P-0309-0003_Response_Letter_from_FDA_ORA_to_Harry_Dutty_Redact.pdf,"August 26, 2022",FDA ORA to Harry Dutty Redact,2022
FDA-2022-P-0310-0003_Response_Letter_from_FDA_ORA_to_Harry_Duty_Redacte.pdf,"August 26, 2022",FDA ORA to Harry Duty Redacte,2022
FDA-2022-P-0311-0003_Response_Letter_from_FDA_ORA_to_Harry_Duty_Redacte.pdf,"August 26, 2022",FDA ORA to Harry Duty Redacte,2022
FDA-2022-P-0324-0003_Interim_Response_from_FDA_CDER_to_Karl_Schwartz_Re.pdf,"September 2, 2022",FDA CDER to Karl Schwartz Re,2022
FDA-2022-P-0324-0004_Response_Letter_from_FDA_CDER_to_Karl_Schwartz.pdf,"March 11, 2022",FDA CDER to Karl Schwartz,2022
FDA-2022-P-0356-0004_Final_Response_Letter_from_FDA_CVM_to_Shasta_Evans.pdf,"August 2, 2024",FDA CVM to Shasta Evans,2022
FDA-2022-P-0392-0013_Final_Response__Letter_from_FDA_CFASN_to_American_.pdf,"July 22, 2022",FDA CFASN to American,2022
FDA-2022-P-0394-0003_Tentative_Response_Letter_from_FDA_CVM_to_Harry_Du.pdf,"September 19, 2022",FDA CVM to Harry Du,2022
FDA-2022-P-0394-0004_Final_Response_Letter_from_FDA_CVM_to_Harry_Duty_R.pdf,3/25/22,FDA CVM to Harry Duty R,2022
FDA-2022-P-0395-0003_Final_CP_Response_Pet_Food_Testing_Records_from_FD.pdf,"September 12, 2022",FD,2022
FDA-2022-P-0395-0004_CP_Response_from_FDA_CVM_to_Harry_Duty_Redacted.pdf,3/23/22,FDA CVM to Harry Duty Redacted,2022
FDA-2022-P-0395-0005_Tentative_CP_Response_from_FDA_CVM_to_Harry_Duty_R.pdf,3/23/22,FDA CVM to Harry Duty R,2022
FDA-2022-P-0405-0003_Tentative_Response_Letter_from_FDA_CVM_to_Harry_Du.pdf,"September 19, 2022",FDA CVM to Harry Du,2022
FDA-2022-P-0405-0004_Final_Response_Letter_from_FDA_CVM_to_Harry_Duty_R.pdf,3/25/22,FDA CVM to Harry Duty R,2022
FDA-2022-P-0451-0003_Interim_response_from_FDA_CVM_to_Chelsea_Kent.pdf,3/25/22,FDA CVM to Chelsea Kent,2022
FDA-2022-P-0475-0003_Response_Letter_from_FDA_CDER_to_Lachman_Consultan.pdf,"March 29, 2022",FDA CDER to Lachman Consultan,2022
FDA-2022-P-0476-0003_Interim_response_from_FDA_CDER_to_Lachman_Consulta.pdf,"March 29, 2022",FDA CDER to Lachman Consulta,2022
FDA-2022-P-0476-0004_Final_Response_Letter_from_FDA_CDER_to_Lachman_Con.pdf,"March 29, 2022",FDA CDER to Lachman Con,2022
FDA-2022-P-0509-0008_Interim_Response_Letter_from_FDA_CDER_to_Arnall_Go.pdf,"March 31, 2022",FDA CDER to Arnall Go,2022
FDA-2022-P-0536-0032_Final_Response_Letter_from_FDA_CDER_to_Bayer_U_S__.pdf,"September 2, 2022",FDA CDER to Bayer U S,2022
FDA-2022-P-0574-0003_Interim_Response_from_FDA_CVM_to_Harry_Duty_Redact.pdf,4/15/22,FDA CVM to Harry Duty Redact,2022
FDA-2022-P-0574-0004_Final_Response_Letter_from_FDA_CVM_to_Harry_Duty.pdf,"August 8, 2024",FDA CVM to Harry Duty,2022
FDA-2022-P-0585-0003_Interim_response_from_FDA_CDER_to_Odin_Pharmaceuti.pdf,"October 7, 2022",FDA CDER to Odin Pharmaceuti,2022
FDA-2022-P-0585-0005_Response_Letter_from_FDA_CDER_to_Odin_Pharmaceutic.pdf,"April 12, 2022",FDA CDER to Odin Pharmaceutic,2022
FDA-2022-P-0594-0006_Response_from_FDA_CDER_to_Fish___Richardson_P_C_.pdf,"April 14, 2022",FDA CDER to Fish   Richardson P C,2022
FDA-2022-P-0599-0003_Interim_Response_from_FDA_CDRH_to_Steven_A__Zecola.pdf,"October 5, 2022",FDA CDRH to Steven A  Zecola,2022
FDA-2022-P-0600-0004_Interim_Response_from_FDA_CFSAN_to_Daniel_Fabrican.pdf,"August 19, 2022",FDA CFSAN to Daniel Fabrican,2022
FDA-2022-P-0600-0005_Response_Letter_from_FDA_CFSAN_to_Natural_Products.pdf,"January 26, 2023",FDA CFSAN to Natural Products,2022
FDA-2022-P-0614-0005_Interim_Response_Letter_from_FDA_CDER_to_Yichang_H.pdf,"April 18, 2022",FDA CDER to Yichang H,2022
FDA-2022-P-0614-0007_Response_Letter_from_FDA_CDER_to_Yichang_Humanwell.pdf,"April 18, 2022",FDA CDER to Yichang Humanwell,2022
FDA-2022-P-0677-0005_Response_Letter_from_FDA_CBER_to_Fatima_Khan_Redac.pdf,"June 17, 2022",FDA CBER to Fatima Khan Redac,2022
FDA-2022-P-0704-0006_Response_Letter_from_FDA_CBER_to_San_Rocco_Therape.pdf,"August 17, 2022",FDA CBER to San Rocco Therape,2022
FDA-2022-P-0747-0008_Final_Response_Letter_from_FDA_CDER_to_RegCon_Solu.pdf,"May 5, 2022",FDA CDER to RegCon Solu,2022
FDA-2022-P-0754-0003_Final_Response_from_FDA_CVM_to_Pet_Schooled_Redact.pdf,5/10/22,FDA CVM to Pet Schooled Redact,2022
FDA-2022-P-0777-0003_Final_Response_from_FDA_CVM_to_Donavan_Melton_Reda.pdf,5/25/22,FDA CVM to Donavan Melton Reda,2022
FDA-2022-P-0872-0011_FDA_CBER_Response__to_Stay_of_Action_Citizen_Petit.pdf,"June 17, 2022",Stay of Action Citizen Petit,2022
FDA-2022-P-0896-0004_Interim_Response_from_FDA_CDER_to_Greenberg_Trauri.pdf,"May 24, 2022",FDA CDER to Greenberg Trauri,2022
FDA-2022-P-0896-0005_Final_Response_from_FDA_CDER_to_Greenberg_Traurig.pdf,"May 24, 2022",FDA CDER to Greenberg Traurig,2022
FDA-2022-P-0979-0006_Approval_Letter_from_FDA_CDER_to_ArentFox_Schiff_L.pdf,"June 3, 2022",FDA CDER to ArentFox Schiff L,2022
FDA-2022-P-1013-0004_Interim_Response_from_FDA_CDER_to_Medley_Pharmaceu.pdf,"June 6, 2022",FDA CDER to Medley Pharmaceu,2022
FDA-2022-P-1013-0006_Final_Response_from_FDA_CDER_to_Medley_Pharmaceuti.pdf,"June 6, 2022",FDA CDER to Medley Pharmaceuti,2022
FDA-2022-P-1039-0007_Response_Letter_from_FDA_CDER_to_Epic_Pharma__LLC.pdf,"June 7, 2022",FDA CDER to Epic Pharma  LLC,2022
FDA-2022-P-1065-0004_Interim_Response_Letter_from_FDA_CDRH_to_Allen_K__.pdf,6/9/22,FDA CDRH to Allen K,2022
FDA-2022-P-1104-0003_Interim_response_from_FDA_CDER_to_Medexus_Pharma__.pdf,"June 9, 2022",FDA CDER to Medexus Pharma,2022
FDA-2022-P-1104-0004_Final_Response_from_FDA_CDER_to_Medexus_Pharma__In.pdf,6/13/22,FDA CDER to Medexus Pharma  In,2022
FDA-2022-P-1125-0003_Tentative_Response_Letter_from_FDA_CVM_to_Harry_Du.pdf,6/13/22,FDA CVM to Harry Du,2022
FDA-2022-P-1125-0004_Final_Response_Letter_from_FDA_CVM_to_Harry_Duty.pdf,"August 08, 2024",FDA CVM to Harry Duty,2022
FDA-2022-P-1151-0062_Interim_Response_from_FDA_CDRH_to_Mark_Baker.pdf,"November 6, 2022",FDA CDRH to Mark Baker,2022
FDA-2022-P-1151-0215_Final_Response_Letter_from_FDA_CDRH_to_Soft_Lights.pdf,"May 24, 2024",FDA CDRH to Soft Lights,2022
FDA-2022-P-1186-0003_Tentative_Response_Letter_from_FDA_CVM_to_Harry_Du.pdf,6/16/22,FDA CVM to Harry Du,2022
FDA-2022-P-1186-0004_Final_Response_Letter_from_FDA_CVM_to_Harry_Duty.pdf,"August 08, 2024",FDA CVM to Harry Duty,2022
FDA-2022-P-1211-0005_Final_Response_to_American_Vapor_Manufacturers_Cit.pdf,"February 2, 2023",American Vapor Manufacturers Cit,2022
FDA-2022-P-1248-0003_Tentative_Response_Letter_from_FDA_CVM_to_Harry_Du.pdf,6/21/22,FDA CVM to Harry Du,2022
FDA-2022-P-1248-0004_Final_Response_Letter_from_FDA_CVM_to_Harry_Duty.pdf,"August 08, 2024",FDA CVM to Harry Duty,2022
FDA-2022-P-1255-0003_Tentative_Response_Letter_from_FDA_CVM_to_Harry_Du.pdf,"August 08, 2024",FDA CVM to Harry Du,2022
FDA-2022-P-1255-0004_Final_Response_Letter_from_FDA_CVM_to_Harry_Duty.pdf,"August 08, 2024",FDA CVM to Harry Duty,2022
FDA-2022-P-1342-0003_Tentative_Response_Letter_from_FDA_CVM_to_Harry_Du.pdf,6/27/22,FDA CVM to Harry Du,2022
FDA-2022-P-1343-0003_Tentative_Response_Letter_from_FDA_CVM_to_Hary_Dut.pdf,6/27/22,FDA CVM to Hary Dut,2022
FDA-2022-P-1343-0004_Final_Response_Letter_from_FDA_CVM_to_Harry_Duty.pdf,"August 08, 2024",FDA CVM to Harry Duty,2022
FDA-2022-P-1367-0003_Final_Response_from_FDA_CVM_to_Harry_Duty_redacted.pdf,6/28/22,FDA CVM to Harry Duty redacted,2022
FDA-2022-P-1399-0075_Response_Letter_from_FDA_CBER_to_Siri___Glimstad_L.pdf,"October 11, 2022",FDA CBER to Siri   Glimstad L,2022
FDA-2022-P-1407-0003_Final_Response_Letter_from_FDA_CVM_to_Harry_Duty_R.pdf,"June 30, 2022",FDA CVM to Harry Duty R,2022
FDA-2022-P-1409-0042_Interim_Response_Letter_from_FDA_CDER_to_Providenc.pdf,"June 28, 2022",FDA CDER to Providenc,2022
FDA-2022-P-1444-0006_Response_Letter_from_FDA_CBER_to_National_Hemophil.pdf,"November 22, 2022",FDA CBER to National Hemophil,2022
FDA-2022-P-1444-0007_Response_Letter_from_FDA_CBER_to_National_Hemophil.pdf,"June 29, 2023",FDA CBER to National Hemophil,2022
FDA-2022-P-1452-0003_Response_Letter_from_FDA_CTP_to_Planet_Vapor_LLC.pdf,"October 18, 2022",FDA CTP to Planet Vapor LLC,2022
FDA-2022-P-1457-0023_180_Day_Interim_Response_Letter_from_FDA_CFSAN_to_.pdf,"December 30, 2022",FDA CFSAN to,2022
FDA-2022-P-1457-0024_180_Day_Interim_Response_Letter_from_FDA_CFSAN_to_.pdf,"December 30, 2022",FDA CFSAN to,2022
FDA-2022-P-1457-0025_180_Day_Interim_Response_Letter_from_FDA_CFSAN_to_.pdf,"December 30, 2022",FDA CFSAN to,2022
FDA-2022-P-1457-0026_I180_Day_Interim_Response_Letter_from_FDA_CFSAN_to.pdf,"December 30, 2022",FDA CFSAN to,2022
FDA-2022-P-1457-0027_180_Day_Interim_Response_Letter_from_FDA_CFSAN_to_.pdf,"December 30, 2022",FDA CFSAN to,2022
FDA-2022-P-1457-0028_180_Day_Interim_Response_Letter_from_FDA_CFSAN_to_.pdf,"December 30, 2022",FDA CFSAN to,2022
FDA-2022-P-1471-0005_Response_Letter_from_FDA_CBER_to_J_W__Howard_Attor.pdf,"August 30, 2022",FDA CBER to J W  Howard Attor,2022
FDA-2022-P-1589-0003_Tentative_Response_Letter_from_FDA_CVM_to_Donavan_.pdf,7/18/22,FDA CVM to Donavan,2022
FDA-2022-P-1589-0004_Final_Response_Letter_from_FDA_CVM_to_Donavan_Melt.pdf,7/18/22,FDA CVM to Donavan Melt,2022
FDA-2022-P-1632-0005_180_day_Interim_response_from_FDA_CDRH_to_Randall_.pdf,"January 4, 2023",FDA CDRH to Randall,2022
FDA-2022-P-1632-0008_Final_Response_Letter_from_FDA_CDRH_to_Randall_Hen.pdf,"January 10, 2025",FDA CDRH to Randall Hen,2022
FDA-2022-P-1643-0242_Tentative_Response_Letter_from_FDA_CVM_to_Associat.pdf,"January 11, 2023",FDA CVM to Associat,2022
FDA-2022-P-1656-0003_Agency_Response_Letter_from_FDA_CDER_to_Fresenius_.pdf,"July 22, 2022",FDA CDER to Fresenius,2022
FDA-2022-P-1667-0003_Response_Letter_from_FDA_CDER_to_Chem_IQ_FZCO.pdf,"July 22, 2022",FDA CDER to Chem IQ FZCO,2022
FDA-2022-P-1668-0010_Interim_Response_Letter_from_FDA_CFSAN_to_Akin_Gum.pdf,"January 17, 2023",FDA CFSAN to Akin Gum,2022
FDA-2022-P-1764-0014_Interim_Response_from_FDA_CBER_to_Charles_River_La.pdf,"January 27, 2023",FDA CBER to Charles River La,2022
FDA-2022-P-1785-0003_Interim_Response_from_FDA_CDER_to_Aurobindo_Pharma.pdf,"August 3, 2022",FDA CDER to Aurobindo Pharma,2022
FDA-2022-P-1785-0005_Response_Letter_from_FDA_CDER_to_Aurobindo_Pharma_.pdf,"August 3, 2022",FDA CDER to Aurobindo Pharma,2022
FDA-2022-P-3121-0007_Response_Letter_form_FDA_CBER_to_Karl_Guenther.pdf,"January 31, 2020",Karl Guenther,2022
FDA-2023-P-0037-0004_Response_Letter_from_FDA_CBER_to_Karl_Guenther_Red.pdf,Dec. 2020,FDA CBER to Karl Guenther Red,2023
FDA-2023-P-0076-0007_Denial_Letter_from_FDA_CTP_to_SMS_BZ__LLC.pdf,"April 21, 2023",FDA CTP to SMS BZ  LLC,2023
FDA-2023-P-0120-0005_Response_Letter_from_FDA_CDER_to_Epic_Pharma__LLC.pdf,"January 10, 2023",FDA CDER to Epic Pharma  LLC,2023
FDA-2023-P-0203-0006_Interim_Response_Letter_from_FDA_CDRH_to_Najam_Azm.pdf,1/20/23,FDA CDRH to Najam Azm,2023
FDA-2023-P-0203-0007_Final_Response_Letter_from_FDA_CDRH_to_Najam_Azmat.pdf,1/20/23,FDA CDRH to Najam Azmat,2023
FDA-2023-P-0219-0009_Interim_Response_Letter_from_FDA_CDRH_to_Service_E.pdf,1/23/23,FDA CDRH to Service E,2023
FDA-2023-P-0232-0003_Response_from_FDA_CDER_to_Hyman__Phelps___McNamra_.pdf,"January 20, 2023",FDA CDER to Hyman  Phelps   McNamra,2023
FDA-2023-P-0233-0011_Interim_Response_from_FDA_CDER_to_Soft_Lights_Foun.pdf,"June 30, 2023",FDA CDER to Soft Lights Foun,2023
FDA-2023-P-0233-0022_Final_Response_from_FDA_CDRH_to_Soft_Lights_Founda.pdf,"May 24, 2024",FDA CDRH to Soft Lights Founda,2023
FDA-2023-P-0360-0191_Response_Letter_from_FDA_CBER_to_Coalition_Advocat.pdf,"April 18, 2023",FDA CBER to Coalition Advocat,2023
FDA-2023-P-0430-0003_Response_Letter_from_FDA_CTP_to_RAI_Services_Compa.pdf,"August 4, 2023",FDA CTP to RAI Services Compa,2023
FDA-2024-P-0105-0007_Response_Letter_from_FDA_CDER_to_Graviti_Pharmaceu.pdf,1/5/24,Graviti Pharmaceuticals Private Limited,2024
FDA-2024-P-0109-0019_Interim_Response_Letter_from_FDA_CDER_to_Bausch_Lo.pdf,1/8/24,Bausch+Lomb,2024
FDA-2024-P-0227-0004_Final_Response_Letter_from_FDA_CDER_to_Zydus_Pharm.pdf,"January 10, 2024",FDA CDER to Zydus Pharm,2024
FDA-2024-P-0279-0007_Final_Response_Letter_from_FDA_CDRH_to_Hyman__Phel.pdf,1/16/24,Nautilus Gloves LLC,2024
FDA-2024-P-0422-0011_Final_Response_Letter_from_FDA_CDER_to_Method_Phar.pdf,"January 12, 2024",FDA CDER to Method Phar,2024
FDA-2024-P-0425-0008_Final_Response_Letter_from_FDA_CDER_to_RegCon_Solu.pdf,"January 22, 2024",FDA CDER to RegCon Solu,2024
FDA-2024-P-0427-0007_Final_Response_Letter_from_FDA_CDER_to_DDReg_Pharm.pdf,"January 19, 2024",FDA CDER to DDReg Pharm,2024
FDA-2024-P-0435-0004_Final_Response_Letter_from_FDA_CDER_to_Zydus_Pharm.pdf,"January 22, 2024",FDA CDER to Zydus Pharm,2024
FDA-2024-P-0521-0005_Interim_Response_Letter_from_FDA_CDER_to_Kasowitz_.pdf,1/26/24,Adventapharma Dwc Llc,2024
FDA-2024-P-0522-0004_Interim_Response_Letter_from_FDA_CDER_to_Kasowitz_.pdf,1/26/24,Adventapharma Dwc Llc,2024
FDA-2024-P-0526-0010_Response_Letter_from_FDA_CDER_to_Lupin_Inc_.pdf,"January 26, 2024",FDA CDER to Lupin Inc,2024
FDA-2024-P-0545-0007_Final_Response_Letter_from_FDA_CDER_to_Hyman__Phel.pdf,"January 29, 2024",FDA CDER to Hyman  Phel,2024
FDA-2024-P-0667-0013_Final_Approval_Letter_from_FDA_CDER_to_Lachman_Con.pdf,"February 5, 2024",FDA CDER to Lachman Con,2024
FDA-2024-P-0761-0003_Interim_Response_Letter_from_FDA_CDER_to_Pharmobed.pdf,2/22/24,"Pharmobedient Consulting, Llc",2024
FDA-2024-P-0761-0005_Final_Response_Letter_from_FDA_CDER_to_Pharmobedie.pdf,"February 21, 2024",FDA CDER to Pharmobedie,2024
FDA-2024-P-0805-0004_Response_Letter_from_FDA_CDER_to_Hyman__Phelps___M.pdf,"February 13, 2024",FDA CDER to Hyman  Phelps   M,2024
FDA-2024-P-0806-2474_Interim_Response_from_FDA_CFSAN_to_Center_for_Scie.pdf,"August 9, 2024",FDA CFSAN to Center for Scie,2024
FDA-2024-P-0827-0005_Final_Response_Letter_from_FDA_CDER_to_Aurobindo_P.pdf,2/14/24,"Aurobindo Pharma Usa, Inc.,",2024
FDA-2024-P-0889-0004_Final_Response_Letter_from_FDA_CVM_to_Aurora_Pharm.pdf,"February 20, 2024",FDA CVM to Aurora Pharm,2024
FDA-2024-P-0973-0003_Interim_Response_Letter_from_FDA_CDER_to_Robin_Web.pdf,2/26/24,Robin Webb,2024
FDA-2024-P-1030-0007_Tentative_Response_from_FDA_CTP_to_William_D__Drak.pdf,2/29/24,FDA CTP to William D  Drak,2024
FDA-2024-P-1058-0003_Interim_Response_Letter_from_FDA_CDER_to_Aimed_All.pdf,"March 1, 2024",FDA CDER to Aimed All,2024
FDA-2024-P-1130-0004_Interim_Response_Letter_from_FDA_CDER_to_Valisure_.pdf,"March 5, 2024",FDA CDER to Valisure,2024
FDA-2024-P-1131-0005_Response_Letter_from_FDA_CDER_to_Fresenius_Kabi_US.pdf,"March 5, 2024",FDA CDER to Fresenius Kabi US,2024
FDA-2024-P-1223-0005_Interim_Response_Letter_from_FDA_CDER_to_Charles_L.pdf,3/13/24,FDA CDER to Charles L,2024
FDA-2024-P-1378-0003_Interim_Response_Letter_from_FDA_CDER_to_Organon_U.pdf,3/20/24,"Organon Usa, Llc",2024
FDA-2024-P-1379-0020_180_Day_Interim_Response_from_FDA_CFSAN_to_Physici.pdf,"September 16, 2024",FDA CFSAN to Physici,2024
FDA-2024-P-1380-0003_Final_Response_Letter_from_FDA_CVM_to_Kohl_Harring.pdf,3/20/24,FDA CVM to Kohl Harring,2024
FDA-2024-P-1403-0008_Response_Letter_from_FDA_CDER_to_Pharmobedient_Con.pdf,"March 20, 2024",FDA CDER to Pharmobedient Con,2024
FDA-2024-P-1440-0003_Interim_Response_Letter_from_FDA_CDER_to_pH_D_Femi.pdf,"March 22,2024",FDA CDER to pH D Femi,2024
FDA-2024-P-1441-0013_Final_Response_Letter_from_FDA_CDER_to_Epic_Pharma.pdf,"March 22, 2024",FDA CDER to Epic Pharma,2024
FDA-2024-P-1483-0007_Final_Response_Letter_from_FDA_CDER_to_Hyman__Phel.pdf,"March 26, 2024",FDA CDER to Hyman  Phel,2024
FDA-2024-P-1570-0004_180_Day_Response_Letter_from_FDA_CFSAN_to_Bongards.pdf,"September 19, 2024",FDA CFSAN to Bongards,2024
FDA-2024-P-1715-0004_Interim_Response_Letter_from_FDA_CDER_to_AbbVie_In.pdf,"April 3, 2024",FDA CDER to AbbVie In,2024
FDA-2024-P-1716-0005_Response_Letter_from_FDA_CVM_to_Aurora_Pharmaceuti.pdf,"April 3, 2024",FDA CVM to Aurora Pharmaceuti,2024
FDA-2024-P-1717-0003_Final_Response_Letter_from_FDA_CVM_to_Kohl_Harring.pdf,4/5/24,FDA CVM to Kohl Harring,2024
FDA-2024-P-1788-0008_Response_Letter_from_FDA_CDER_to_Pharmobedient_Con.pdf,"April 10, 2024",FDA CDER to Pharmobedient Con,2024
FDA-2024-P-1810-0008_Final_Response_Letter_from_FDA_CDER_to_Pharmobedie.pdf,"April 10, 2024",FDA CDER to Pharmobedie,2024
FDA-2024-P-1870-0007_Final_Response_Letter_from_FDA_CDER_to_Newcastle_B.pdf,"April 15, 2024",FDA CDER to Newcastle B,2024
FDA-2024-P-1871-0007_Interim_Response_Letter_from_FDA_CDER_to_Advanced_.pdf,"April 15, 2024",FDA CDER to Advanced,2024
FDA-2024-P-1913-0006_Final_Response_Letter_from_FDA_CDER_to_Fast_Track_.pdf,"April 17, 2024",FDA CDER to Fast Track,2024
FDA-2024-P-1916-1820_Final_Response_Letter_from_FDA_CVM_to_Association_.pdf,"October 18, 2024",FDA CVM to Association,2024
FDA-2024-P-1937-0003_Final_Response_Letter_from_FDA_CVM_to_Kohl_Harring.pdf,"April 18, 2024",FDA CVM to Kohl Harring,2024
FDA-2024-P-1960-0003_Final_Response_Letter_from_FDA_ORA_to_Kohl_Harring.pdf,"April 22, 2024",FDA ORA to Kohl Harring,2024
FDA-2024-P-1988-0004_Interim_Response_Letter_from_FDA_CDER_to_HealthyWo.pdf,"April 22, 2024",FDA CDER to HealthyWo,2024
FDA-2024-P-2084-0006_Interim_Response_Letter_from_FDA_HFP_to_PETA_Found.pdf,"October 22, 2024",FDA HFP to PETA Found,2024
FDA-2024-P-2085-0007_Final_Response_Letter_from_FDA_CDER_to_Hospira_Inc.pdf,"April 26, 2024",FDA CDER to Hospira Inc,2024
FDA-2024-P-2148-0004_Final_Response_Letter_from_FDA_CDER_to_Nese_Deveno.pdf,May 30 2024,FDA CDER to Nese Deveno,2024
FDA-2024-P-2150-0009_Response_Letter_from_FDA_CDER_to_Parenteral_Techno.pdf,"April 24, 2024",FDA CDER to Parenteral Techno,2024
FDA-2024-P-2151-0126_Interim_Response_Letter_from_FDA_HFP_to_UnidosUS.pdf,"November 4, 2024",FDA HFP to UnidosUS,2024
FDA-2024-P-2215-0003_Interim_Response_Letter_from_FDA_CDRH_to_Metaltron.pdf,"October 28, 2024",FDA CDRH to Metaltron,2024
FDA-2024-P-2220-0005_Final_Response_Letter_from_FDA_CDER_to_Encube_Ethi.pdf,"May 6, 2024",FDA CDER to Encube Ethi,2024
FDA-2024-P-2272-0005_Response_Letter_from_FDA_CDER_to_Aurobindo_Pharma_.pdf,"May 7, 2024",FDA CDER to Aurobindo Pharma,2024
FDA-2024-P-2314-0005_Response_Letter_from_FDA_CDER_to_Aurobindo_Pharma_.pdf,"May 9, 2024",FDA CDER to Aurobindo Pharma,2024
FDA-2024-P-2326-0009_Response_Letter_from_FDA_CDER_to_Hyman__Phelps___M.pdf,"July 10, 2024",FDA CDER to Hyman  Phelps   M,2024
FDA-2024-P-2379-0009_Interim_Response_Letter_from_FDA_CDER_to_The_Human.pdf,"May 15, 2024",FDA CDER to The Human,2024
FDA-2024-P-2461-0003_Interim_Response_from_FDA_CTP_to_Ho_Chunk__Inc__on.pdf,"November 12, 2024",FDA CTP to Ho Chunk  Inc  on,2024
FDA-2024-P-2513-0004_Final_Response_Letter_from_FDA_CDER_to_Innogenix__.pdf,"March 5, 2024",FDA CDER to Innogenix,2024
FDA-2024-P-2514-0004_Final_Response_Letter_from_FDA_CDER_to_Zydus_Pharm.pdf,"May 22, 2024",FDA CDER to Zydus Pharm,2024
FDA-2024-P-2515-0005_Final_Response_Letter_from_FDA_CDER_to_Encube_Ethi.pdf,"May 22, 2024",FDA CDER to Encube Ethi,2024
FDA-2024-P-2538-0008_Response_Letter_from_FDA_CDER_to_Hyman__Phelps___M.pdf,"May 23, 2024",FDA CDER to Hyman  Phelps   M,2024
FDA-2024-P-2625-0004_Response_Letter_from_FDA_ORA_to_J_R_Imports_LLC_Re.pdf,"October 18, 2024",FDA ORA to J R Imports LLC Re,2024
FDA-2024-P-2730-0003_Response_Letter_from_FDA_CBER_to_Kenneth_D__Eichen.pdf,"June 22, 2023",FDA CBER to Kenneth D  Eichen,2024
FDA-2024-P-2752-0008_Response_Letter_from_FDA_CDER_to_Hyman__Phelps___M.pdf,"June 6, 2024",FDA CDER to Hyman  Phelps   M,2024
FDA-2024-P-2753-0008_Response_Letter_from_FDA_CDER_to_Hyman__Phelps___M.pdf,"June 6, 2024",FDA CDER to Hyman  Phelps   M,2024
FDA-2024-P-2757-0008_Response_Letter_from_FDA_CDER_to_Hyman__Phelps___M.pdf,"June 6, 2024",FDA CDER to Hyman  Phelps   M,2024
FDA-2024-P-2758-0008_Response_Letter_from_FDA_CDER_to_Hyman__Phelps___M.pdf,"June 6, 2024",FDA CDER to Hyman  Phelps   M,2024
FDA-2024-P-2778-0013_Final_Response_Letter_from_FDA_CDER_to_Pharmobedie.pdf,"June 7, 2024",FDA CDER to Pharmobedie,2024
FDA-2024-P-2779-0012_Response_Letter_from_FDA_CDER_to_Hyman__Phelps___M.pdf,"June 10, 2024",FDA CDER to Hyman  Phelps   M,2024
FDA-2024-P-2846-0004_Final_Response_Letter_from_FDA_CDRH_to_Pyrexar_Med.pdf,"October 28, 2024",FDA CDRH to Pyrexar Med,2024
FDA-2024-P-2885-0007_Final_Response_Letter_from_FDA_CDER_to_Hyman__Phel.pdf,"June 17, 2024",FDA CDER to Hyman  Phel,2024
FDA-2024-P-2909-0007_Final_Response_Letter_from_FDA_CDER_to_Hyman__Phel.pdf,"June 17, 2024",FDA CDER to Hyman  Phel,2024
FDA-2024-P-2932-0007_Response_Letter_from_FDA_CDER_to_Newcastle_Bioscie.pdf,"June 19, 2024",FDA CDER to Newcastle Bioscie,2024
FDA-2024-P-2952-0005_Interim_Response_Letter_from_FDA_CDER_to_Sarah_A__.pdf,"June 20, 2024",FDA CDER to Sarah A,2024
FDA-2024-P-2955-0006_Interim_Response_Letter_from_FDA_CDER_to_Dsquare_L.pdf,"June 19, 2024",FDA CDER to Dsquare L,2024
FDA-2024-P-3090-0011_Response_Letter_from_FDA_CDER_to_Epic_Pharma__LLC.pdf,"June 28, 2024",FDA CDER to Epic Pharma  LLC,2024
FDA-2024-P-3188-0007_Final_Response_Letter_from_FDA_CDER_to_Lachman_Con.pdf,"July 3, 2024",FDA CDER to Lachman Con,2024
FDA-2024-P-3293-0011_Final_Response_Letter_from_FDA_CDER_to_Newcastle_B.pdf,"July 9, 2024",FDA CDER to Newcastle B,2024
FDA-2024-P-3357-0004_Final_Response_Letter_from_FDA_CDRH_to_Randall_Hen.pdf,"January 10, 2025",FDA CDRH to Randall Hen,2024
FDA-2024-P-3479-0003_Final_Response_Letter_from_FDA_CDER_to_Jingwei_Pha.pdf,"July 24, 2024",FDA CDER to Jingwei Pha,2024
FDA-2024-P-3482-0004_Final_Response_Letter_from_FDA_CDER_to_Qilu_Pharma.pdf,"July 24, 2024",FDA CDER to Qilu Pharma,2024
FDA-2024-P-3563-0005_Final_Response_Letter_from_FDA_CDER_to_Hyman__Phel.pdf,"July 29, 2024",FDA CDER to Hyman  Phel,2024
FDA-2024-P-3567-0007_Response_Letter_from_FDA_CDER_to_Lachman_Consultin.pdf,"July 25, 2024",FDA CDER to Lachman Consultin,2024
FDA-2024-P-3571-0009_Final_Response_Letter_from_FDA_CDER_to_Premier_Con.pdf,"July 29, 2024",FDA CDER to Premier Con,2024
FDA-2024-P-3573-0005_Response_Letter_from_FDA_CDER_to_Premier_Research_.pdf,"July 29, 2024",FDA CDER to Premier Research,2024
FDA-2024-P-3699-0004_Response_Letter_from_FDA_CDER_to_Zydus_Pharmaceuti.pdf,"August 02, 2024",FDA CDER to Zydus Pharmaceuti,2024
FDA-2024-P-3761-0003_Final_Response_Letter_from_FDA_CDRH_to_Spark_Biome.pdf,"December 15, 2024",FDA CDRH to Spark Biome,2024
FDA-2024-P-3820-0011_Interim_Response_Letter_from_FDA_HFP_to_Agent_for_.pdf,"February 6, 2025",FDA HFP to Agent for,2024
FDA-2024-P-3821-0004_Final_Response_Letter_from_FDA_CVM_to_Aurora_Pharm.pdf,"August 12, 2024",FDA CVM to Aurora Pharm,2024
FDA-2024-P-3822-0003_Interim_Response_Letter_from_FDA_CDER_to_Universit.pdf,"August 10, 2024",FDA CDER to Universit,2024
FDA-2024-P-3881-0007_Response_Letter_from_FDA_CDER_to_Zydus_Pharmaceuti.pdf,"August 13, 2024",FDA CDER to Zydus Pharmaceuti,2024
FDA-2024-P-3905-0008_Response_Letter_from_FDA_CDER_to_Lachman_Consultan.pdf,"August 15, 2024",FDA CDER to Lachman Consultan,2024
FDA-2024-P-3997-0006_Interim_Response_Letter_from_FDA_CDER_to_Aylstock_.pdf,"August 20, 2024",FDA CDER to Aylstock,2024
FDA-2024-P-4015-0003_Final_Response_Letter_from_FDA_CVM_to_Kohl_Harring.pdf,"August 22, 2024",FDA CVM to Kohl Harring,2024
FDA-2024-P-4134-0009_Response_Letter_from_FDA_CDER_to_Pharmobedient_Con.pdf,"August 24, 2024",FDA CDER to Pharmobedient Con,2024
FDA-2024-P-4135-0004_Response_Letter_from_FDA_CDER_to_Fresenius_Kabi_US.pdf,"August 29, 2024",FDA CDER to Fresenius Kabi US,2024
